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OPTIMISING RV-PA VENTRICULOARTERIAL-COUPLING TO IMPROVE 
RV DIASTOLIC FUNCTION IN PATIENTS WITH CARDIOPULMONARY 
DISORDERS 
 
RICHARD G. AXELL 
 
FEBRUARY 2017 
 
In recent years, an increasing body of evidence has emerged postulating that right 
ventricular (RV) - pulmonary artery (PA) ventriculoarterial coupling may offer insight 
into the transition from RV adaptation to RV maladaptation in different cardiopulmonary 
disorders and heart failure. RV-PA ventriculoarterial coupling is a matching between 
RV contractility (Ees – End-Systolic Elastance) and afterload (Ea – Effective Arterial 
Elastance). While ventriculoarterial coupling has been extensively described in the LV 
and used to determine optimal conditions for the efficient transfer to blood from the 
ventricle into the aorta, it remains unclear whether this relationship can be translated to 
the thinner walled RV that pumps at lower pressures against a more compliant 
pulmonary vascular system. Therefore, the pressure-volume (PV)-loop studies in this 
thesis were undertaken to assess whether ventriculoarterial uncoupling due to 
pressure overload or sub-optimal contractility contributed to further RV diastolic 
dysfunction. 
An in-vivo porcine model of RV-PA ventriculoarterial coupling was developed to define 
optimal conditions. This animal model was used to provide insights into two clinical 
patient groups that have RV dysfunction due to: i) long-term RV pressure overload in 
patients with a clinical diagnosis of chronic thromboembolic disease  (CTED) / 
pulmonary hypertension (CTEPH); and ii) aortic valve stenosis transmitted by 
ventricular interdependence and septal wall reconfiguration in patients treated with 
transcatheter aortic valve implantation (TAVI). 
The animal model determined an ventriculoarterial coupling ratio at maximal stroke 
work (Ees/Eamax sw = 0.68±0.23) threshold, below which cardiac output and RV stroke 
work fell. In the first clinical study this threshold was used to reclassify 25% of a cohort 
of patients with CTED or CTEPH. Two patients with CTED were identified with an 
EesEa below 0.68 suggesting occult RV dysfunction whilst three patients with CTEPH 
demonstrated Ees/Ea≥0.68 suggesting residual RV energetic reserve. In the second 
clinical study ventricular interdependence phenomena caused septal reconfiguration 
and increased RV volumes after valve deployment, due to the reduction in LV 
afterload. However, the rapid pacing (RP) protocol used to stabilise the aortic valve 
during deployment also caused RP-induced ischemia and stunning. This resulted in the 
reduction of Ees and led to Ees/Ea uncoupling and further diastolic dysfunction.  
This work has demonstrated that: Low Ees/Ea aligns with features of RV maladaptation 
in CTED. Characterization of Ees/Ea in CTED may allow for better identification of 
occult RV dysfunction in patients with otherwise normal pulmonary hemodynamics; and 
a reduction in Ees following TAVI correlates with increased RV diastolic dysfunction, 
due to RP-induced ischemia and stunning. 
Key words: Right Ventricle; Diastolic Dysfunction; Ventriculoarterial Coupling; RV 
Energetic Reserve; Maximal Stroke Work  
 Page vi 
Table of Contents 
 
ACKNOWLEDGEMENTS ............................................................................................... II	  
ABSTRACT .................................................................................................................... V	  
TABLE OF CONTENTS ................................................................................................ VI	  
LIST OF FIGURES ....................................................................................................... XII	  
LIST OF TABLES ....................................................................................................... XIX	  
NOTATION ................................................................................................................... XX	  
LIST OF APPENDICES .............................................................................................. XXI	  
AIMS OF THESIS ........................................................................................................... 1	  
1	   A THEORY OF RV-PA VENTRICULOARTERIAL COUPLING AND RV 
DIASTOLIC DYSFUNCTION .......................................................................................... 2	  
1.1	   INTRODUCTION ......................................................................................................... 2	  
1.2	   THE CIRCULATORY SYSTEM ..................................................................................... 4	  
1.3	   THE RIGHT VENTRICLE ............................................................................................. 8	  
1.4	   THE ASSESSMENT OF RV DIASTOLIC DYSFUNCTION ............................................... 10	  
1.4.1	   Non-Invasive Assessment of RV Diastolic Dysfunction .............................................. 11	  
1.4.2	   Invasive Assessment of RV Diastolic Dysfunction ...................................................... 13	  
1.5	   FACTORS AFFECTING RV DIASTOLIC DYSFUNCTION ............................................... 16	  
1.5.1	   Coronary Flow Reserve .............................................................................................. 16	  
1.5.2	   Ventricular Interdependence ....................................................................................... 17	  
1.5.3	   Ventriculoarterial Coupling .......................................................................................... 19	  
 Page vii 
1.6	   TRANSLATING SUNAGAWA’S THEORY OF VENTRICULOARTERIAL COUPLING TO THE 
RV 21	  
1.7	   SUMMARY .............................................................................................................. 36	  
2	   MATERIALS AND METHODS ................................................................................ 38	  
2.1	   INTRODUCTION ....................................................................................................... 38	  
2.2	   RESEARCH GOVERNANCE ...................................................................................... 39	  
2.2.1	   Statistical Power ......................................................................................................... 39	  
2.2.2	   Statistical Analysis ...................................................................................................... 39	  
2.2.3	   Governance for Animal Studies .................................................................................. 40	  
2.2.4	   Governance for Human Studies ................................................................................. 40	  
2.2.5	   Conduct of Work ......................................................................................................... 41	  
2.3	   CONDUCTANCE THEORY ........................................................................................ 43	  
2.3.1	   The Millar Conductance Catheter ............................................................................... 45	  
2.3.2	   Calibration Factors ...................................................................................................... 47	  
2.3.3	   The PV-Loop ............................................................................................................... 52	  
2.4	   PV-LOOP DATA ACQUISITION ................................................................................. 57	  
2.4.1	   Millar MPVS Ultra ........................................................................................................ 57	  
2.4.2	   Millar MPVS Ultra Control Interface ............................................................................ 60	  
2.4.3	   ADInstruments PowerLab 16/30 Series ...................................................................... 69	  
2.4.4	   ADInstruments LabChart Pro Software ....................................................................... 71	  
2.5	   PV-LOOP DATA ANALYSIS ..................................................................................... 80	  
2.5.1	   Steady State PV-Loop Analysis .................................................................................. 80	  
2.5.2	   Load Independent PV Loop Analysis .......................................................................... 86	  
2.6	   DETERMINATION OF CARDIAC OUTPUT ................................................................... 90	  
2.6.1	   Thermodilution ............................................................................................................ 91	  
2.6.2	   Fick Principle ............................................................................................................... 91	  
2.7	   ECHOCARDIOGRAPHIC ASSESSMENT ...................................................................... 93	  
2.7.1	   Ultrasound Machines .................................................................................................. 93	  
2.7.2	   Aortic Valve Assessment ............................................................................................ 93	  
2.7.3	   RV Functional Assessment ......................................................................................... 95	  
 Page viii 
2.8	   ELECTRICAL SAFETY ............................................................................................. 96	  
2.9	   SUMMARY .............................................................................................................. 96	  
3	   THE DEVELOPMENT OF AN PORCINE MODEL OF RIGHT 
VENTRICULOARTERIAL COUPLING ......................................................................... 97	  
3.1	   AN EX-VIVO MODEL OF LEFT VENTRICULOARTERIAL INTERACTION: VALIDATION OF 
SUNAGAWA’S MODEL ..................................................................................................... 98	  
3.1.1	   Introduction ................................................................................................................. 98	  
3.1.2	   Methods ...................................................................................................................... 98	  
3.1.3	   Results ...................................................................................................................... 111	  
3.1.4	   Discussion ................................................................................................................. 122	  
3.2	   AN EX-VIVO MODEL OF RIGHT VENTRICULOARTERIAL INTERACTION ..................... 124	  
3.2.1	   Introduction ............................................................................................................... 124	  
3.2.2	   Methods .................................................................................................................... 124	  
3.2.3	   Results ...................................................................................................................... 132	  
3.2.4	   Discussion ................................................................................................................. 137	  
3.3	   AN IN-VIVO MODEL OF RIGHT VENTRICULOARTERIAL INTERACTION ...................... 140	  
3.3.1	   Introduction ............................................................................................................... 140	  
3.3.2	   Methods .................................................................................................................... 140	  
3.3.3	   Results ...................................................................................................................... 144	  
3.3.4	   Discussion ................................................................................................................. 156	  
3.4	   SUMMARY ............................................................................................................ 158	  
4	   THE DETERMINATION OF MAXIMAL EFFICIENCY AND SW FROM AN IN-VIVO 
PORCINE MODEL OF RIGHT VENTRICULOARTERIAL COUPLING ..................... 159	  
4.1	   INTRODUCTION ..................................................................................................... 159	  
4.2	   METHODS ............................................................................................................ 159	  
4.2.1	   Surgical Preparation ................................................................................................. 159	  
4.2.2	   RV Functional Assessment of the Open-Chested Porcine Heart ............................. 159	  
4.2.3	   Statistical Analysis .................................................................................................... 161	  
4.3	   RESULTS ............................................................................................................. 161	  
 Page ix 
4.3.1	   Demographics ........................................................................................................... 161	  
4.3.2	   Stroke Work, Efficiency and the Pressure-Volume Relationship .............................. 163	  
4.3.3	   Relations between Afterload Quantified by Ea and RV Function ............................. 168	  
4.3.4	   Relations between Ventriculoarterial Coupling Quantified by Ees/Ea and RV Function
 171	  
4.4	   DISCUSSION ......................................................................................................... 174	  
4.5	   SUMMARY ............................................................................................................ 176	  
5	   VENTRICULAR REMODELLING IN PATIENTS WITH CHRONIC 
THROMBOEMBOLIC PULMONARY VASCULAR DISEASE AND HYPERTENSION: 
UNLOCKING PATHOLOGY THROUGH VENTRICULOARTERIAL INTERACTION178	  
5.1	   INTRODUCTION ..................................................................................................... 178	  
5.2	   METHODS ............................................................................................................ 180	  
5.2.1	   Patient Population ..................................................................................................... 180	  
5.2.2	   Catheterization .......................................................................................................... 180	  
5.2.3	   RV Functional Assessment ....................................................................................... 183	  
5.2.4	   Statistical Analysis .................................................................................................... 183	  
5.2.5	   Outcomes .................................................................................................................. 183	  
5.3	   RESULTS ............................................................................................................. 184	  
5.3.1	   Demographics, Right Heart Catheterisation and RV Haemodynamic Data after 
Classification of Patients by mPAP ....................................................................................... 184	  
5.3.2	   Demographics, Right Heart Catheterisation and RV Haemodynamic Data after 
Classification of Patients with CTED or CTEPH by the Ees/Ea Coupling Ratio at the 
Threshold for Maximal SW Determined from the Animal Model. .......................................... 188	  
5.3.3	   Demographics, Right Heart Catheterisation and RV Haemodynamic Data after 
Classification of Patients by Afterload as Quantified by Ea at the Threshold for Maximal SW 
Determined from the Animal Model. ...................................................................................... 192	  
5.4	   DISCUSSION ......................................................................................................... 197	  
5.5	   SUMMARY ............................................................................................................ 200	  
 Page x 
6	   VENTRICULAR REMODELLING POST CONTRALATERAL TRANSCATHETER 
AORTIC VALVE IMPLANTATION (TAVI): A VENTRICULAR INTERDEPENDENCE 
PARADOX .................................................................................................................. 201	  
6.1	   INTRODUCTION ..................................................................................................... 201	  
6.2	   METHODS ............................................................................................................ 205	  
6.2.1	   Patient Population ..................................................................................................... 205	  
6.2.2	   Study Protocol ........................................................................................................... 205	  
6.2.3	   Anaesthetic Protocol ................................................................................................. 207	  
6.2.4	   Pre-TAVI Cardiac Catheterization ............................................................................. 207	  
6.2.5	   Pressure Volume Loop Data Acquisition .................................................................. 209	  
6.2.6	   Echocardiographic Assessments .............................................................................. 209	  
6.2.7	   Rapid Pacing ............................................................................................................. 210	  
6.2.8	   TAVI implantation ...................................................................................................... 210	  
6.2.9	   Offline RV Hemodynamic Measurements ................................................................. 211	  
6.2.10	   Statistical Analysis .................................................................................................. 211	  
6.3	   RESULTS ............................................................................................................. 212	  
6.3.1	   Patient Characteristics .............................................................................................. 212	  
6.3.2	   Echocardiographic Assessment ................................................................................ 215	  
6.3.3	   RV Hemodynamic Assessment ................................................................................ 217	  
6.4	   DISCUSSION ......................................................................................................... 229	  
6.5	   SUMMARY ............................................................................................................ 233	  
7	   CONCLUSIONS AND FUTURE WORK ............................................................... 234	  
7.1	   ANIMAL MODEL ................................................................................................... 234	  
7.2	   RV REMODELLING IN PATIENTS WITH LONG TERM PRESSURE OVERLOAD ............. 235	  
7.3	   RV REMODELLING IN PATIENTS WITH AORTIC VALVE STENOSIS ............................ 235	  
7.4	   CONCLUSION SUMMARY ....................................................................................... 236	  
7.5	   FUTURE WORK .................................................................................................... 237	  
8	   REFERENCES ...................................................................................................... 238	  
 Page xi 
9	   APPENDICES ....................................................................................................... 262	  
9.1	   APPENDIX A – RELATIONS BETWEEN AFTERLOAD QUANTIFIED BY EA AND RV 
FUNCTION ..................................................................................................................... 262	  
9.2	   APPENDIX B – RELATIONS BETWEEN VENTRICULOARTERIAL COUPLING QUANTIFIED 
BY EES/EA AND RV FUNCTION ...................................................................................... 267	  
9.3	   APPENDIX C - BIBLIOGRAPHY OF PUBLISHED WORK ............................................. 272	  
9.3.1	   Published Work described in this Thesis .................................................................. 272	  
9.3.2	   Published Work not described in this Thesis ............................................................ 274	  
9.3.3	   Book Chapters .......................................................................................................... 278	  
 
  
 Page xii 
List of Figures 
FIGURE 1-1 THE CIRCULATORY SYSTEM, TAKEN FROM 
HTTP://WWW.FREERIDER.RO/WP-CONTENT/UPLOADS/2015/12/HEART-RATE.JPG .. 5	  
FIGURE 1-2 THE CARDIAC CYCLE, TAKEN FROM 
HTTP://WWW.SLIDESHARE.NET/PRAVEENNAGULA/CARDIAC-CYCLE-29216898 ....... 6	  
FIGURE 1-3 (A) PATHOLOGICAL SPECIMEN OF THE RV WITH THE FREE-WALL 
REMOVED TO SHOW THE THREE ANATOMICAL REGIONS. (B) PATHOLOGICAL 
SPECIMEN OF THE HEART CUT TRANSVERSELY TO SHOW THE CRESCENT SHAPE 
OF THE RV. TAKEN FROM WARNES (2009) ..................................................................... 9	  
FIGURE 1-4 THE NORMAL RV PV-LOOP DERIVED FROM THE CONDUCTANCE 
CATHETER TECHNIQUE. .................................................................................................. 15	  
FIGURE 1-5 THE FOUR MAJOR COMPONENTS OF THE CIRCULATORY SYSTEM IN A 
BILATERALLY COUPLED SYSTEM, TAKEN FROM SUNAGAWA ET AL. (1984) ........... 22	  
FIGURE 1-6 CHARACTERISING THE LEFT VENTRICULAR AND ARTERIAL SYSTEM IN 
TERMS OF END-SYSTOLIC PRESSURE TO STROKE VOLUME, THE INTERSECTING 
STROKE VOLUME REPRESENTS THE POINT WHERE THE VENTRICLE IS COUPLED 
TO THE ARTERIAL SYSTEM, TAKEN FROM SUNAGAWA ET AL. (1983) ...................... 24	  
FIGURE 1-7 THE GRAPHICAL REPRESENTATION OF LV VENTRICULOARTERIAL 
COUPLING TAKEN FROM SUNAGAWA ET AL. (1987) ................................................... 28	  
FIGURE 1-8 THE EFFECTS OF CHANGING (A) AFTERLOAD; (B) PRELOAD; AND (C) 
CONTRACTILITY ON THE LV VENTRICULOARTERIAL COUPLING PRESSURE 
VOLUME RELATIONSHIP AT (BLACK) BASELINE; (BLUE) REDUCED; AND (RED) 
INCREASED, TAKEN FROM SUNAGAWA ET AL. (1987) ................................................ 30	  
FIGURE 1-9 LV PRESSURE-VOLUME RELATIONSHIP. THE END-SYSTOLIC PRESSURE 
VOLUME RELATIONSHIP IS CHARACTERISED BY SLOPE EES AND VOLUME AXIS 
INTERCEPT V0. THE PRESSURE-VOLUME AREA (PVA) IS THE SUM OF EXTERNAL 
STROKE WORK (SW) AND POTENTIAL ENERGY (PE) TAKEN FROM BURKHOFF AND 
SAGAWA (1986) ................................................................................................................. 32	  
FIGURE 1-10 (TOP LEFT) THEORETICAL RELATION BETWEEN AFTERLOAD QUANTIFIED 
BY EFFECTIVE ARTERIAL ELASTANCE (EA) AND STROKE WORK; (BOTTOM LEFT) 
AND EFFICIENCY TAKEN FROM BURKHOFF AND SAGAWA (1986); (TOP RIGHT) 
 Page xiii 
EXPERIMENTAL RELATION BETWEEN AFTERLOAD QUANTIFIED BY EFFECTIVE 
ARTERIAL ELASTANCE (EA) AND STROKE WORK; (BOTTOM RIGHT) AND 
EFFICIENCY TAKEN FROM DE TOMBE ET AL. (1993) ................................................... 34	  
FIGURE 1-11 (TOP) THEORETICAL RELATION BETWEEN AFTERLOAD QUANTIFIED BY 
EFFECTIVE ARTERIAL ELASTANCE (EA) AND STROKE WORK TAKEN FROM 
BURKHOFF AND SAGAWA (1986). LV ENERGETIC RESERVE (GREEN) BELOW THE 
THRESHOLD FOR EA AT MAXIMAL STROKE WORK (EA MAX SW) AND LV FAILURE 
BEYOND THIS AFTERLOAD THRESHOLD. (BOTTOM) EXPERIMENTAL RELATION 
BETWEEN THE INVERSE LV VENTRICULOARTERIAL (EA/EES) COUPLING RATIO 
AND STROKE WORK TAKEN FROM DE TOMBE ET AL. (1993). LV ENERGETIC 
RESERVE (GREEN) BELOW THE THRESHOLD FOR EA/EES AT MAXIMAL STROKE 
WORK (EA/EES MAX SW) AND LV FAILURE BEYOND THIS INVERSE 
VENTRICULOARTERIAL COUPLING THRESHOLD. ....................................................... 35	  
FIGURE 2-1 (A) MILLAR (HOUSTON, TEXAS, USA) CONDUCTANCE CATHETER; (B) 
POSITIONED IN THE RIGHT VENTRICLE UNDER FLUOROSCOPIC GUIDANCE ........ 46	  
FIGURE 2-2 INCREASE IN RV VOLUME DURING A HYPERTONIC SALINE INJECTION ..... 49	  
FIGURE 2-3 (TOP) LOAD-INDEPENDENT FAMILY OF RV PV-LOOPS SHOWING ESPVR, 
EDPVR AND EA; (BOTTOM) PRSW EXAMPLE ................................................................ 54	  
FIGURE 2-4 (TOP) SINGLE BEAT ESTIMATION OF THE MAXIMAL ISOVOLUMIC 
PRESSURE (PMAX). THIS IS A SCREEN CAPTURE OF A PATIENT WITH CTED FROM 
CHAPTER 5. (BOTTOM) SINGLE BEAT ESTIMATION OF EES USING PMAX (THIS IS 
NOT TO SCALE). ................................................................................................................ 56	  
FIGURE 2-5 MILLAR (HOUSTON, TEXAS, USA) MPVS ULTRA FRONT PANEL HARDWARE 
CONNECTIONS .................................................................................................................. 59	  
FIGURE 2-6 MILLAR MPVS ULTRA CONTROL INTERFACE CATHETER CONFIGURATION 
TAB SCREEN CAPTURE ................................................................................................... 61	  
FIGURE 2-7 MILLAR MPVS ULTRA CONTROL INTERFACE CATHETER CALIBRATION TAB 
SCREEN CAPTURE ........................................................................................................... 63	  
FIGURE 2-8 MILLAR MPVS ULTRA CONTROL INTERFACE RHO CUVETTE TAB SCREEN 
CAPTURE ........................................................................................................................... 66	  
FIGURE 2-9 MILLAR (HOUSTON, TEXAS, USA) MPVS ULTRA CUVETTE ............................ 68	  
 Page xiv 
FIGURE 2-10 ADINSTRUMENTS (NEW SOUTH WALES, AUSTRALIA) POWERLAB 16/30 
FRONT PANEL HARDWARE CONNECTIONS ................................................................. 70	  
FIGURE 2-11 ADINSTRUMENTS LABCHART RV MEASUREMENT SETUP SCREEN 
CAPTURE ........................................................................................................................... 72	  
FIGURE 2-12 PRESSURE CHANNEL CALIBRATION SCREEN CAPTURE ............................ 75	  
FIGURE 2-13 VOLUME CHANNEL CALIBRATION SCREEN CAPTURE ................................. 77	  
FIGURE 2-14 LABCHART RV DATA SELECTION SCREEN CAPTURE .................................. 81	  
FIGURE 2-15 LABCHART CO CORRECTION SCREEN CAPTURE ........................................ 83	  
FIGURE 2-16 LABCHART SALINE CALIBRATION SCREEN S CAPTURE .............................. 85	  
FIGURE 2-17 LABCHART PV-LOOP VIEW SCREEN CAPTURE ............................................. 87	  
FIGURE 2-18 LABCHART PRSW PLOT SCREEN CAPTURE .................................................. 89	  
FIGURE 3-1 CONCEPT DESIGN FOR THE LV WORKING HEART PERFUSION RIG .......... 100	  
FIGURE 3-2 TRANSMEDICS (ANDOVER, MA, USA) ORGAN CARE SYSTEM (OCS) ......... 102	  
FIGURE 3-3 MODIFIED TRANSMEDICS (ANDOVER, MA, USA) OCS IN LV WORKING 
HEART MODE .................................................................................................................. 104	  
FIGURE 3-4 MODIFIED TRANSMEDICS (ANDOVER, MA, USA) OCS PRIMED WITH BLOOD
 .......................................................................................................................................... 107	  
FIGURE 3-5 MODIFIED TRANSMEDICS (ANDOVER, MA, USA) OCS IN WORKING HEART 
MODE AND FUNCTIONAL ASSESSMENT WITH PV-LOOPS ........................................ 110	  
FIGURE 3-6 A FAMILY OF PV-LOOPS RECORDED DURING A PRELOAD REDUCTION ... 114	  
FIGURE 3-7 A FAMILY OF PV-LOOPS RECORDED DURING AN INCREASING AFTERLOAD
 .......................................................................................................................................... 117	  
FIGURE 3-8 STEADY-STATE LV PV-LOOPS AT BASELINE (BLUE) AND AFTER 5 
ΜG/KG/MIN DOPAMINE (RED) ....................................................................................... 120	  
FIGURE 3-9 SCHEMATIC OF THE RV WORKING HEART PERFUSION RIG ....................... 125	  
FIGURE 3-10 IN-HOUSE ISOLATED RV WORKING HEART PERFUSION RIG .................... 127	  
FIGURE 3-11 PORCINE HEART INSTRUMENTED ON THE RV WORKING HEART RIG IN 
LANGENDORFF PERFUSION ......................................................................................... 129	  
FIGURE 3-12 RV WORKING HEART MODE WITH FUNCTIONAL ASSESSMENT WITH PV-
LOOPS .............................................................................................................................. 131	  
FIGURE 3-13 STEADY-STATE RV PV-LOOPS AT DURING A 10 ΜG/KG/MIN DOPAMINE 
INFUSION ......................................................................................................................... 135	  
 Page xv 
FIGURE 3-14 IN-VIVO OPEN-CHESTED PORCINE HEART INSTRUMENTED WITH THE 
CONDUCTANCE CATHETER (A) WITH PA SNARE RELEASED (B) WITH PA SNARE 
PARTIALLY OCCLUDED TO INCREASE THE AFTERLOAD ON THE RV ..................... 143	  
FIGURE 3-15 IN-VIVO PORCINE STEADY-STATE RV PV-LOOP ......................................... 146	  
FIGURE 3-16 A FAMILY OF PV-LOOPS RECORDED DURING AN IVC SNARE .................. 148	  
FIGURE 3-17 A FAMILY OF PV-LOOPS RECORDED DURING AN PA SNARE .................... 151	  
FIGURE 3-18 STEADY-STATE RV PV-LOOPS AT BASELINE (BLUE) AND AFTER 5 ΜG/KG 
/MIN DOPAMINE (RED) ................................................................................................... 154	  
FIGURE 4-1 SW-EA RV PV-LOOP RELATIONSHIP RECORDED DURING THE PA SNARE IN 
A SINGLE SUBJECT. RV ENERGETIC RESERVE IS HIGHLIGHTED IN THE GREEN-
HATCHED BOX (EA ≤ 0.5); RV FAILURE IS HIGHLIGHTED IN THE RED-HATCHED BOX 
(EA < 0.5). ......................................................................................................................... 160	  
FIGURE 4-2 RV PV-LOOPS RECORDED DURING A PA SNARE TO INCREASE 
AFTERLOAD. PV-LOOPS ARE HIGHLIGHTED AT BASELINE (BLUE); MAXIMAL 
EFFICIENCY (GREEN) AND MAXIMAL SW (RED) ......................................................... 164	  
FIGURE 4-3 ANIMAL MODEL RV HEMODYNAMIC DATA FOR (A) SW; (B) CO; (C) ESV; (D) 
SW/PVA; (E) EA; AND (F) ESP AT BASELINE (BL) AND THE PA OCCLUSION TIME 
POINT FOR MAXIMAL EFFICIENCY (MAX EFF), MAXIMAL SW (MAX SW) AND 
MAXIMAL PA OCCLUSION (MAX OCC). * P < 0.05; ** P < 0.01; *** P < 0.001. ............. 167	  
FIGURE 4-4 ANIMAL MODEL RELATION BETWEEN AFTERLOAD QUANTIFIED BY EA AND 
A) SW; B) SW/PVA; AND C) CO. POOLED DATA FROM 18 HEARTS ARE SHOWN 
(N=324). MEAN REGRESSION LINES WITH 95% PREDICTION INTERVALS ARE 
DISPLAYED. ..................................................................................................................... 169	  
FIGURE 4-5 OPTIMUM EA FOR MAXIMAL SW VS. MAXIMAL EFFICIENCY DETERMINED 
FROM THE 18 PORCINE SUBJECTS. DOTTED LINE – SHOWS LINE OF IDENTITY. 170	  
FIGURE 4-6 RELATION BETWEEN THE VENTRICULOARTERIAL COUPLING RATIO 
(EES/EA) AND A) SW; B) SW/PVA (SW/PVA); C) CO. .................................................... 172	  
FIGURE 4-7 OPTIMUM EES/EA COUPLING RATIOS FOR MAXIMAL SW VS. MAXIMAL 
EFFICIENCY DETERMINED FROM THE 18 PORCINE SUBJECTS. DOTTED LINE – 
SHOWS LINE OF IDENTITY. ........................................................................................... 173	  
FIGURE 5-1 CONDUCTANCE CATHETER POSITIONED IN THE RV UNDER 
FLUOROSCOPIC GUIDANCE ......................................................................................... 182	  
 Page xvi 
FIGURE 5-2 TYPICAL RV PV-LOOP MORPHOLOGIES FOR PATIENTS WITH CTED (BLUE) 
AND CTEPH (RED) .......................................................................................................... 187	  
FIGURE 5-3 THE INDIVIDUAL DATA POINTS FOR THE PATIENTS WITH CTED OR CTEPH 
OVERLAID ON TOP OF THE MEAN REGRESSION LINES DETERMINED FROM THE 
ANIMAL MODEL FOR THE RELATION BETWEEN VENTRICULOARTERIAL COUPLING 
RATIO (EES/EA) AND A) SW; B) SW/PVA; AND C) CO. ................................................ 191	  
FIGURE 5-4 THE INDIVIDUAL DATA POINTS FOR THE PATIENTS WITH CTED OR CTEPH 
OVERLAID ON TOP OF THE MEAN REGRESSION LINES DETERMINED FROM THE 
ANIMAL MODEL FOR THE RELATION BETWEEN AFTERLOAD QUANTIFIED BY EA 
AND A) SW; B) SW/PVA; AND C) CO. ............................................................................. 195	  
FIGURE 5-5 THE INDIVIDUAL DATA POINTS FOR THE PATIENTS WITH CTED OR CTEPH 
TO COMPARE EES/EA WITH EA. PATIENTS WITH RV ENERGETIC RESERVE ARE 
HIGHLIGHTED IN THE GREEN-HATCHED BOX (EES/EA ≥ 0.68 AND EA ≤ 0.5); 
PATIENTS WITH RV FAILURE ARE HIGHLIGHTED IN THE RED-HATCHED BOX 
(EES/EA < 0.68 AND EA < 0.5). ....................................................................................... 196	  
FIGURE 6-1 EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE TAKEN FROM 
HTTP://WWW.EDWARDS.COM/EU/PRODUCTS/TRANSCATHETERVALVES/PAGES/SA
PIEN3.ASPX?WT.AC=S3CAMPAIGNPROD (ACCESSED 30.01.2016) ......................... 204	  
FIGURE 6-2 FLOWCHART ILLUSTRATING THE STUDY PROTOCOL AND TIMELINE ....... 206	  
FIGURE 6-3 (TOP) FLUOROSCOPIC IMAGE OF PRELOAD REDUCTION BY IVC BALLOON 
OCCLUSION AND RV PV-LOOP ACQUISITION WITH A CONDUCTANCE CATHETER 
(BOTTOM) FLUOROSCOPIC IMAGE OF A CONDUCTANCE CATHETER LOCATED IN 
THE RV DURING SAPIEN XT VALVE DEPLOYMENT. ................................................... 208	  
FIGURE 6-4 COMPARISONS OF RV DIASTOLIC FUNCTION (LEFT) TAU AND (RIGHT) EDP 
AT BASELINE (PRE-TAVI – BLUE) AFTER RAPID PACING TEST CAPTURE (RPTC – 
BLACK) AND AFTER VALVE DEPLOYMENT (POST-TAVI - RED). ** P < 0.01, *** P < 
0.001. ................................................................................................................................ 220	  
FIGURE 6-5 FAMILIES OF RV PV-LOOPS RECORDED AT BASELINE (PRE-TAVI - BLUE) 
AND AFTER VALVE DEPLOYMENT (POST-TAVI - RED) DURING PRELOAD 
REDUCTION WITH IVC BALLOON OCCLUSION TO DETERMINE EES AND EDPVR . 221	  
FIGURE 6-6 COMPARISONS OF DIASTOLIC FUNCTION (TOP LEFT) TIME CONSTANT OF 
ISOVOLUMIC RELAXATION – TAU, (BOTTOM LEFT) END-DIASTOLIC PRESSURE – 
 Page xvii 
EDP, AND SYSTOLIC FUNCTION (TOP RIGHT) MAXIMAL RATE OF ISOVOLUMIC 
CONTRACTION – DP/DT MAX, (BOTTOM RIGHT) STOKE WORK – SW, NORMALISED 
TO PRE-TAVI VALUES AT BASELINE (PRE-TAVI), DURING VALVE DEPLOYMENT (VD) 
AT 1, 2, 3 MINS POST VALVE DEPLOYMENT AND LATE (MEDIAN 17 MIN: IQR 12 TO 
23) AFTER VALVE DEPLOYMENT (POST-TAVI). MEAN ± SEM. .................................. 223	  
FIGURE 6-7 COMPARISONS BETWEEN GA SUB-GROUP (BLUE) AND CS SUB-GROUP 
(RED) FOR: (A) TAU, (B) EDP, (C) DP/DT MAX, (D) PRSW, (E) EES/EA NORMALISED 
TO PRE-TAVI VALUES, AND (F) NUMBER OF RP BEATS AFTER RPTC AND POST-
TAVI. MEAN ± SEM. ......................................................................................................... 225	  
FIGURE 6-8 COMPARISONS OF PACING BURDEN AND DIASTOLIC FUNCTION FOR (A) 
TAU AND (B) EDP DISPLAYED FOR THOSE WITH BASELINE NORMAL RV FUNCTION 
(BLUE) AND RV DYSFUNCTION (RED). ......................................................................... 226	  
FIGURE 6-9 COMPARISON OF THE EFFECT OF RP ON SUBGROUPS WITH PRE-
EXISTING RV DYSFUNCTION AND DIASTOLIC FUNCTION (A) TAU, (B) EDP, AT 
BASELINE (PRE-TAVI), AFTER THE PACING CHECK (POST-RPTC) AND LATE AFTER 
THE VALVE WAS DEPLOYED (POST-TAVI). COMPARISONS OF PRE-EXISTING 
PULMONARY HYPERTENSION AND DIASTOLIC FUNCTION (C) TAU, (D) EDP, AT 
BASELINE (PRE-TAVI), AFTER THE PACING CHECK (POST-RPTC) AND LATE AFTER 
THE VALVE WAS DEPLOYED (POST-TAVI). P-VALUES ARE DISPLAYED BETWEEN 
GROUPS. .......................................................................................................................... 228	  
FIGURE 9-1 (TOP) RELATION BETWEEN AFTERLOAD QUANTIFIED BY EFFECTIVE 
ARTERIAL ELASTANCE (EA) AND END-SYSTOLIC VOLUME; (BOTTOM) AND END-
DIASTOLIC VOLUME. ...................................................................................................... 262	  
FIGURE 9-2 (TOP) RELATION BETWEEN AFTERLOAD QUANTIFIED BY EFFECTIVE 
ARTERIAL ELASTANCE (EA) AND END-SYSTOLIC PRESSURE; (BOTTOM) AND END-
DIASTOLIC PRESSURE. ................................................................................................. 263	  
FIGURE 9-3 (TOP) RELATION BETWEEN AFTERLOAD QUANTIFIED BY EFFECTIVE 
ARTERIAL ELASTANCE (EA) AND MAXIMUM RATE OF ISOVOLUMIC CONTRACTION; 
(BOTTOM) AND MAXIMUM RATE OF ISOVOLUMIC RELAXATION. ............................ 264	  
FIGURE 9-4 (TOP) RELATION BETWEEN AFTERLOAD QUANTIFIED BY EFFECTIVE 
ARTERIAL ELASTANCE (EA) AND EJECTION FRACTION; (BOTTOM) AND STROKE 
VOLUME. .......................................................................................................................... 265	  
 Page xviii 
FIGURE 9-5 RELATION BETWEEN AFTERLOAD QUANTIFIED BY EFFECTIVE ARTERIAL 
ELASTANCE (EA) AND THE TIME CONSTANT OF DIASTOLIC RELAXATION (TAU). 266	  
FIGURE 9-6 (TOP) RELATION BETWEEN THE VENTRICULOARTERIAL COUPLING RATIO 
(EES/EA) AND END-SYSTOLIC VOLUME; (BOTTOM) AND END-DIASTOLIC VOLUME.
 .......................................................................................................................................... 267	  
FIGURE 9-7 (TOP) RELATION BETWEEN THE VENTRICULOARTERIAL COUPLING RATIO 
(EES/EA) AND END-SYSTOLIC PRESSURE; (BOTTOM) AND END-DIASTOLIC 
PRESSURE. ..................................................................................................................... 268	  
FIGURE 9-8 (TOP) RELATION BETWEEN THE VENTRICULOARTERIAL COUPLING RATIO 
(EES/EA) AND MAXIMUM RATE OF ISOVOLUMIC CONTRACTION; (BOTTOM) AND 
MAXIMUM RATE OF ISOVOLUMIC RELAXATION. ........................................................ 269	  
FIGURE 9-9 (TOP) RELATION BETWEEN THE VENTRICULOARTERIAL COUPLING RATIO 
(EES/EA) AND EJECTION FRACTION; (BOTTOM) AND STROKE VOLUME. ............... 270	  
FIGURE 9-10 RELATION BETWEEN THE VENTRICULOARTERIAL COUPLING RATIO 
(EES/EA) AND THE TIME CONSTANT OF DIASTOLIC RELAXATION. ......................... 271	  
 
  
 Page xix 
List of Tables 
TABLE 2-1 ADINSTRUMENTS LABCHART RV CHANNEL DESCRIPTION ............................. 73	  
TABLE 3-1 DEMOGRAPHIC DATA .......................................................................................... 112	  
TABLE 3-2 LV HAEMODYNAMIC DATA FOR EACH PV-LOOP DURING A PRELOAD 
REDUCTION ..................................................................................................................... 115	  
TABLE 3-3 LV HAEMODYNAMIC DATA FOR EACH PV-LOOP DURING AN AFTERLOAD 
INCREASE ........................................................................................................................ 118	  
TABLE 3-4 LV HAEMODYNAMIC DATA AT BASELINE AND AFTER A DOPAMINE INFUSION 
TO INCREASE CONTRACTILITY .................................................................................... 121	  
TABLE 3-5 DEMOGRAPHIC DATA .......................................................................................... 133	  
TABLE 3-6 RV PV-LOOP DATA ............................................................................................... 136	  
TABLE 3-7 IN-VIVO PORCINE DEMOGRAPHIC DATA .......................................................... 145	  
TABLE 3-8 RV HAEMODYNAMIC DATA FOR EACH PV-LOOP DURING AN IVC SNARE ... 149	  
TABLE 3-9 RV HAEMODYNAMIC DATA FOR EACH PV-LOOP DURING AN PA SNARE .... 152	  
TABLE 3-10 RV PV-LOOP DATA ............................................................................................. 155	  
TABLE 4-1 IN-VIVO PORCINE DEMOGRAPHIC DATA .......................................................... 162	  
TABLE 4-2 ANIMAL MODEL RV HEMODYNAMIC DATA AT BASELINE, MAXIMAL 
EFFICIENCY, MAXIMAL SW AND DURING THE MAXIMAL OCCLUSION .................... 166	  
TABLE 5-1 DEMOGRAPHICS, RIGHT HEART CATHETERISATION AND RV HEMODYNAMIC 
DATA AFTER CLASSIFICATION OF PATIENTS BY MPAP AT REST. .......................... 185	  
TABLE 5-2 DEMOGRAPHICS, RIGHT HEART CATHETERISATION AND RV HEMODYNAMIC 
DATA AFTER CLASSIFICATION OF PATIENTS WITH CTED OR CTEPH BY THE 
EES/EA COUPLING RATIO AT THE THRESHOLD FOR MAXIMAL SW. ....................... 189	  
TABLE 5-3 DEMOGRAPHICS, RIGHT HEART CATHETERISATION AND RV HEMODYNAMIC 
DATA AFTER CLASSIFICATION OF PATIENTS WITH CTED OR CTEPH BY 
AFTERLOAD AS QUANTIFIED BY EA AT THE THRESHOLD FOR MAXIMAL SW. ...... 193	  
TABLE 6-1 PATIENT DEMOGRAPHIC DATA .......................................................................... 213	  
TABLE 6-2 ECHOCARDIOGRAPHIC DATA ............................................................................ 216	  
TABLE 6-3 RV HEMODYNAMIC DATA .................................................................................... 218	  
 
 Page xx 
Notation 
CI  Cardiac Index 
CO Cardiac Output 
CTEPH  Chronic Thromboembolic Pulmonary Hypertension 
CTED Chronic Thromboembolic Disease 
dP/dt max Maximal Rate of Isovolumic Contraction 
dP/dt min Maximal Rate of Isovolumic Relaxation 
Ea Effective Arterial Elastance 
Echo Echocardiography 
EDP End-Diastolic Pressure 
EDPVR End-Diastolic Pressure Volume Relationship 
ESPVR End-Systolic Pressure Volume Relationship 
EDV End-Diastolic Volume 
Ees  End-Systolic Elastance 
ESV End-Systolic Volume 
LV Left Ventricle 
MAP Mean Arterial Pressure 
mPAP Mean Pulmonary Artery Pressure 
PCWP  Pulmonary Capillary Wedge Pressure 
PH Pulmonary Hypertension 
PRSW Preload Recruitable Stroke Work 
PV-loop Pressure-Volume Loop 
PVR Pulmonary Vascular Resistance 
RA  Right Atrium 
RHC Right Heart Catheterisation  
RV Right Ventricle 
TAPSE Tricuspid Annular Plane Systolic Excursion 
TAVI Transcatheter Aortic Valve Implantation 
TDIs Tissue Doppler Imaging  
 Page xxi 
List of Appendices 
APPENDIX A - RELATIONS BETWEEN AFTERLOAD QUANTIFIED BY EA AND RV 
FUNCTION…………………………………………………………………………..262 
APPENDIX B - RELATIONS BETWEEN VENTRICULOARTERIAL COUPLING 
QUANTIFIED BY EES/EA AND RV FUNCTION……………………………………..267 
APPENDIX C – BIBLIOGRAPHY OF PUBLISHED WORKS………………………….272 
 
 Page 1 
Aims of Thesis 
The aims of this thesis were to determine whether: 
• A ventriculoarterial coupling mismatch causes right ventricular diastolic 
dysfunction 
• A porcine model of right ventricular – pulmonary artery ventriculoarterial 
coupling can determine the optimal coupling ratio at maximal stroke work 
• A ventriculoarterial coupling mismatch causes right ventricular diastolic 
dysfunction in patients with pulmonary hypertension 
• Patients with aortic stenosis undergoing transcatheter aortic valve implantation 
have improved right ventricular diastolic function after left ventricular afterload 
reduction following valve implantation; due to ventricular interdependence 
phenomena leading to changes in left ventricular – right ventricular interaction 
through septal wall reconfiguration 
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1 A Theory of RV-PA Ventriculoarterial Coupling and RV 
Diastolic Dysfunction 
1.1 Introduction 
William Harvey is considered the father of modern cardiac physiology after he first 
deduced the existence of blood recirculation and experimentally demonstrated 
pulmonary blood flow (Comtor, 1982) in his monograph titled “Du Motu Cordis” 
published in 1628. While the importance of the left ventricle (LV) has long been 
accepted; the importance of the right ventricle (RV) in cardiac function has been 
debated greatly over the last 400 years. Starr et al. (1943) reported as late as the mid-
twentieth century that the RV had no greater purpose other than to provide a capacitive 
reservoir to the pulmonary circulation. In more recent times RV function, or more 
specifically diastolic RV function, has been accepted as an important indicator in the 
assessment of ventricular dysfunction in heart failure (Riggs, 1993).  
The phenomenon of RV diastolic dysfunction was first described in 1993 by Riggs 
(1993) and abnormalities in RV diastolic function underlie many pathologies (Cicala et 
al., 2002; Dourvas et al., 2004; Florea et al., 2000; Chakko et al., 1990; Habib and 
Zoghbi, 1992). However, the underlying mechanisms and precise role of RV diastolic 
dysfunction in heart failure remain poorly described and are compounded by imprecise 
definitions of diastolic dysfunction; with the term being used to describe many variants 
in diastolic pathophysiology and function, such as changes in myocardial relaxation 
time (Caso et al., 2001), ventricular wall structure (Schwarz and Dashti, 2010), 
myocardial stiffening (Schwarz and Dashti, 2010), ventricular wall thickening (Schwarz 
and Dashti, 2010), and abnormal ventricular chamber geometry (Schwarz and Dashti, 
2010).  
Diastolic dysfunction is a mechanical irregularity in the intrinsic properties of the 
ventricular muscle function during diastole (Van Herck et al., 2005). However, this 
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could be directly or indirectly related to changes in arterial distensibility; attributable to 
changes in coronary flow; a passive change in ventricular compliance; or a dynamic 
change in ventricular relaxation. RV diastolic dysfunction can be caused by any 
combination of abnormalities in RV distensibility (Chin and Coghlan, 2012), RV 
relaxation (Chin and Coghlan, 2012), pericardial constraint (Chin and Coghlan, 2012), 
and LV distension (Chin and Coghlan, 2012). RV compliance is dependent on 
myocardial elasticity (Wauthy et al., 2004), end-diastolic volume (Moon et al., 1997) 
and right coronary artery pressure (Moon et al., 1997). An increase in RV pressure 
causes increased RV wall stress and dilatation of the ventricle which flattens the inter-
ventricular septum (Guazzi et al., 2012). This shift in septal wall position causes the RV 
to become more spherical in structure and impairs LV function. Abnormalities in LV 
pressure and end-diastolic volume affect RV diastolic function by limiting RV volume 
(Chin et al., 2008; Zeng et al., 2011). 
Recent work has postulated that RV- pulmonary artery (PA) ventriculoarterial coupling 
may offer insight into the transition from RV adaptation to RV maladaptation (Kuehne 
et al., 2004). Simplistically, RV-PA ventriculoarterial coupling is a matching between 
RV contractility and afterload (Sunagawa et al., 1984). This can be used to interpreted 
RV function and RV adaptation to afterload.  
The work set out in this thesis aims to address whether ventriculoarterial coupling 
derived from the conductance technique can be used to unlock the mechanisms of RV 
diastolic function and give clinical insight into the role of RV diastolic dysfunction in 
different cardiopulmonary disorders and heart failure.  
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1.2 The Circulatory System 
The heart is a pump that propels blood around the body in conduit vessels (Figure 1-1). 
The heart is made up of four chambers: the upper chambers, or atria, receive the blood 
returning to the heart and transfer it to the lower chambers, ventricles, which then 
pump the blood from the heart. The two chambers on the right side send deoxygenated 
blood to the lungs (pulmonary circulation). The two chambers on the left side supply 
oxygenated blood through arteries to the rest of the body (systemic circulation). The 
ventricles contract during systole and relax during diastole. During early diastole 
isovolumic relaxation occurs, the pressure within the RV diminishes below pulmonary 
pressure, closing the pulmonary valve and opening the tricuspid valve. Rapid RV filling 
occurs at the end of isovolumic relaxation during the continued decline in RA pressure 
that began during isovolumic relaxation due to the suction mechanism caused by the 
pressure gradient across the RV-RA. The RA then actively contracts during the slow 
ventricular filling phase to contribute the final 20% of ventricular filling. At the start of 
isovolumic RV contraction ventricular pressure increases, exceeding RA pressure and 
causing the tricuspid valve to close. The pressure within the RV continues to increase 
until it exceeds the pulmonary pressure, forcing the pulmonary valve to reopen and 
blood to flow into the pulmonary artery. The blood continues to flow into the PA until 
the pressure in the RV falls below pulmonary pressure again and the cycle is repeated 
(Figure 1-2). 
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Figure 1-1 The circulatory system, taken from http://www.freerider.ro/wp-
content/uploads/2015/12/heart-rate.jpg 
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Figure 1-2 The cardiac cycle, taken from http://www.slideshare.net/PraveenNagula/cardiac-cycle-
29216898 
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The primary purpose of the RV and pulmonary circulation is to deliver blood to the 
lungs for gaseous exchange. The pulmonary artery (PA) is a thin elastic vessel that 
branches out to support numerous lobar pulmonary arteries, pulmonary arterioles and 
alveolar capillaries. Since the gaseous exchange happens within thin, permeable 
alveolar membranes, pulmonary pressures must remain low to prevent pulmonary 
oedema (abnormal build-up of fluid in the lungs) (Homik et al., 1988).  Since the 
pulmonary circulatory system is in series with the systemic circulatory system, the 
entire cardiac output (CO) has to pass through the lungs. Therefore, the demand on 
the RV is considerably different to that in the LV. Not only must the RV deliver a low 
pressure, high volume pulmonary circulatory system, it has to be able to buffer 
energetic changes in pressure, volume and flow rates due to changes in cardiac 
output, respiration and LV haemodynamics.  
In routine clinical care, pulmonary vascular resistance (PVR) is used to determine the 
afterload experienced by the RV. PVR is defined as the resistance in the pulmonary 
vascular bed against which the RV must eject blood. However, PVR is predominately 
determined from the small vessel resistance or physical obstruction of the larger 
pulmonary vessels and ignores the pulsatile nature of both pressure and flow. PVR can 
be determined using the equation:  
Equation 1-1 
𝑃𝑉𝑅 =    𝑚𝑃𝐴𝑃 − 𝐿𝐴𝑃 ×  80𝐶𝑂  
Where 𝑚𝑃𝐴𝑃 is the mean PA pressure, 𝐿𝐴𝑃 is the left atrial pressure and 𝐶𝑂 is the 
cardiac output. While the pulsatile nature of PA load is low in health, the pulsatile load 
may be amplified in different disease states such as pulmonary embolism (Castelain et 
al., 2001) and septic shock (Lambermont et al., 1999). In this way, full characterization 
of the resistance to blood flow in the pulmonary circulation can only be determined 
from combined parameter models such as the windkessel model (Grant and 
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Paradowski, 1987), which encompass all three major components: PVR; pulmonary 
artery compliance; and dynamic inductance. Compliance describes the elastic 
properties of the vessel, defined as the ratio of volume to pressure change. These 
elastic vessel properties buffer blood flow during RV ejection, which helps to reduce 
the overall pulmonary artery pressure exposed to the distal vasculature. Inductance 
describes the dynamic response of the vessel as it adapts to changes in the blood flow 
through the vessel due to the relative mass and inertia of the blood.  
In this thesis, the conductance technique will be used to confirm effective arterial 
elastance (Ea), defined as the ratio of end-systolic pressure to stroke volume, as a 
combined parameter model of pulmonary afterload. This has been well characterised in 
experimental models of the systemic (Sunagawa et al., 1983) and pulmonary 
(Morimont et al., 2008) circulation.  
1.3 The Right Ventricle  
The normal RV is a complex geometrical shape (Dell'Italia, 1991). The RV is described 
in terms of three anatomical components (Figure 1-3A): an inlet made up of the 
tricuspid valve, chordae tendineae and papillary muscles; a coarse trabeculae 
myocardium; and an outflow tract or conus extending from the pulmonary valve (Goor 
and Lillehei, 1975; Ho and Nihoyannopoulos, 2006). The normal RV free wall contracts 
in a peristaltic movement, starting at the base and apex and finishing at the outflow 
tract (Dell'Italia, 1991). There is a delay of approximately 25 – 50 ms between the start 
of the contraction at the inflow to outflow tract regions (Dell'Italia, 1991) and the outflow 
tract remains contracted longer. The RV muscle fibres predominantly shorten in the 
long axis during contraction, a small inward motion of the free wall ejects the same 
stroke volume as the LV.  
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Figure 1-3 (A) Pathological specimen of the RV with the free-wall removed to show the three 
anatomical regions. (B) Pathological specimen of the heart cut transversely to show the crescent 
shape of the RV. Taken from Warnes (2009) 
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In contrast to the LV that couples with the systemic circulation, the RV is coupled to the 
pulmonary circulation, which under normal loading conditions has a lower vascular 
resistance and higher arterial distensibility (Dell'Italia, 1991). Therefore, in health the 
RV pressures are much lower than LV pressures (Zipes and Braunwald, 2005); the RV 
chamber remains concave towards the LV during both systole and diastole (Figure 
1-3B); and the RV has a thin ventricular free wall that has a muscle mass 
approximately one-sixth of the LV (Dell'Italia, 1991). Connections between the muscle 
fibres of the RV and LV tether the ventricles together through the inter-ventricular 
septum. Septal wall reconfiguration, along with the effect of the pericardium causing 
pericardial constraint (which in health contributes 70% of RV diastolic function), has an 
impact on the diastolic phenomenon known as ventricular independence (Dell'Italia, 
1991; Brookes et al., 1998). The size, shape and compliance of one ventricle can 
directly affect the size, shape and haemodynamic function of the contralateral ventricle 
(Santamore and Dell'Italia, 1998a), caused by ventricular-ventricular interactions, 
through septal wall motion reconfiguration assuming minimal free wall motion caused 
by pericardial constraint. The muscle fibres of the RV free wall are orientated 
transversely and squeeze the blood within the ventricle in a circumferential 
compression motion (Saleh et al., 2006). The inter-ventricular septum is formed of an 
ascending and descending apical loop of obliquely orientated muscle fibres (Torrent-
Guasp et al., 2001), which continue to form the LV free wall. Therefore, the higher LV 
pressures and oblique orientation of the septal muscle fibres means the septal twist 
and shortening during contraction accounts for a significant proportion of the RV 
ejection force during systole.  
1.4 The Assessment of RV Diastolic Dysfunction 
The detailed assessment of the RV contractile performance is challenging due to the 
complex geometric shape of the RV structure. Since the pulmonary circulation is 
fundamentally different to the systemic circulation, the contractile performance of the 
better characterised LV is not transferrable to the RV (Bellofiore and Chesler, 2013). 
 Page 11 
Clinical RV diastolic dysfunction can be assessed non-invasively using imaging 
techniques such as Echocardiography (Chakko et al., 1990; Zimbarra Cabrita et al., 
2013) and Cardiac Magnetic Resonance (CMR) (Kilner, 2011; Kilner et al., 2010); and 
invasively using Radionuclide Angiography (Davlouros et al., 2006), Right Heart 
Catheterisation (RHC) (Kolb and Hassoun, 2012) and Conductance Catheterisation 
(McKay et al., 1984; McCabe et al., 2014). 
1.4.1 Non-Invasive Assessment of RV Diastolic Dysfunction 
1.4.1.1 Echocardiography 
Echocardiography is a non-invasive ultrasound assessment technique that can be 
used to assess RV function (Davlouros et al., 2006). Typically RV volume is assessed 
in comparison to the LV, described as either normal, mildly, moderately or severely 
enlarged (Warnes, 2009). The complex geometrical shape and trabeculated internal 
structure of the RV, combined with the long- and short-axis measurement techniques 
(Lai et al., 2008), mean the mathematical modelling assumptions that are needed to 
quantify LV volume and function from 2D echocardiography are based on geometric 
assumptions that do not translate to the RV (Warnes, 2009). The continued 
improvement of real-time 3D echocardiography allows volumes to be calculated which 
are comparable with the gold standard MRI-derived volumes (Leibundgut et al., 2010). 
However, limitations with defining the endocardial border of the thin walled RV means 
those volumes are typically smaller than those derived by MRI (Danton et al., 2003). 
2D echocardiography can be used to measure septal wall motion, with the LV 
eccentricity index (LVEI) being a measure of ventricular interdependence (Ryan et al., 
1985). The LVEI describes the geometrical relationship between the LV and RV (Ryan 
et al., 1985). The LVEI is calculated by dividing the distance between the inferior to the 
anterior free wall, by the distance between the septum to the lateral free wall (Ryan et 
al., 1985; Wilkins et al., 2005). An EI > 1 is considered abnormal and geometrically 
describes a D-Shaped LV (Wilkins et al., 2005). Spectral Doppler echocardiography 
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can be used to diagnose RV diastolic dysfunction by performing measurements on the 
flow across the tricuspid valve (Chakko et al., 1990). Characteristically two waves are 
seen on the spectral Doppler trace; the passive pre-load filling of the ventricle (E-
wave); and the active filling with atrial systole (A-wave). In the normal RV, the E-wave 
velocity is greater than the A-wave velocity. An E/A ratio < 1 is abnormal indicating 
slow filling and RV diastolic dysfunction. The E/A ratio can be termed pseudo-
normalized where the E/A ratio appears to be normal, however, by performing a 
Valsalva manoeuvre and repeating the measurements the irregular relaxation pattern 
can be unmasked. Tissue Doppler Imaging (TDI) can be used to measure the RV 
Isovolumic Relaxation Time (IVRT), a measure of diastolic function. The RV IVRT is 
the time interval between the closure of the pulmonary valve and the opening of the 
tricuspid valve. An RV IVRT >75ms is considered abnormal (Zimbarra Cabrita et al., 
2013). RV IVRT has been shown to correlate well with pulmonary arterial systolic 
pressure (Zimbarra Cabrita et al., 2013). Tricuspid annular plane systolic excursion 
(TAPSE) represents the distance of systolic excursion of the RV annular plane to the 
RV apex. It is obtained using M-Mode aligned through the triscupid lateral annulus in a 
four-chamber view and measuring the longitudinal displacement at systole. In the 
normal RV TAPSE should be greater than 15-20 mm (Jurcut et al., 2010), and has 
been shown to correlate well with isotopic RV ejection fraction (Kaul et al., 1984). RV 
fractional area change (FAC) expresses the percentage change in RV area between 
end-diastole and end-systole. It has been shown to have a good correlation with MRI-
derived RV ejection fraction (Morcos et al., 2009). The main limitation when calculating 
RV FAC is the need for good endocardial boarder delineation, which can be 
challenging in the trabeculated RV. All echocardiographic measures of RV function are 
load-dependant. Therefore, measurements made on different occasions can be difficult 
to correlate and interpret correctly.  
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1.4.1.2 Cardiac Magnetic Resonance Imaging 
Cardiac Magnetic Resonance (CMR) is considered the gold standard technique for 
non-invasively assessing RV mass, volume and ejection fraction (Kilner, 2011; Kilner et 
al., 2010); and has been shown to correlate well with disease severity (van Wolferen et 
al., 2007). However, coarse trabeculations and difficulties in defining the endocardial 
border can make this difficult (Niemann et al., 2007; Winter et al., 2008), leading to 
considerable inter- and intra-operator variability in the precision of the measurement of 
RV function (Sheehan et al., 2008). CMR also excludes patients with metallic 
implantable devices and has a relatively high cost when compared with other functional 
imaging assessment techniques (Babu-Narayan et al., 2005). Limits on the spatial 
resolution of the CMR image acquisition process means the images have to be 
processed offline and do not provide a beat-to-beat real-time assessment of RV size 
and function. Currently, novel applications only extend as far as calculating mean 
pressures (Reiter et al., 2008). 
1.4.2 Invasive Assessment of RV Diastolic Dysfunction 
1.4.2.1 Radionuclide Angiography 
Radionuclide Angiography was first developed over 50 years ago (Folse and 
Braunwald, 1962) and once considered as the gold standard technique for assessing 
RV function (Davlouros et al., 2006). Radionuclide Angiography has all but been 
replaced by newer non-invasive methods like echocardiography and CMR (Vogel et al., 
1997; Pignatelli et al., 2003; Samyn, 2004). This replacement of Radionuclide 
Angiography is mainly due to the invasive nature of the technique, the requirement of a 
potentially significant dose of ionising radiation and contrast agents (Davlouros et al., 
2006); and the fact it is not as accurate as the other non-invasive methods (Davlouros 
et al., 2006). 
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1.4.2.2 Right Heart Catheterisation 
Right Heart Catheterisation (RHC) remains the gold standard assessment technique 
for pulmonary and RV pressures (Kolb and Hassoun, 2012). An increased pressure in 
the RV is often associated with RV dilatation that causes the septum to shift towards 
the LV causing LV diastolic dysfunction. The RHC can measure load-dependent 
indices of RV function such as the time constant of diastolic relaxation (tau) (Weiss et 
al., 1976; Raff and Glantz, 1981; Matsubara et al., 1995) and the first derivative of RV 
Pressure (dP/dt min) (Bachman et al., 2013). Both are load-dependent, and cannot 
assess how the ventricle is coupled with the pulmonary vasculature. 
1.4.2.3 Conductance Catheterisation 
The Pressure-Volume (PV)-loop derived by a conductance catheter is a sensitive 
invasive measure of LV (Baan et al., 1984) and RV function (McKay et al., 1984). 
However, due to the cost of the equipment, invasive nature of the procedure and 
technical complexities in the measurement technique it is currently limited to a 
research setting. The significant clinical contribution of the conductance catheter to RV 
function is the real-time beat-to-beat assessment of simultaneous ventricular pressures 
and volumes. The RV PV-loop (Figure 1-4) can be interrogated to determine systolic 
and diastolic properties of myocardial performance. Typically the RV PV-loop is 
triangular in loop morphology as the ejection of blood from the ventricle continues 
during pressure decline within the ventricle due to the increased compliance of the 
pulmonary vasculature structure. The PV-loop can also offer a load-independent 
measure of RV contractility and compliance, currently unobtainable by other invasive 
and non-invasive methods (Kass et al., 1986; Kass et al., 1988). This load-independent 
measure is obtained by collecting a family of PV-loops while altering the pre-load on 
the ventricle, typically achieved by an Inferior Vena Cava (IVC) balloon occlusion (Kass 
et al., 1986; Kass et al., 1988). Conductance theory is described in detail in Section 
2.3.  
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Figure 1-4 The normal RV PV-loop derived from the conductance catheter technique.  
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1.5 Factors Affecting RV Diastolic Dysfunction  
Three main factors that have been independently described which could have an effect 
on RV diastolic dysfunction: Coronary Flow Reserve, Ventricular Interdependence and 
Ventriculoarterial Coupling. 
1.5.1 Coronary Flow Reserve 
Coffman and Gregg first described the concept of Coronary Flow Reserve (CFR) 1960, 
where the coronary circulation was described to have a maximal hyperaemic blood 
flow capacity (Coffman and Gregg, 1960). At rest, coronary flow depends on 
myocardial oxygen demand which is affected by heart rate (Ramanathan and Skinner, 
2005), ventricular contractility (Ramanathan and Skinner, 2005) and ventricular load 
(Ramanathan and Skinner, 2005). Coronary flow at rest when the myocardial oxygen 
demand is constant is within the limits of autoregulation and can be considered 
independent of perfusion pressure (Rigo, 2005). During hyperemia there is an increase 
in microvascular volume and myocytes adjacent to these vessels are stretched, 
opening stretch-activated calcium channels, causing calcium influx and augmentation 
of calcium-dependent myofibrillar contractility, known as the Gregg effect (Gregg, 
1963). Reactive hyperaemia is an augmentation of coronary flow due to coronary 
vasodilatation to repay the oxygen debt (Heyndrickx et al., 1975). In a model of LV 
supply ischemia (Hoole et al., 2010) this hyperemic response masks stunning in the 
early phase of reperfusion (Stahl et al., 1986). Interestingly, diastolic dysfunction 
remains depressed during this period and this may be due to a scaffold effect from 
distended coronary and collateral vessels during hyperemia that stiffens the ventricular 
cavity (Hoole et al., 2010). At maximal microvascular dilation, coronary flow can no 
longer be considered autoregulated, and coronary flow varies linearly with perfusion 
pressure (Rigo, 2005). CFR is the difference between the basal coronary flow during 
the autoregulation plateau and the hyperaemic coronary flow during maximal 
microvascular dilation (Rigo, 2005). Therefore, CFR is expressed by the ratio between 
basal and hyperaemic coronary flow. Since the hyperaemic coronary flow is linearly 
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related to perfusion pressure, CFR can also be expressed as the relationship between 
instantaneous maximal coronary diastolic flow and pressure (Mancini et al., 1989; de 
Bruyne et al., 1996), measured using invasive Doppler and pressure wires. The normal 
range for CFR, when measured with Doppler catheters, is 3.5 to 4.5 (Marcus et al., 
1987), and is clinically considered abnormal < 2.0 (Westerhof et al., 2006). 
Clinically, CFR is a useful tool for understanding basic physiological function (De Rosa 
et al., 2011); interpreting the effects of structural (De Rosa et al., 2011) and 
pharmacological (Galderisi and D'Errico, 2008) interventions on coronary flow. CFR 
has been demonstrated as a sensitive marker for patient outcome, with 
echocardiographic studies showing that preserved CFR in the Right Coronary Artery 
(RCA) predict a favourable patient outcome (Cortigiani et al., 2009), whereas an 
impaired or reduced CFR is a predictor of dysfunction and worse patient outcome 
(Cortigiani et al., 2009; Rigo et al., 2011). Although little work has been completed to 
look at the effect of CFR on the RV function, studies have demonstrated links between 
impaired CFR and LV diastolic dysfunction (Galderisi et al., 2001; Galderisi et al., 
2002; Teragaki et al., 2003). Galderisi et al. (2008) demonstrated that decreased CFR 
is associated with impaired relaxation and increased filling pressures; thus, reduced 
CFR is independent of LV geometry and pre-load. Patients with diabetes mellitus have 
a reduced CFR, which may cause myocardial ischemia due to a disturbance of 
coronary microcirculation and lead to LV diastolic dysfunction (Strauer et al., 1997; 
Kalkan et al., 2013). However, this is further complicated as the coronary flow velocity 
waveforms differ between the RCA and LCA (Hadjiloizou et al., 2008), so the studies 
on CFR and LV diastolic dysfunction may or may not be transferable to the RCA and 
RV diastolic dysfunction.  
1.5.2 Ventricular Interdependence 
Bernheim (1910) first demonstrated the concept of ventricular interdependence in 
1910, where RV function was shown to be compromised by compression of the RV 
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through dilation of the LV. Subsequently, Henderson and Prince demonstrated that RV 
filling was influenced by LV function in 1914 (Henderson, 1914). There is not a 
functional left- and right-sided septum, hence abnormalities in LV or RV function 
directly affects the contralateral ventricle and vice versa. Ventricular interdependence 
means that the dysfunction of one ventricle will lead to the dysfunction of the 
contralateral ventricle and eventual heart failure. An increase in ventricular dysfunction 
will result in an increase in the end-diastolic pressure and cause the septum to bow 
towards the contralateral ventricle in the presence of an intact pericardium (Saleh et 
al., 2006). This geometrical change in chamber orientation directly affects the 
orientation of the septal muscle fibres and will reduce the contribution of septal 
contraction to the overall contraction of both ventricles (Saleh et al., 2006). LV 
dysfunction can alter the geometry of the two ventricles and the position of the septal 
wall and may cause RV contraction to be predominantly provided by weaker 
contraction of the RV free wall. Clinical echocardiographic studies of patients with 
aortic stenosis (Efthimiadis et al., 1999) and those with systemic hypertension (Chakko 
et al., 1990; Cicala et al., 2002), have shown that the subsequent increase in LV 
pressures can lead to RV diastolic dysfunction. Similarly, clinical echocardiographic 
studies in patients with hypertrophic cardiomyopathy (Efthimiadis et al., 2002) and 
those with RV hypertrophy (Kitahori et al., 2009) have shown elevated RV pressures 
have been reported to cause LV diastolic dysfunction. 
The ability to use the conductance catheter simultaneously to derive PV-loops in the 
LV and RV could feasibly allow for the critical analysis of LV-RV interaction in many 
clinical pathologies (Faber et al., 2006). Therefore, this may offer new therapeutic 
approaches for the treatment of RV dysfunction, e.g. by treating and improving LV 
function ventricular interdependence should reduce the inter-ventricular load on the RV 
and subsequently improve RV function.  
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1.5.3 Ventriculoarterial Coupling 
Sunagawa et al. (1983) first described the concept of ventriculoarterial coupling in 1983 
using an isolated canine heart model and is fundamental to the correct interpretation of 
RV function. To understand ventriculoarterial coupling in the RV, we must first consider 
the normal healthy LV, coupled to the aorta. During systole, the aorta acts as an 
energy reservoir and delivers energy back to the LV during diastole. Effectively, all the 
energy expended during the pulsatile contraction of the LV is converted into flow 
energy due to the elastic recoil of the aorta (Yaginuma et al., 1985; Sasayama and 
Asanoi, 1991) hence, the LV can be considered to be well coupled with the aorta. The 
normal healthy RV is coupled with the pulmonary vascular structure, but the coupling is 
more complex than with the aorta. The pulmonary artery is a relatively short elastic 
proximal vessel that branch early into the pulmonary trunk. This relatively short elastic 
proximal portion of the pulmonary vessels means that 25-40% of the energy expended 
during the pulsatile contraction of the RV is not converted in to flow energy due to the 
restricted elastic recoil of the pulmonary vessels (Grignola et al., 2007; Saouti et al., 
2010). Further stiffening of the pulmonary vessels will increase the afterload on the 
ventricle, increasing the systolic pressure (Chen et al., 1998) and will cause 
abnormalities in diastolic relaxation times and pressures (Leite-Moreira et al., 1999). 
Although non-invasive Echocardiography and CMR are widely accepted as the clinical 
standard for the assessment of RV function they cannot provide a load-independent 
beat-to-beat assessment of RV contractility. An assessment of ventriculoarterial 
coupling cannot be performed using non-invasive methods without making 
assumptions about pressures and volumes. Load-independent assessment can be 
provided from interrogating the PV-loop measured using a conductance catheter. This 
was first performed in the RV by McKay et al. (1984), where they successfully used the 
Valsalva manoeuvre to collect a family of loops from which the load independent 
parameters could be calculated. The ventriculoarterial coupling ratio is defined by the 
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relationship between the End-Systolic Elastance (Ees) and the Effective Arterial 
Elastance (Ea): 
Equation 1-2 
𝑉𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑜𝑎𝑟𝑡𝑒𝑟𝑖𝑎𝑙 − 𝐶𝑜𝑢𝑝𝑙𝑖𝑛𝑔  𝑅𝑎𝑡𝑖𝑜 =    𝐸!𝐸!" 
The 𝐸!"  of the RV is defined by as the slope of the end-systolic pressure volume 
relationship (ESPVR). The ESPVR can be measured by obtaining a family of loops 
from a preload reduction, routinely performed by an inferior vena cava (IVC) balloon 
occlusion. 𝐸! is a steady state parameter which offers an assessment of RV afterload 
that incorporates the principal elements of the windkessel model of the pulmonary 
vascular bed (Sunagawa et al., 1983; Sunagawa et al., 1985). The PV-loop derived 
from a conductance catheter allows 𝐸! to be calculated from the ratio of End-Systolic 
Pressure (𝑃!") to Stroke Volume (𝑆𝑉): 
Equation 1-3 
𝐸! =   𝑃!"𝑆𝑉 
The ratio between 𝐸!" and 𝐸!  describes the energetic efficiency of the energy transfer 
between the RV and pulmonary vasculature. Typically a normal coupling ratio is close 
to 1.0; the RV and pulmonary vessels would be considered uncoupled if the 𝐸!"/𝐸! 
ratio was anything less than or greater than 1.0 (Kawaguchi et al., 2003).  
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1.6 Translating Sunagawa’s Theory of Ventriculoarterial Coupling 
to the RV 
Sunagawa et al. (1987) deconstructed the circulatory system into four major 
components (left heart - systemic vascular bed; right heart - pulmonary vascular bed) 
in a bilaterally coupled system (Figure 1-5) (Sunagawa et al., 1984). The cardiac output 
(𝐶𝑂) through each of the functional blocks (systemic and pulmonary) were calculated 
from the pressure across the inflow and outflow. The 𝐶𝑂 of the left heart - systemic 
vascular bed, 𝐶𝑂!, was defined by: 
Equation 1-4 
𝐶𝑂! =   𝐹!   𝑃!" ,𝑃!"  
Where 𝐹!  is the systemic flow, 𝑃!"  is the mean right atrial pressure and 𝑃!"  is the mean 
left atrial pressure. In the same way, the 𝐶𝑂 of the right heart - pulmonary vascular 
bed, 𝐶𝑂!, was defined by: 
Equation 1-5 
𝐶𝑂! =   𝐹!   𝑃!" ,𝑃!"  
Where 𝐹!   is the pulmonary flow. Since the 𝐶𝑂  through both the systems must be 
identical, the closed-loop CO was determined from the equilibrium flow when 𝐹! =   𝐹!. 
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Figure 1-5 The four major components of the circulatory system in a bilaterally coupled system, 
taken from Sunagawa et al. (1984) 
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The coupling between the ventricular and arterial systems was then characterised 
using the ESPVR. Since ESPVR is a sensitive load-independent marker of contractility, 
the relationship between left ventricular end-systolic pressure (𝑃!") and stroke volume 
was defined by: 
Equation 1-6 
𝑃!" =   𝐸!"   𝑉!" − 𝑆𝑉 −   𝑉!  
Where 𝐸!"  is the slope of the ESPVR, 𝑉!" is end-diastolic volume, and 𝑉! is the volume 
axis intercept of the ESPVR slope. Therefore, for a given 𝑉!", 𝑃!" varies linearly and 
inversely with 𝑆𝑉 (Figure 1-6), so the ventricular system could be characterised in 
terms of a 𝑃!"-  𝑆𝑉 relationship.  
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Figure 1-6 Characterising the left ventricular and arterial system in terms of end-systolic pressure 
to stroke volume, the intersecting stroke volume represents the point where the ventricle is 
coupled to the arterial system, taken from Sunagawa et al. (1983) 
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The arterial system was also characterised in terms of a 𝑃!" -   𝑆𝑉  relationship. 
Graphically both systems are coupled at the intersection between the two lines (Figure 
1-6). The relationship between the mean arterial pressure (𝑀𝐴𝑃) and mean arterial 
flow (𝐹!) was defined by: 
Equation 1-7 
𝑀𝐴𝑃 =   𝑅!𝐹! 
Where 𝑅! is the total arterial resistance. From the assumption that 𝑃!" equals 𝑀𝐴𝑃 and 𝐹! can be estimated with 𝑆𝑉 divided by the cycle length of cardiac contraction (𝑇), the 𝑃!"  was defined by: 
Equation 1-8 
𝑃!" =   𝑅!𝑇   𝑆𝑉 
Therefore the slope of the 𝑃!"-  𝑆𝑉 relationship, more commonly termed the effective 
arterial Elastance (𝐸!), could be approximated by:  
Equation 1-9 
𝐸! =   𝑅!𝑇  
Expermentally, Sunagawa et al. (1984) used a working heart perfusion model to isolate 
LV ejection against fixed arterial resistances (afterload) and demonstrated a high 
correlation (r = 0.999; P < 0.001) between 𝑅!/  𝑇  and the PV-loop derived 𝐸! . 
Therefore, 𝐸!  can be estimated using the 𝑃!" -   𝑆𝑉  relationship with a high level of 
accuracy by dividing the total arterial resistance by the duration of one cardiac cycle. 
The slopes of the 𝑃!"-  𝑆𝑉 relationships have the units of volume elastance (mmHg / ml). 
The arterial system is treated as an elastic chamber with effective arterial elastance 
(𝐸!) and the ventricle is treated as an elastic chamber with end-systolic elastance (𝐸!"). 
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The arterial elastance is not a direct measure of the physical elastance or compliance 
of the arterial system. Rather it is termed the effective arterial elastance as it changes 
more in terms with physical arterial resistance then arterial compliance. Characterising 
the arterial and ventricular systems in terms of the 𝑃!" -   𝑆𝑉  relationship allows the 
determination of the intersecting 𝑆𝑉 that would result in a coupled ventricular-arterial 
system, derived from Equation 1-6 and Equation 1-8: 
Equation 1-10 
𝑆𝑉 =   𝐸!"   𝑉!" −   𝑉!𝐸!" + 𝐸!  
After predicting the equilibrium 𝑆𝑉 when the ventricle is coupled to the arterial system, 
it is possible to determine how much blood volume will be transferred from the first 
elastic chamber (left ventricle – with a known volume elastance and initial volume) to 
the second elastic chamber (arterial system - with a known volume elastance). The 
distribution of blood volume between the two chambers is determined by the ratio of 
the volume elastance values or more commonly termed the ventriculoarterial coupling 
ratio (𝐸!"/𝐸!). 
Sunagawa et al. (1987) developed a simplified graphical approach of using the 
pressure-volume relationship to describe the ventriculoarterial coupling ratio in terms of 
changes in arterial resistance (afterload), end-diastolic volume (preload) and 
contractility on stroke volume. His work demonstrated that the fundamental concept of 
ventriculoarterial coupling could be graphically represented using the end-systolic 
pressure and ventricular volume plane (Figure 1-7) rather than needing to measure the 
arterial system directly (Figure 1-6). In this graphical representation, Line A is the slope 
of the arterial ESPVR,  𝐸!, and is determined by connecting a straight line between the 
end-systolic pressure point on the PV-loop with the volume axis intercept, the end-
diastolic volume. Line B is the slope of the ventricular ESPVR, 𝐸!", which can be 
determined by plotting a family of PV-loops during a change in preload, typically 
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determined from a preload reduction. Line B has a volume intercept  𝑉!. Graphically, the 
intersecting point between the arterial and ventricular ESPVR lines, A and B 
respectively, determines how the ventricle is coupled with the arterial system. The 
stroke volume is the difference between the end-diastolic volume and end-systolic 
volume.   
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Figure 1-7 The graphical representation of LV ventriculoarterial coupling taken from Sunagawa et 
al. (1987) 
  
 Page 29 
Sunagawa et al. (1987) then demonstrated how this graphical approach could be used 
to observe how changes in arterial resistance (afterload), end-diastolic volume 
(preload) and contractility affect stroke volume and subsequently influence the 
ventriculoarterial coupling parameters. Figure 1-8A shows the effect of varying 
afterload (arterial resistance) while maintaining a constant preload and contractility. 
Since 𝐸!  can be estimated from 𝑅!/  𝑇 , increasing the arterial resistance (Red) 
increases the slope of the arterial ESPVR (𝐸! ). Hence, the 𝑆𝑉  decreases as the 
intersection between the arterial and ventricular ESPVR moves to the right. 
Conversely, a decrease in arterial resistance (Blue) will cause the 𝑆𝑉 to increase as the 
intersection between the arterial and ventricular ESPVR moves to the left. Figure 1-8B 
shows the effect of varying LV preload (end-diastolic volume) while maintaining a 
constant afterload and contractility. An increase in the end-diastolic volume (Red) will 
cause the arterial ESPVR (𝐸!) to shift to the right, hence, 𝑆𝑉 increases. Conversely, a 
decrease in the end-diastolic volume (Blue) will cause the arterial ESPVR (𝐸!) to shift 
to the left, hence, 𝑆𝑉  decreases. Figure 1-8C shows the effect of varying LV 
contractility while maintaining a constant afterload and preload. An increase in the LV 
contractility (Red) will increase the slope of the ventricular ESPVR while maintaining 
the same volume intercept (𝑉!). Since the slope of the arterial ESPVR (𝐸!) remains 
constant, 𝑆𝑉  increases. Conversely, a decrease in the LV contractility (Blue) will 
decrease the slope of the ventricular ESPVR and subsequently decrease the 𝑆𝑉. 
  
 Page 30 
 
Figure 1-8 The effects of changing (A) afterload; (B) preload; and (C) contractility on the LV 
ventriculoarterial coupling pressure volume relationship at (Black) baseline; (Blue) reduced; and 
(Red) increased, taken from Sunagawa et al. (1987) 
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The PV-loop can be used to determine the mechanical efficiency of the ventricle as it 
pumps blood around the body. The efficiency of the heart to pump blood against the 
vascular system can be defined by the ratio of mechanical work done by the heart and 
the energy consumed by the heart to perform this work. In normal aerobic conditions, 
the source of the heart muscles energy can be considered proportional to the oxygen 
consumed by the myocardium from coronary blood flow. The total mechanical work 
performed by the LV is the sum of the external stroke work (SW) that propels the blood 
from the ventricle and mechanical potential energy (PE) stored in the ventricle at the 
end of each contraction (Suga, 1979). However, the theory of ventriculoarterial 
interaction only incorporates the mechanical work required to propel blood from the 
ventricle in to the aorta, the LV SW (Burkhoff and Sagawa, 1986). Therefore, from the 
theory of ventriculoarterial interaction, LV efficiency can be defined by the ratio 
between LV SW and oxygen consumption (Burkhoff and Sagawa, 1986).  
The pressure volume relationship can be used to determine Pressure-Volume Area 
(PVA), a linear surrogate for the oxygen consumed by the myocardium from coronary 
blood flow (Suga et al., 1980; Suga et al., 1983; Suga et al., 1984). PVA is defined as 
the sum of the SW (area bound within the PV-loop) and PE (triangular portion defined 
by the ESPVR and EDPVR) shown in Figure 1-9. Therefore, ventricular efficiency can 
be calculated from the equation: 
Equation 1-11 
𝑉𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟  𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 𝑆𝑊𝑃𝑉𝐴 
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Figure 1-9 LV pressure-volume relationship. The end-systolic pressure volume relationship is 
characterised by slope Ees and volume axis intercept V0. The pressure-volume area (PVA) is the 
sum of external stroke work (SW) and potential energy (PE) taken from Burkhoff and Sagawa 
(1986) 
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In health, the SW-Ea relationship is ideally coupled to maintain optimal cardiac output 
but it is possible to determine the maximal achievable efficiency (SW/PVA) and 
maximal SW in response to an acute artificial increase in afterload (Ea). This has been 
demonstrated in both theoretical (Burkhoff and Sagawa, 1986) and experimental (De 
Tombe et al., 1993) relationships between LV function and increasing aortic afterload. 
Figure 1-10 shows that Burkhoff and Sagawa (1986) used a theoretical model for 
predicting that maximal efficiency occurs at a lower afterload than maximal SW. This 
finding was supported by the experimental canine isolated heart model developed by 
De Tombe et al. (1993). The Ea at which maximal SW is reached is termed Eamax sw 
(Figure 1-11B). Below the Eamax sw threshold there is LV energetic reserve, however, if 
exceeded there is no energetic reserve and LV dysfunction will ensue (Burkhoff and 
Sagawa, 1986).  
Since auto-regulation takes between 30 to 60 seconds for ventricular contractility to 
adapt in response to increasing afterloads (von Anrep, 1912), it is possible to use an 
acute variation in afterload change to determine the SW-Ees/Ea relationship. In the 
isolated canine heart De Tombe et al. (1993) determined maximal SW occurred at the 
inverse ventriculoarterial coupling ratio (Ea/Ees) of 0.80 ± 0.16 (Figure 1-11B). The 
inverse Ea/Ees coupling ratio at which maximal SW is reached is termed Ea/Eesmax sw. 
Below this inverse Ea/Eesmax sw coupling threshold there is LV energetic reserve, 
however, if exceeded there is no energetic reserve and LV dysfunction will ensue.  
However, the ventriculoarterial coupling ratio is normally presented as LV contractility 
over LV afterload (Ees/Ea). Therefore, the Ees/Ea coupling ratio at which maximal SW 
is reached is termed Ees/Ea max sw. If this Ees/Ea max sw coupling threshold is exceeded 
there is LV energetic reserve, however, below this threshold there is no energetic 
reserve and LV dysfunction will ensue. 
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Figure 1-10 (Top Left) Theoretical relation between afterload quantified by effective arterial 
elastance (Ea) and stroke work; (Bottom Left) and efficiency taken from Burkhoff and Sagawa 
(1986); (Top Right) Experimental Relation between afterload quantified by effective arterial 
elastance (Ea) and stroke work; (Bottom Right) and efficiency taken from De Tombe et al. (1993) 
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Figure 1-11 (Top) Theoretical relation between afterload quantified by effective arterial elastance 
(Ea) and stroke work taken from Burkhoff and Sagawa (1986). LV energetic reserve (green) below 
the threshold for Ea at maximal stroke work (Ea MAX SW) and LV failure beyond this afterload 
threshold. (Bottom) Experimental relation between the inverse LV ventriculoarterial (Ea/Ees) 
coupling ratio and stroke work taken from De Tombe et al. (1993). LV energetic reserve (green) 
below the threshold for Ea/Ees at maximal stroke work (Ea/Ees MAX SW) and LV failure beyond this 
inverse ventriculoarterial coupling threshold.   
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1.7 Summary 
This chapter has described a number of physiological and structural differences 
between the LV and RV; and why the pulmonary circulation is fundamentally different 
to the systemic circulation (Dell'Italia, 1991). In contrast to the LV, the RV is coupled to 
the compliant pulmonary circulation and operates at lower pressure. The RV chamber 
remains concave towards the LV during both systole and diastole. The RV has a thin 
ventricular free wall that has a muscle mass approximately one-sixth of the LV 
(Dell'Italia, 1991). Therefore, the contractile performance of the better characterised LV 
may not be directly transferrable to the RV (Bellofiore and Chesler, 2013). 
The normal healthy RV is coupled with the pulmonary vascular structure, but the 
coupling is more complex than with the aorta. The pulmonary artery is a relatively short 
elastic proximal vessel that branch early into the pulmonary trunk. This relatively short 
elastic proximal portion of the pulmonary vessels means that 25-40% of the energy 
expended during the pulsatile contraction of the RV is not converted into flow energy 
due to the restricted elastic recoil of the pulmonary vessels (Grignola et al., 2007; 
Saouti et al., 2010). Further stiffening of the pulmonary vascular vessels will increase in 
the afterload on the ventricle, increasing the systolic pressure (Chen et al., 1998) and 
will cause abnormalities in diastolic relaxation times and pressures (Leite-Moreira et 
al., 1999). 
The aim of this work is to determine if the theory described for LV maximal efficiency 
and maximal SW from the pressure volume relationship could be translated to the 
lower pressure RV and less compliant pulmonary circulation. Chapter 3 describes the 
methodological development of a new large animal model for the assessment of RV-
PA ventriculoarterial coupling. Using a PA snare to partially occlude the PA while 
keeping RV contractility and heart rate constant in a healthy swine heart to record RV 
PV-loops during preload reduction. This new model was used in Chapter 4 to assess 
how RV efficiency and RV SW varied in response to changes in the PA loading 
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conditions (Ea), RV contractility (Ees) and RV ventriculoarterial coupling (Ees/Ea). 
Relations for RV afterload (quantified by Ea) and RV ventriculoarterial coupling 
(quantified by Ees/Ea) defined maximal efficiency and maximal SW values within a 
physiologically normal porcine RV. 
These data were then applied in two clinical cohorts with pathological RV loading: 
symptomatic patients with Chronic Thromboembolic Pulmonary Hypertension – 
CTEPH and Chronic Thromboembolic Disease without pulmonary hypertension - 
CTED (Chapter 5 – elevated Ea). In a complimentary clinical study, the affects of 
ventricular interdependence on RV contractility and the RV-PA ventriculoarterial 
coupling ratio following Transcatheter Aortic Valve Implantation (TAVI) was assessed 
(Chapter 6 – changing Ees). 
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2 Materials and Methods 
2.1 Introduction 
This chapter describes the materials and methods for the development of an animal 
model:  
1. The effect of right ventricular (RV) – pulmonary artery (PA) ventriculoarterial 
coupling ratio on the maximal efficiency and maximal stroke work as RV 
function adjusts to maintain ejection of blood against increasing afterload 
and the translation of this animal model into two clinical studies:  
1. The effect of different pulmonary hypertension (PH) etiologies (chronic 
thromboembolic disease (CTED) and chronic thromboembolic pulmonary 
hypertension (CTEPH)) on RV function and RV-PA ventriculoarterial coupling 
2. The effect of left ventricular (LV) afterload reduction on RV function and RV-PA 
ventriculoarterial coupling following transcatheter aortic valve implantation 
(TAVI) 
All the studies in this thesis use the conductance technique to determine the real-time 
beat-to-beat measurement of right ventricular pressures and volumes in animals and 
humans. Principles of conductance theory to assess RV function are discussed, 
followed by the protocol used for data acquisition and analysis. Principles of the 
thermodilution technique and Fick are discussed, as the Pressure-volume (PV)-loops 
were calibrated from cardiac output determined by thermodilution technique or Fick. In 
the TAVI study, an echocardiographic assessment was performed to assess aortic 
valve, left ventricular (LV) and RV function. Principles of echocardiographic 
assessment are discussed. 
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2.2 Research Governance 
2.2.1 Statistical Power 
The studies were powered to the primary outcome measure of Tau between treatment 
groups. The number of subjects had been calculated from previous work (Read et al., 
2011). To detect a change in Tau of 10 ± 8 ms between groups, we estimated 11 
subjects would be required (α = 0.05, β = 0.2). Therefore, the aim was to recruit 15 
subjects into each treatment group or study arm to allow for any withdrawal of consent 
or incomplete datasets.  
2.2.2 Statistical Analysis 
The specific statistical tests used to describe the data analysed in each clinical study 
are described in greater detail in each chapter. All statistical analysis was performed 
using SigmaPlot 12.5 (Systat Software Inc, San Jose California, USA) statistical 
analysis package. In summary, continuous data was expressed as mean ± 1.S.D. 
Paired Student t-tests were used as a parametric statistical test to compare a change 
that occurred before or after an intervention, or between patient groups when the 
observed effects were normally distributed. The null hypothesis was rejected when 
p<0.05. Linear regression analysis was used as a parametric statistical test to find the 
straight line that most closely predicted the value of the dependent variable, given the 
observed value of the independent variable. The Pearson correlation coefficient (R) 
was used as a parametric statistical test to measure the linear correlation between two 
independent variables. Linear regression and the Pearson correlation coefficient were 
used extensively throughout this thesis to determine PRSW, ESPVR, EDPVR and the 
parallel conductance volume (Vc). The Bland-Altman method (Bland and Altman, 1986) 
was used to compare a new measurement technique with an established one to 
determine whether the two data sets agree sufficiently.  
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2.2.3 Governance for Animal Studies 
All the animal studies were performed at a specialist facility at the Royal Veterinary 
College in Hatfield, London. All the studies were performed using Large White pigs 
under terminal anaesthesia and was approved by the Home Office (Project Licence 
70/7967). All animals received humane care under the Code of practice for the housing 
and care of animals bred, supplied or used for scientific purposes. The code of practice 
sets out the standards of care and accommodation of animals required by the Animals 
(Scientific) Procedures Act 1986 and provides advice about the way in which those 
responsible under ASPA may comply with those requirements, published 2014. 
2.2.4 Governance for Human Studies 
All patient studies were performed at Papworth Hospital NHS Foundation Trust, 
Cambridgeshire. The Trust Research & Development Department sponsored all 
studies, and the National Research Ethics Service (NRES) Local Research Ethics 
Committee granted ethics approval. Individual informed consent was obtained before 
the study. All studies complied with the principles outlined in the Declaration of Helsinki 
in 1964 (Rickham, 1964; World Medical, 2013). These were as follows for the clinical 
studies: 
1. Study Title: Analysis of exercise responses in chronic thromboembolic 
disease. Approved by Cambridge South local research ethics committee 
(REC number 12/EE/0085). Approved by Papworth Hospital NHS 
Foundation Trust, Research & Development Department.  
2. Study Title: Diastolic RV EvAluation with Millar catheter in patients 
undergoing transfemoral Transcatheter Aortic Valve Implantation – DREAM 
TAVI study. Approved by Cambridge South local research ethics committee 
(REC number 12/EE/0473). Approved by Papworth Hospital NHS 
Foundation Trust, Research & Development Department. The study trial 
number was UKCRN ID 14028. 
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2.2.5 Conduct of Work 
2.2.5.1 Location of Work 
The animal studies were conducted in the Biological Services Unit at the Royal 
Veterinary College, Hatfield, London. The conductance data was recorded on a 
Papworth Hospital NHS Foundation Trust laptop and then backed up onto a secure 
server at Cambridge University Hospital NHS Foundation Trust for analysis.  
The interventional studies were conducted in the Cardiac Catheterisation Laboratories 
at Papworth Hospital NHS Foundation Trust. The conductance data was recorded on a 
Papworth Hospital NHS Foundation Trust laptop and then backed up onto a secure 
server at Cambridge University Hospital NHS Foundation Trust for analysis. The 
echocardiographic data was downloaded off the machine onto a secure server at 
Cambridge University Hospital NHS Foundation Trust. The fluoroscopic images were 
downloaded and stored on a secure server at Cambridge University Hospital NHS 
Foundation Trust. 
2.2.5.2 Work Conducted by the Author 
The author was involved in all aspects of the work presented from the first inception. 
For the animal studies, the author wrote the protocols and developed the ex-vivo 
perfusion rig. Dr Simon Messer (Cardiothoracic Transplant Fellow and PhD student) 
wrote the application for approval from the Home Office. For the interventional studies, 
the author wrote the protocols, the applications for approval from ethics committees 
and Papworth Research and Development Department under the supervision of Dr 
Stephen Hoole (Consultant Interventional Cardiologist and Chief Investigator).  
For the animal studies, Dr Hatim Alibhai (Consultant Veterinary Anaesthetist) was 
responsible for the humane care of the animals. The animal studies were performed 
under Dr Simon Messer’s Project Licence. Dr Hatim Alibhai performed the anaesthetic 
preparation of the animals, and Dr Simon Messer performed the surgical preparation. 
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The author acquired and analysed the in-vivo conductance catheter data. The author 
developed the ex-vivo perfusion rig. The author took the explanted heart and perfused 
the heart on the ex-vivo perfusion rig. The author modified the rig from Langendorff 
perfusion into a working heart mode and acquired and analysed the ex-vivo 
conductance catheter data. 
For the interventional studies, Dr Stephen Hoole (Consultant Interventional 
Cardiologist) recruited the patients into the studies. The author oversaw all the 
interventional procedures to ensure compliance with the protocol. The Consultant 
Interventional Cardiologist responsible for the care of the patient performed the 
interventional procedures. The author acquired and analysed the conductance catheter 
data. The Consultant Cardiologist responsible for the echocardiographic assessment 
during the interventional procedure performed the additional measurements required 
for the research protocol. The author transferred the echocardiographic data to a 
secure server at Cambridge University Hospital NHS Foundation Trust and performed 
all analysis.  
In all the studies, the author performed all data analysis, statistical analysis and 
presentation of the data.   
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2.3 Conductance Theory 
The modern-day conductance catheter has stood the test of time and remains identical 
to the one first used by Baan et al. (1984). A measure of intra-ventricular volume is 
obtained based on the electrical conductance of the blood within the ventricular cavity. 
Since blood is a relatively good conductor of electricity (Blood Resistivity ≈160 Ω cm) 
(Geddes and Baker, 1967) and the ventricular wall is a relatively poor one (ventricular 
wall resistivity ≈ 400 Ω cm) (Geddes and Baker, 1967); at end-diastole a full ventricle 
will have a high conductance whereas at end-systole a partially filled or empty ventricle 
will have low conductance (Baan et al., 1984; Baan et al., 1981). 
The conductance catheter has a series of equally spaced platinum electrodes 
(between 8 to 12) mounted on an angiographic pigtail catheter that can be positioned 
in a ventricle under fluoroscopic guidance. A single field excitation conductance 
catheter will have eight equally spaced electrodes. The outermost electrodes are used 
to generate an intracavity electric field, typically 20-kHz and 30µA. The remaining 
sensing electrode pairs are used to measure the cylindrical volume defined by the 
endocardial surface of the ventricular wall and the equipotential surface of the 
electrodes (Baan et al., 1981). Total ventricular volume can be approximated by 
considering the paired volumes as a column of cylindrical volumes stacked on top of 
each other. Dual field excitation catheters use additional pairs of electrodes (up to 12 
electrodes in total) to provide a second electric field of opposite polarity (Steendijk et 
al., 1992) to increase electric field homogeneity. During the cardiac cycle, changes in 
the cross-sectional area of the ventricular cavity cause variations in the resistance 
between the two sensing electrodes and lead to changes in the electrical conductance 
measured. The relationship between resistance and cross-sectional area of the 
ventricle is given by:  
Equation 2-1 
𝑅 = 𝜌𝐿𝐴  
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Where 𝑅 = resistance (ohms), 𝜌 = blood resistivity (ohms / cm), 𝐿 = distance between 
the sensing electrodes or inter-electrode distance (cm) and 𝐴 = cross-sectional area of 
the ventricle (cm2). Since the blood conductivity (𝐺) is the reciprocal of resistance it can 
be calculated from the formula: 
Equation 2-2 
𝐺 = 1𝑅 = 𝐴𝜌𝐿 
As an alternating current is applied to the outermost electrodes, the remaining sensing 
electrode pairs measure the potential difference across the electrodes to derive the 
time-varying conductance (𝐺(!)) for the ventricular segment. The relationship between 
the time-varying ventricular volume and the time-varying conductance (𝐺(!)) is given by: 
Equation 2-3 
𝑉(!) = 1𝛼 𝐿!𝜎 𝐺(!) − 𝐺(!)  
Where 𝛼  = dimensionless slope factor, 𝐿  = inter-electrode length (cm), 𝜎  = blood 
conductivity (cm / ohm) and 𝐺(!) = parallel conductance of structures extrinsic to the 
volume of blood in the ventricular cavity (1 / ohm). Although the formulae was 
developed by Baan et al. (1984) for use within the Left Ventricle (LV), which can be 
considered as a single ellipsoid chamber, and the equation assumes the region at the 
apex of the LV (not interrogated by the conductance catheter) to have a volume equal 
to one-third of the most distal segment.  This technique has been used successfully by 
many researchers (McKay et al., 1984; Bishop et al., 1997; Tabima et al., 2010) in the 
Right Ventricle (RV), which can be considered as crescentic in cross-section and 
triangular when viewed from the side. White et al. (1995) demonstrated a good 
correlation between known volumes and conductance derived volumes using human 
post-mortem ventricular casts.  
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2.3.1 The Millar Conductance Catheter 
The Millar (Houston, Texas, USA) conductance catheter used throughout these studies 
is shown in Figure 2-1Error! Reference source not found. The catheter is a 7F 8 
electrode over 5 or 6 centimetres. Typically a 5 cm catheter would be used with 6 cm 
catheters only used with larger patients. The 5 cm catheter has 8 electrodes spaced 
7.1 mm apart. The 6 cm catheter has 8 electrodes spaced 8.6 mm apart. Electrodes 1 
and 8 are used to generate the 20kHz electric field. The remaining electrode pairs (2-3, 
3-4, 4-5, 5-6, 6-7) are used to measure the potential difference generated across each 
catheter segment. A pressure transducer is located between electrodes 4 and 5 to 
measure ventricular pressure simultaneously. The catheter has a pigtail at the end to 
prevent it from damaging the ventricular wall. The catheter is 120 cm long and has two 
connection ports at the distal end of the catheter that are used to transmit the volume 
and pressure signals to the Millar MPVS Ultra box (Section 2.4). The conductance 
catheter was inserted into the patient via a 7F sheath using either a femoral or jugular 
approach. The catheter was then advanced into the RV under fluoroscopic guidance 
and was used to visually check the catheter was correctly positioned in the ventricle 
(Figure 2-1).  
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Figure 2-1 (A) Millar (Houston, Texas, USA) conductance catheter; (B) positioned in the right 
ventricle under fluoroscopic guidance 
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2.3.2 Calibration Factors 
The theory of the conductance technique volume measurements is based on a number 
of contested assumptions (Salo et al., 1986): 
1. The ventricle has a uniform cross section; 
2. The resistivity of blood is homogeneous and isotropic (the blood has the same 
properties in all directions); 
3. The ventricle is surrounded by an electrical insulator (no current can transmit 
beyond the ventricular wall); and 
4. The electric field produced by the catheter is homogeneous throughout the 
blood volume and parallel to the long axis of the ventricle. 
Assumption two is considered to be correct (Salo et al., 1986). However, assumptions 
three and four can introduce significant errors in ventricular volume estimation if not 
taken into consideration. Two calibration factors are used to determine the absolute 
ventricular volume from conductance measurements. To help reduce the errors 
associated with assumption three an estimation of the volume offset, known as parallel 
conductance (Vc) is used to account for the current that is transmitted beyond the 
ventricular cavity. To help reduce the errors associated with assumption four an 
estimation of the dimensionless slope factor known as alpha (𝛼) to correct for the 
inhomogeneity of the electric field and correcting the difference between the absolute 
blood volume and that determined by the conductance technique.  
2.3.2.1 Parallel Conductance  
One of the main limitations and sources of error with the conductance technique is that 
the current created by the excitation electrodes on the catheter extends beyond the 
ventricular cavity, contradicting the third assumption. It extends beyond the ventricle 
and measures the conductivity of the structures extrinsic to the blood within the 
ventricle. For the RV this is predominantly from the contralateral LV, myocardium and 
lungs. Therefore, the conductance measured by the conductance catheter 
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overestimates the blood conductance due to parallel conductance 𝐺(!) . This 
overestimation of blood conductance creates a volume offset (Vc), which in turn 
overestimates the absolute ventricular volume (Kornet et al., 2000). 
Parallel conductance is determined using the saline dilution technique. The technique 
is based on the analysis of temporary changes in blood resistivity which occur during 
an injection of a small bolus of hypertonic saline (Baan et al., 1984). A controlled 
injection of approximately 5ml of 10% hypertonic saline is injected into the blood 
upstream of the ventricle. This upstream injection allows for the hypertonic saline to 
mix with the blood by the time it reaches the ventricle. The blood / hypertonic saline 
mixture will enter the ventricle and increases the blood conductivity in the RV and is 
subsequently displayed as an increase in the blood volume detected within the RV.  
The bolus of hypertonic saline increases the measured blood conductivity without 
altering the actual volume of blood within the ventricle. The blood conductivity of the 
surrounding structures remains constant. Since the absolute stroke volume remains 
constant, the changes in the conductance values observed are due to the alterations in 
blood conductivity. Figure 2-2A shows the RV PV-loops recorded during an injection of 
hypertonic saline. The conductance catheter senses an increase in blood conductivity 
during the saline injection, which is subsequently displayed as an increase in the blood 
volume detected within the ventricle. The End-Diastolic Volume (Ved) and End-Systolic 
Volume (Ves) points are identified for each beat during the hypertonic saline injection. 
The Ves point is plotted against the Ved point for each beat. A linear regression of 
these points are performed and the point where the regression line intercepts the line 
of identity (ESV = EDV) is equal to G(p), the volume of blood measured by the 
conductance catheter due to the current conducted through the ventricular wall and 
into the surrounding structures (Figure 2-2B). 
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Figure 2-2 Increase in RV volume during a hypertonic saline injection 
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2.3.2.2 Dimensionless Slope Factor Alpha 
The second limitation and potential source of error with the conductance technique is 
the accuracy of the conductance-derived absolute blood volume and must be 
considered when interpreting the conductance-derived assessment of RV function. The 
dimensionless slope factor alpha (α) is a result of the inhomogeneity of the excitation 
field and is an estimate of the slope between the conductance derived stroke volume 
and the actual stroke volume. This is further complicated by the fact that the 
dimensionless slope factor alpha varies with ventricular size. Alpha is estimated from 
the relationship of cardiac output derived from conductance as a ratio of that calculated 
from the Fick Principle or thermodilution method described in Section 2.6.  
The variability of alpha with ventricular size can be explained by considering that the 
non-uniformity of the electric field is caused by the excitation electrodes acting like 
point sources rather than flat plates (Salo, 1989). A point source electrode placed in a 
ventricle of a non-uniform cross section will generate an inhomogeneous electric field 
within the ventricular cavity, contradicting the fourth assumption. Therefore, as the 
density of the electric field decreases exponentially with the distance from the axis of 
the catheter, field inhomogeneity increases with ventricular volume. Therefore, the 
electric field strength is greatest closest to the longitudinal axis of the catheter. Hence, 
the electrodes measure the larger electric fields proximal to the longitudinal axis of the 
catheter with a higher sensitivity than the weaker distal fields. This electric field 
inhomogeneity means the conductance-derived volumes will always underestimate the 
true ventricular volume. 
The proportion of the ventricle interrogated by the conductance catheter further affects 
the value of the dimensionless slope factor alpha. Considering an ideal homogeneous 
electric field, an alpha value of 0.65 would indicate that the catheter is interrogating 
only 65% of the ventricle. Therefore, a catheter should be selected to match the length 
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of the long axis of the ventricle to minimise the effect of the ventricular length to 
catheter length ratio on alpha.  
2.3.2.3 Blood Resistivity 
An accurate measurement of blood resistivity (Rho = 1 / Conductivity) is fundamental to 
the conductance catheter method. Blood resistivity is known to vary with temperature 
(Geddes, 1973) and haematocrit (Gollan, 1970). The Millar (Houston, Texas, USA) 
MPVS Ultra system used throughout this thesis (Described in Chapter 2), measures 
the temperature of the blood sample while taking a measurement of blood resistivity. 
This prevents changes in the temperature of the patient’s circulating blood affecting the 
measured resistivity.  
Blood is a suspension of red blood cells, white blood cells and platelets in plasma. The 
percentage of cells within the blood sample is called the packed cell volume. Red blood 
cells (haematocrit) form the majority of the blood. Therefore, the percentage of 
haematocrit is nearly equal to the packed cell volume. Blood is an electrolytic solution 
containing a variety of suspended and dissolved substances. Hence, the resistivity of 
the blood sample is dependent on the packed cell volume (Hill 1975); with a reduction 
in the packed cell volume, causing the blood resistivity to lower. 
The studies were performed in a Catheter Laboratory where the patients’ temperature 
is monitored and kept constant. However, since fluids may have been given during the 
procedure, a blood resistivity measurement would be taken at the start and end of the 
procedure to ensure there were not any changes in blood resistivity caused by 
changes in blood haematocrit. Care must also be taken to ensure that the time from 
collecting the sample to performing the measurement is kept to a minimum to ensure 
that the measurement of blood resistivity is performed with the sample at the same 
temperature as the patients’ circulating blood.  
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2.3.3 The PV-Loop 
The PV-loop recorded using the conductance catheter provides an accurate, beat-to-
beat assessment of the ventricular function. A steady state PV-loop can be used to 
calculate a wide variety of load-dependant parameters of ventricular function. However, 
load-independent parameters of the ventricular function are determined by obtaining a 
family of PV-loops recorded during a pre-load reduction. All measurement recordings 
were repeated to ensure consistent and accurate data were recorded. 
2.3.3.1 Load-Dependant Parameters 
A steady state PV-loop can be used to calculate a wide variety of load-dependant 
parameters of ventricular function including; heart rate, cardiac output, stroke volume, 
end-systolic volume, end-diastolic volume, end-systolic pressure, end-diastolic 
pressure, ejection fraction, maximum and minimum rates of pressure decay and the 
time constant of diastolic relaxation. After selecting a steady state PV-loop in LabChart, 
these parameters are automatically calculated and displayed in the haemodynamics 
table as described in section 2.5. However, these parameters remain load-dependant, 
which means they are affected by the preload and afterload conditions on the ventricle. 
Most parameters can also be derived from standard techniques of assessing 
ventricular function. 
There are two important load-dependant measures of diastolic function. The minimum 
rate of pressure decay (dP/dt min) is a measure of ventricular compliance or “stiffness”. 
A larger value would indicate a stiffer, less compliant ventricle with increased diastolic 
dysfunction. The time constant of isovolumic relaxation (Tau) (Weiss et al., 1976; Raff 
and Glantz, 1981; Matsubara et al., 1995) represents the exponential decay of the RV 
pressure during isovolumic relaxation. Although it is an index of diastolic function that is 
considered load dependent, it is predominantly only affected by heart rate, with an 
increased heart rate reducing the time for the diastolic filling. Typically Tau is 
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approximately 52-56ms in a healthy ventricle and would increase as diastolic 
dysfunction increases (Read et al., 2011; McCabe et al., 2014). 
2.3.3.2 Load-Independent Parameters 
The load-independent assessment of RV function can be measured by obtaining a 
family of PV-loops during a preload reduction (Figure 2-3). Typically a preload 
reduction is achieved by inflating a balloon in the Inferior Vena Cava (IVC). The End 
Systolic Pressure Volume Relationship (ESPVR) is a measure of ventricular 
contractility and describes the maximal pressure that can be generated by the RV for a 
given volume. ESPVR is calculated from the gradient of the linear regression of the 
end-systolic point on the PV-loop for each beat. The gradient of the ESPVR linear 
regression is known as the End Systolic Elastance (Ees). This line becomes steeper 
and shifts to the left as contractility increases. The ESPVR is insensitive to changes in 
preload, afterload and heart rate.  
The End Diastolic Pressure Volume Relationship (EDPVR) is a measure of ventricular 
compliance and describes the passive filling properties of the RV. EDPVR is calculated 
from the gradient of the regression of the end-diastolic point on the PV-loop for each 
beat. The ESPVR is insensitive to changes in preload, afterload and heart rate. The 
slope of the EDPVR regression is the reciprocal of the ventricular compliance. Bishop 
et al. (1997) demonstrated that the occlusion of the right coronary artery caused an 
upward and leftwards shift of the EDPVR, which then returned to normal on 
reperfusion. Therefore, impaired ventricular filling or diastolic dysfunction will result in a 
smaller End-Diastolic Volume for a given End-Diastolic Pressure. 
The Preload Recruitable Stroke Work (PRSW) is a measure of myocardial contractility. 
PRSW is calculated from the gradient of the linear regression of the stroke work with 
end-diastolic volume. The PRSW is insensitive to changes in afterload and heart rate. 
The slope of the PRSW linear regression line becomes steeper, and shifts to the left as 
contractility increases (Figure 2-3).  
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Figure 2-3 (Top) Load-independent family of RV PV-loops showing ESPVR, EDPVR and Ea; 
(Bottom) PRSW example 
  
 Page 55 
2.3.3.3 Single-Beat Determination of the Ventriculoarterial Coupling Ratio 
In patients where it is not possible to insert an additional venous sheath and position a 
balloon in the IVC to create a preload reduction, computer-modeling techniques were 
used to predict Ees from a steady-state single-beat PV-loop. The relationship between 
maximal isovolumic pressure (Pmax) and EDV is a marker of ventricular contractility 
(Sunagawa et al., 1980). The single-beat method has been validated in the LV 
(Sunagawa et al., 1980) and RV (Brimioulle et al., 2003). The method assumes that the 
ESPVR is the same in ejecting and isovolumic beats, and the maximal pressure of an 
isovolumic beat (Pmax) can be extrapolated from a single normal ejecting beat 
(Brimioulle et al., 2003). The RV PV-loop pressure and volume data was exported from 
LabChart into a Matlab (MathWorks, MA, USA) file format. Pmax was determined by 
fitting the equation: 
Equation 2-4 
𝑃 = 𝑎 + 𝑏𝑠𝑖𝑛(𝑐𝑡 + 𝑑) 
where P is the instantaneous pressure and t is time, to the RV pressure values before 
the maximal rate of isovolumic contraction (dP/dt max) and just after the maximal rate 
of isovolumic relaxation (dP/dt min) (Figure 2-4). Coefficients a-d were computed by a 
least squares nonlinear fitting equation in Matlab using the Levenberg-Marquardt 
method (Marquardt, 1963). Pmax was then obtained from the equation: 
Equation 2-5 
𝑃𝑚𝑎𝑥 = 𝑎 + 2𝑏 
The ESPVR line was drawn as the tangential line from the Pmax point at EDV, to the 
end-systolic point on the steady-state PV-loop (Figure 2-4). Ees was calculated as the 
slope of the Pmax-ESP divided by the SV. As previously described, Ea was calculated 
as the slope of the ESP divided by the SV. 
 Page 56 
 
 
Figure 2-4 (Top) Single beat estimation of the maximal isovolumic pressure (Pmax). This is a 
screen capture of a patient with CTED from Chapter 5. (Bottom) Single beat estimation of Ees 
using Pmax (This is not to scale). 
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2.4 PV-Loop Data Acquisition 
The Millar MPVS Ultra (Millar, Houston, Texas, USA) PV-loop system was used to 
simultaneously measure high-fidelity ventricular pressure and volume in-vivo in a 
human heart and in-vivo and ex-vivo in a mammalian heart. This was connected to an 
ADInstruments PowerLab 16/30 Series (ADInstruments, New South Wales, Australia) 
sixteen-channel amplifier. The output from the PowerLab was then displayed and data 
recorded using the ADInstruments LabChart Pro 8.0 (ADInstruments, New South 
Wales, Australia) software.  
2.4.1 Millar MPVS Ultra 
The Millar MPVS Ultra front panel connections are shown in Figure 2-5. The power 
indicator will illuminate green when the system is turned on and receiving power. There 
are four custom input connectors. The Cuvette input is colour-coded light grey and can 
be used to connect the cuvette (Figure 2-9) to the system and measure blood resistivity 
for volume calibration. The ECG input is colour coded green and can be used to 
connect a slaved ECG in to the system. The PV-loop input is colour coded black and 
can be used to connect the Millar multi-segment conductance catheter to the system. A 
specialist interface cable is required that connect directly to the white low profile and 
grey circular connectors on the Millar conductance catheter and the other end plugs 
into the PV-loop input. The cable transmits a signal to-and-from the volume sensing 
electrodes to the MPVS Ultra, and to-and-from the pressure sensor bridge to the 
MPVS Ultra. The cable can also be used to measure an internal ECG waveform. The 
Pressure-Only input is colour coded blue and can be used to connect a pressure 
catheter to the system. There are two analogue Pressure Output channels (CH 1 and 
CH 2) that can be used to output the pressure signals via a BNC connector to an input 
on the ADInstruments PowerLab 16/30. The pressure output signals are scaled to 1V / 
100 mmHg. There are eight analogue Volume Output Channels (Composite, S1 – S7); 
the Composite Volume output channel outputs the analogue sum of the individual 
volume segments; the seven-volume segments (V1-V7) output the analogue signal for 
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each of the separate volume segments. The outputs are connected to the 
ADInstruments PowerLab 16/30 with a BNC connector. The analogue ECG Output 
channel can be used to output the signal measured from the internal conductance 
catheter ECG. 
The rear panel on the Millar MPVS Ultra has a mini-USB connector, which can be used 
with a mini-USB to USB (v1.1 or later) cable to connect the Millar MPVS Ultra system 
to the Windows PC running the Millar MPVS Ultra Control Interface (See Section 
2.4.2). On initial set-up with the PC software drivers had to be installed and the unique 
serial number for each Millar MPVS Ultra box had to be registered on the PC before 
the Control Interface can communicate with the box. At the start of each research 
study, the USB cable between the Millar MPVS Ultra system and the PC must be 
connected before the entire system is switched on. An IEC power cable connector can 
be used to connect the Millar MPVS Ultra System to the mains power supply. The 
Millar MPVS Ultra system is a Class I Type CF medical device. Therefore, the Millar 
MPVS Ultra system metal casing is connected directly to the earth pin on the power 
socket.  
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Figure 2-5 Millar (Houston, Texas, USA) MPVS Ultra front panel hardware connections 
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2.4.2 Millar MPVS Ultra Control Interface 
The Millar MPVS Ultra Control Interface is an intuitive graphical interface that can be 
used to select and configure the catheter, calibrate the system and measure blood 
resistivity. The multi-segment mode must be activated to perform PV-loop 
measurements on a larger animal or human subject.  
2.4.2.1 Catheter Configuration Tab 
The Catheter Configuration tab (Figure 2-6) can be used to configure the hardware to 
operate with a specific model of Millar catheter, by setting the electrode configuration, 
field configuration, excitation current and gain. The Catheter Configuration Locked 
button must be activated (so that the button reads Catheter Configuration Unlocked) to 
make changes can be made to the Catheter Configuration tab This locking mechanism 
prevents any inadvertent changes to the catheter configuration and system settings 
while the system is in use. The Millar MPVS Ultra Control Interface will default to the 
catheter configuration that was used last. The Catheter Configuration button 
automatically locks after a period of 60 seconds inactivity. The Millar Catheter 
Selection field is set up with the custom catheters used for the human research 
studies. Typically we would use a 7F 8 Electrode over 5 cm (electrode spacing 7.1 
mm) catheter with an x100 gain setting or a 7F 8 Electrode over 6 cm (electrode 
spacing 8.6 mm) catheter with an x100 gain setting. The Blood Resistivity field can 
then be used to enter the value of the measured blood resistivity. At the start of the 
research study, this would be set to 180-ohm/cm to calibrate the system.  
 Page 61 
 
Figure 2-6 Millar MPVS Ultra control interface catheter configuration tab screen capture 
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2.4.2.2 Catheter Calibration Tab 
The Catheter Calibration tab (Figure 2-7) can be used to calibrate the pressure and 
volume signals electronically. The pressure reading is numerically displayed on the 
Catheter Calibration tab, with a measurement range from -25 mmHg to 200 mmHg and 
scale 1.0 V / 100 mmHg. The MPVS Ultra provides 5.0 V excitation to the transducers 
that have an assumed sensitivity of 5.0 µV / V / mmHg. The MPVS is designed to work 
with Millar catheters with 1000 ohm input impedance and 1000 ohm output impedance. 
The active button on the Pressure tab is highlighted in green. To calibrate the pressure 
signal the 0-mmHg button should be activated, so that the MPVS Ultra will output a 
0.0-volt signal. The 100-mmHg button should then be activated so that the MPVS Ultra 
will output a 1.0-volt signal. The LabChart software can then be used to perform a two-
point calibration on the pressure channel, setting point one to 0 mmHg and point two to 
100 mmHg. The Transducer button should then be activated so that the MPVS Ultra 
will read the pressure measured by the pressure sensor on the Millar catheter. The 
pressure offset can then be manually adjusted to set the zero point. After confirming 
the Transducer button is activated on the Catheter Calibration tab, the pressure sensor 
on the Millar catheter should be submerged in body temperature water. The Balance 
Locked button should then be activated so that the button now reads Balance 
Unlocked. Then by activating the AUTO ZERO button the desired pressure channel is 
set to zero mmHg. The Balance Unlocked button should then be activated to lock the 
pressure controls. However, the button automatically locks after a period of 60 seconds 
inactivity.  
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Figure 2-7 Millar MPVS Ultra control interface catheter calibration tab screen capture 
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The Composite Volume reading is numerically displayed on the Catheter Calibration 
tab. The values displayed on the calibration buttons change according to the current 
catheter configuration and are derived from Bann’s equation. Therefore, the segment 
volumes are derived from the current set values for alpha, rho and segment length. 
The values displayed on the calibration button represent the per-segment conductance 
/ volume. When the button is activated, the corresponding composite volume is 
displayed on the right-hand side of the button. A measurement of blood resistivity is 
performed during the clinical procedure as described in Section 2.4. At the start of a 
case, the correct size catheter is selected along with setting the blood resistivity to 180 
ohms / cm on the Catheter Configuration tab, as described in Section 2.4. The data 
acquisition system incorporates six internal resistors of known conductance that are 
used to convert the voltage signal into a volume. Only two buttons will be selectable at 
any given range; the available button will be beige and the unavailable buttons will be 
greyed out (Figure 2-7). The MPVS Control Interface automatically determines the 
available buttons from the catheter segment length and gain setting selected on the 
Catheter Configuration tab, as described in Section 2.4. Figure 2-7 shows the volume 
options available for a 7F 5cm over 8 electrode catheter when the blood resistivity is 
set to 180 ohms / cm. To calibrate the lower range of the volume segments the 12.1-ml 
button should be activated (highlighted green), so that the MPVS Ultra will output a 
12.1 ml volume signal on the five volume segment volume channels and a 60.34 ml 
volume signal is outputted on the composite volume channel. To calibrate the upper 
range of the volume segments the 43.2-ml button should then be activated (highlighted 
green), so that the MPVS Ultra will output a 43.2 ml volume signal on the five volume 
segment volume channels and a 216.0 ml volume signal is outputted on the composite 
volume channel. The Transducer button should then be activated so that the MPVS 
Ultra will read the volumes measured on the five volume segments and the composite 
volume on the Millar catheter. At the end of the procedure, the volume calibration is 
repeated after correcting the blood resistivity value displayed on the Catheter 
Calibration tab to the measured blood resistivity.  
 Page 65 
2.4.2.3 Rho Cuvette Tab 
The Rho Cuvette tab (Figure 2-8) was used to measure the subjects’ blood resistivity. 
The Millar Cuvette Selection field was used to identify the Millar MPVS Ultra cuvette 
used to perform the measurement (Figure 2-9). The K Factor is a calibration value 
supplied by Miller for the specific Millar MPVS Ultra Cuvette supplied with the system. 
The K Factor is used to reduce the error in resistivity reading caused by slight 
variations that are inherent in the design of the cuvette. Three different cuvettes are 
used with the system, so care must be taken to ensure the correct Cuvette with the 
correct K-Factor was selected in the Rho Cuvette tab when performing a measurement 
of blood resistivity. The Millar MPVS Ultra is set up to allow for seven different gain 
settings which can be used to optimise the accuracy of the resistivity reading 
depending on the fluid to be measured. When performing measurements on human 
and animal blood, the blood resistivity measurements should be carried out with the 
gain set to x 2.  
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Figure 2-8 Millar MPVS Ultra control interface Rho cuvette tab screen capture 
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The cuvette must be connected to the Cuvette input to perform a measurement of 
blood resistivity from a sample of the subjects’ blood, as shown in Figure 2-5. The 
appropriate cuvette must be selected in the Cuvette Selection field. The cuvette should 
be placed on a flat dry surface. Using a heparinised syringe the operator will draw up 3 
to 5 ml of blood from the subject. While wearing protective gloves, the syringe of blood 
is then taken from the operator and injected into the well on the cuvette. The blood 
should be level with the top surface of the cuvette. Click on the Measure button in the 
Rho Cuvette tab and the Measured Snapshot will then display the measured resistivity, 
temperature and conductivity of the blood sample. The blood sample is disposed of 
using the correct Catheter Laboratory procedures. The cuvette is rinsed with warm 
water and then air-dried.  
  
 Page 68 
 
Figure 2-9 Millar (Houston, Texas, USA) MPVS Ultra cuvette 
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2.4.3 ADInstruments PowerLab 16/30 Series 
The ADInstruments PowerLab 16/30 Series front panel connections are shown Figure 
2-10. The PowerLab has three indicators at the left-hand side of the panel. All three 
indicators turn on briefly when the PowerLab is switched on. The Power indicator will 
illuminate blue when the system is turned on and receiving power. The Status indicator 
will flash yellow and then illuminate green when the system is turned on and receiving 
power. The Trigger indicator will flash yellow and turn off when a trigger signal is 
received the indicator will illuminate yellow. The Status indicator is used to 
communicate what is happening between the PowerLab and PC. The Status indicator 
will: illuminate green when the system is receiving power and is idle; illuminate yellow 
when it is sampling or communicating with the PC; illuminate red and flash if the 
system has detected a communication fault. The PowerLab has sixteen independent 
BNC connector inputs (1 – 16). The analogue inputs can receive external signals in the 
±2 mV to ±10 V range with a maximum input voltage of ±15 V. A fixed 25 kHz analogue 
low pass filter is attached to each analogue input. Digital signal processing can be 
performed on each analogue input using the LabChart software (See Section 2.4) to 
set the gain, filtering, AC/DC coupling and to calibrate the input signals. The input 
impedance between the analogue inputs and earth pin on the rear panel is 100 Ohms. 
The analogue inputs are connected to the pressure output (P1), volume outputs 
(Composite, V1 – V5) and ECG Output on the Millar MPVS Ultra system using BNC 
connectors.  The rear panel on the PowerLab has a USB port (v1.1 or later), which can 
be used with a USB cable to connect the PowerLab to the Windows PC running the 
LabChart software (See Section 2.4). At the start of each case, the USB cable between 
the PowerLab and the PC must be connected before the entire system is switched on. 
An IEC power cable connector can be used to connect the PowerLab to the mains 
power supply. The PowerLab is a Class I Type CF medical device, and an earth pin is 
provided which provides a direct connection to the earth pin on the power socket and 
the PowerLab metal casing.  
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Figure 2-10 ADInstruments (New South Wales, Australia) PowerLab 16/30 front panel hardware 
connections 
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2.4.4 ADInstruments LabChart Pro Software 
2.4.4.1 ADInstruments LabChart Pro Settings File 
A settings file was created to specify the different recording and display setting for each 
channel. To create a settings file (Figure 2-11) the Channel Settings Dialogue was 
opened when the Laptop was connected to the ADInstruments PowerLab and Millar 
MPVS Ultra boxes. In the bottom left-hand corner of the Channel Settings Dialogue, 
the number of channels was increased to 26. Channels 1 -16 correspond to the 16 
BNC input connected to the front panel of the PowerLab. The remaining channels 17 – 
26 are used for arithmetic data processing. The channel descriptions for a single RV 
setup are shown in Table 2-1. A number of the channels are switched off during RV 
measurement since the ADInstruments PowerLab, and Millar MPVS Ultra boxes 
remain permanently connected up to perform simultaneous LV and RV measurements.  
  
 Page 72 
 
Figure 2-11 ADInstruments LabChart RV measurement setup screen capture 
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Table 2-1 ADInstruments LabChart RV channel description 
Channel  Channel Description Channel Source 
1 OFF N/A 
2 RV Pressure Millar MPVS Ultra Pressure Output P1 
3 OFF N/A 
4 OFF N/A 
5 OFF N/A 
6 OFF N/A 
7 OFF N/A 
8 OFF N/A 
9 ECG Millar MPVS Ultra ECG Output 
10 RV Composite Volume Millar MPVS Ultra Volume Output Composite 
11 RV Volume Segment 1 Millar MPVS Ultra Volume Output S1 
12 RV Volume Segment 2 Millar MPVS Ultra Volume Output S2 
13 RV Volume Segment 3 Millar MPVS Ultra Volume Output S3 
14 RV Volume Segment 4 Millar MPVS Ultra Volume Output S4 
15 RV Volume Segment 5 Millar MPVS Ultra Volume Output S5 
16 Slaved ECG BNC ECG Output from Catheter Laboratory 
17 OFF N/A 
18 dp/dt(RV) Derivative of Channel 2 
19 OFF N/A 
20 HR (RV) Cyclic Measurement Channel 2 
21 OFF N/A 
22 SV (RV) Cyclic Measurement Channel 26 
23 OFF N/A 
24 CO (RV) Arithmetic -  (Channel 20*Channel 22)/1000 
25 OFF N/A 
26 RV Comp Millar Arithmetic -  (1/alpha)*Ch10-Vc 
  
 Page 74 
2.4.4.2 LabChart Pro Data Collection   
At the start of the research study the Millar MPVS Ultra, ADInstruments PowerLab and 
Laptop were connected as described above. The RV LabChart settings file was loaded, 
and Millar MPVS Ultra Control Interface was opened on the laptop. In the LabChart file, 
the Start button was activated on the bottom right-hand corner of the Chart View. The 
MPVS Ultra Control Interface was then used to input the 2-point calibration signal for 
both the pressure and volume channels as described in Section 2.4. The calibration 
signal was highlighted on Channel 2 (RV Pressure). The Channel Function popup 
menu was selected on Channel 2 (RV Pressure), and the Units Conversion button was 
selected to open the Units Conversion dialogue. The pressure trace was selected for 
the 0.0-mmHg input signal, and the mean voltage was then calibrated to corresponded 
to 0.0-mmHg pressure (Figure 2-12).  The pressure trace was selected for the 100.0-
mmHg input signal, and the mean voltage was then calibrated to corresponded to 100-
mmHg pressure.   
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Figure 2-12 Pressure channel calibration screen capture 
  
 Page 76 
The calibration signal was highlighted on Channel 10 (RV Composite Volume) to 
calibrate the composite volume channel. The Channel Function popup menu was 
selected on Channel 10 (RV Composite Volume), and the Units Conversion button was 
selected to open the Units Conversion dialogue. As previously described in Section 
2.4, for a 5cm catheter an 180 ohm/cm calibration signal would be used to calibrate the 
volume channels at the start of the study. The volume trace was selected for the 216.0 
ml input signal and the Point 1 mean voltage was then calibrated to corresponded to a 
216-ml volume (Figure 2-13). The volume trace was selected for the 60.34 ml input 
signal, and the Point 2 mean voltage was then calibrated to corresponded to a 60.34-
ml volume. To calibrate the composite volume channel, the calibration signal was 
highlighted on Channel 11 (RV Volume Segment 1). The Channel Function popup 
menu was selected on Channel 11 (RV Volume Segment 1), and the Units Conversion 
button was selected to open the Units Conversion dialogue. The volume trace was 
selected for the 43.2 ml input signal and the Point 1 mean voltage was then calibrated 
to corresponded to a 43.2-ml volume. The volume trace was selected for the 12.1 ml 
input signal, and the Point 2 mean voltage was then calibrated to corresponded to a 
12.1-ml volume. This process was repeated for the remaining four segment volume 
channels 12 (RV Volume Segment 2) – 15 (RV Volume Segment 5).  
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Figure 2-13 Volume channel calibration screen capture 
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The sterile Millar conductance catheter was connected to the Millar MPVS Ultra, and 
pressure channel zeroed to atmospheric pressure as described in Section 2.4. Via a 
femoral or jugular approach, the operator positioned the catheter in the RV. After 
activating the sampling button, the position of the catheter in the RV was confirmed 
using the XY View and that pressure and volume signals were received on all channels 
on the Chart View. The Toggle Data Recording / Monitoring button could then be used 
to change between data monitoring mode (used to observe the PV-loop without 
recording data) and data recording mode. A saline calibration was then performed to 
correct for parallel conductance. The Toggle Data Recording / Monitoring button was 
used to start the file recording. The ventilator was stopped at end-expiration, or the 
patient was asked to perform a breath hold by the operator. The preset file marker 
PWC 10mls of 10% NaCl was used to mark a saline injection on the LabChart file. The 
operator injected 5mls of hypertonic saline followed by a 5ml saline flush into the port 
on the venous sheath. The XY View was monitored to ensure an increase in the stroke 
volume was recorded. The Toggle Data Recording / Monitoring button was used to 
switch back to monitoring mode. The ventilator was started, or the patient was told that 
they could start breathing. The saline injection was repeated to ensure an accurate 
volume offset could be calculated. 
Steady state PV-loops were recorded by using the Toggle Data Recording / Monitoring 
button to start the file recording. The ventilator was stopped at end-expiration, or the 
patient was asked to perform a breath hold by the Operator. The preset file marker 
Baseline was used to mark a steady state PV-loop recording on the LabChart file. 
Approximately 10 to 15 steady state PV-loops were recorded before the ventilator was 
started or the patient was told that they could start breathing. All recordings were 
repeated to ensure consistent and accurate data was collected.  
Load independent PV-loops were recorded using an IVC balloon occlusion to alter the 
preload on the heart. The operator used a further femoral venous sheath to position a 
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34ml-sizing balloon in the mouth of the right atrium. The Toggle Data Recording / 
Monitoring button was used to start the file recording. The ventilator was stopped at 
end-expiration or the patient was asked to perform a breath hold by the consultant 
cardiologist. The preset file marker IVC Occlusion was used to mark an IVC Occlusion 
PV-loop recording on the LabChart file. The balloon was inflated with a contrast agent 
by the operator to occlude the IVC. Approximately 15 to 20 seconds of PV-loops were 
recorded before the balloon was deflated. The ventilator was started, or the patient was 
told that they could start breathing. All recordings were repeated to ensure consistent 
and accurate data was collected. 
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2.5 PV-Loop Data Analysis 
2.5.1 Steady State PV-Loop Analysis 
PV-loop data was analysed offline using LabChart Pro 8.0 software package. The files 
were link anonymised on the laptop and transferred to a desktop PC for analysis. The 
Analysis Manager function was used to mark and record a selection of six steady state 
PV-loops that were recorded at end-expiration during a breath hold or suspended 
ventilation (Figure 2-14). The correct data points are located using the comments 
(Baseline) that were marked on the file during the clinical procedure. The PV-loops 
were recorded on the analysis manager using the following coding:  
RV Description (comment number): Alpha (Conductance CO / Actual CO) – Vc 
Description - Baseline or Post Intervention 
Comment Number – cross-reference to the comment number that the PV-loops 
correspond to on the LabChart file 
Conductance CO – CO derived from the conductance catheter 
Actual CO – CO derived from Fick or Thermodilution technique 
Vc – Volume correction derived by the saline injection technique  
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Figure 2-14 LabChart RV data selection screen capture 
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The conductance derived CO was then calculated for the steady state PV-loops. This 
was performed to correct for the dimensionless slope factor Alpha described in 
section2.3. On the PV-loop taskbar, the Settings button was selected to open the PV-
loop Setting dialogue (Figure 2-15). The pressure signal was then set to Channel 2 (RV 
Pressure), and the volume signal was set to Channel 10 (RV Composite Volume). The 
analysis region was set to the selection only. The OK button was then selected to run 
the analysis and close the PV-loop Setting dialogue. On the PV-loop taskbar, the 
Hemodynamics Table button was selected to open the hemodynamics table and the 
conductance derived CO was recorded. The Arithmetic channel calculation was then 
opened on Channel 26 (RV Comp – Millar) so that the following equation could be 
entered to correct for the dimensionless slope factor Alpha: 
(1/(Conductance CO / Actual CO)) * Ch10 – 1 
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Figure 2-15 LabChart CO correction screen capture 
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The saline calibration was then analysed to correct for the volume offset described in 
section 2.3. The correct data points were located using the comment (saline 
calibration) that was marked on the file during the clinical procedure. The Analysis 
Manager was used to mark and record a selection of PV-loops collected during the 
injection of 10% hypertonic saline. The PV-loops were recorded in the analysis 
manager using the following coding: 
Vc (comment number) = Volume Offset 
Vc = Saline injection derived volume correction 
Comment number – cross-reference to the comment number the PV-loops 
correspond to on the LabChart file 
Volume offset – volume of blood to be subtracted 
On the PV-loop taskbar, the Settings button was selected to open the PV Loop Setting 
dialogue. The pressure signal was then set to Channel 2 (RV Pressure), and the 
volume signal was set to Channel 26 (RV Comp – Millar). The analysis region was set 
to the selection only. The OK button was then selected to run the analysis and close 
the PV-loop Setting dialogue. On the PV Loop taskbar the PV-loop Plots button was 
selected, and then the Saline Calibration button was selected on the drop down tab to 
open the Saline Calibration plot (Figure 2-16). The analysed Vc is then displayed in the 
top left-hand corner. This value was recorded. The arithmetic channel calculation was 
then opened on Channel 26 (RV Comp – Millar) so that the following equation could be 
entered to correct for the parallel conductance Vc: 
(1/(Conductance CO / Actual CO)) * Ch10 – Vc  
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Figure 2-16 LabChart saline calibration screen s capture   
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The steady state PV-loops were then selected in the Analysis Manager. On the PV-
loop taskbar, the Settings button was selected to open the PV-loop Setting dialogue. 
The pressure signal was then set to Channel 2 (RV Pressure), and the volume signal 
was set to Channel 26 (RV Comp – Millar). The analysis region was set to the selection 
only. The OK button was then selected to run the analysis and close the PV-loop 
Setting dialogue. On the PV-loop taskbar, the Hemodynamics Table button was 
selected to open the hemodynamics table detailing all the hemodynamic parameters 
for the analysed PV-loops. This data was then transferred to an excel file for further 
statistical analysis.  
2.5.2 Load Independent PV Loop Analysis 
The Analysis Manager was used to mark and record a selection of PV-loops that were 
recorded during an IVC balloon occlusion as described in section 2.3. The correct data 
points were located using the comment (IVC Occlusion) that was marked on the file 
during the clinical procedure. The PV-loops are recorded on the analysis manager 
using the following coding: 
RV Description IVC Occlusion (comment number): ESPVR; EDPVR; PRSW 
Description - Baseline or Post Intervention 
Comment Number – cross-reference to the comment number the PV-loops 
correspond to on the LabChart file 
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Figure 2-17 LabChart PV-loop view screen capture   
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On the PV-loop taskbar, the Settings button was selected to open the PV-loop Setting 
dialogue. The pressure signal was then set to Channel 2 (RV Pressure), and the 
volume signal was set to Channel 26 (RV Comp – Millar). The analysis region was set 
to selection only. The OK button was then selected to run the analysis and close the 
PV-loop Setting dialogue. To determine ESPVR and EDPVR, on the PV-loop taskbar, 
the PV-loop View button was selected to open the PV-loop View plot (Figure 2-17). 
Individual PV-loops were selected by clicking on the loop number at the left-hand side 
of the PV-loop View plot. Only PV-loops with a checked box next to the respective PV-
loop number are included in the analysis. If an ectopic beat was included in the 
analysis, that beat was removed by un-checking the box. The ESPVR and EDPVR 
best-fit regressions values for the selected PV-loops are displayed in the top right-hand 
corner of the PV-loop View plot. To determine PRSW, on the PV-loop task bar, the PV-
loop Plots button was selected. The PRSW Plot button was selected on the drop down 
tab to open the PRSW plot. The PRSW best-fit regression value for the selected PV-
loops was displayed in the top right-hand corner of the PRSW plot. The values for 
ESPVR, EDPVR and PRSW were recorded on the record in the analysis manager. The 
data was transferred to an Excel file for statistical analysis.  
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Figure 2-18 LabChart PRSW plot screen capture   
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2.6 Determination of Cardiac Output 
Cardiac output (𝐶𝑂) is the effective volume of blood expelled by the ventricles per unit 
time and is used as a measure of the performance and health of the heart. A 
maintained 𝐶𝑂 is essential to deliver all the metabolic agents to the body and remove 
the unwanted waste products. 𝐶𝑂 is given by the following equation: 
Equation 2-6 
𝐶𝑂 = 𝐻𝑅  ×  𝑆𝑉 
Where the heart rate (𝐻𝑅) is in beats per minute and the stroke volume (𝑆𝑉) is the 
volume of blood pumped from a ventricle in a single heartbeat (l). The 𝐶𝑂 is directly 
correlated to the size of the patient, by way of standardising to the body surface area 
(𝐵𝑆𝐴) (m2). Cardiac index (𝐶𝐼) is given by the following equation: 
Equation 2-7 
𝐶𝐼 =    𝐶𝑂𝐵𝑆𝐴 
The ejection fraction (𝐸𝐹 ) is the volumetric fraction of blood ejected in a single 
heartbeat, and is given by the following equation: 
Equation 2-8 
𝐸𝐹 =    𝑆𝑉𝐸𝐷𝑉 
Where the end-diastolic volume (𝐸𝐷𝑉) is the volume of blood left in the ventricle at the 
end of diastole. The end-systolic volume would be the volume of blood left in the 
ventricle at the end of systole. Throughout the research completed during the clinical 
studies CO was calculated invasively using the thermodilution method and the Fick 
principle; and non-invasively using echocardiography techniques.  
 Page 91 
2.6.1 Thermodilution 
The pulmonary artery catheter, known as the Swan-Ganz catheter, allows the direct 
measurement of right atrial, right ventricular, and pulmonary artery pressures and 
blood saturations. It also allows the indirect measurement left atrial or wedge pressure 
by inflating the balloon when positioned in a pulmonary artery. By inserting a venous 
sheath into the internal jugular or femoral vein, the catheter can be passed along the 
vein and positioned within the right atrium, passed into the right ventricle, then out into 
the pulmonary artery. After inflating the balloon when the catheter is in the pulmonary 
capillary, a wedge pressure (PCWP) can be recorded as a measure of the left atrial 
pressure transmitted back through pulmonary veins to pulmonary capillaries and 
recorded when catheter wedged in a peripheral branch.  
The catheter is also used to perform the thermodilution method of determining CO. The 
catheter is advanced into the pulmonary artery, and the balloon is inflated to float the 
catheter tip into the pulmonary artery. When in-situ the balloon is deflated. The tip of 
the catheter contains a temperature-sensitive thermistor that is used to measure the 
transient temperature change after injection of a small bolus (10 ml) of cold saline 
(0.9% NaCl). By measuring the blood temperature a known distance from the tip of the 
catheter, CO can be calculated by measuring the resistance change of the thermistor 
as a function of time as it responds to the pulmonary artery blood temperature change 
due to the injected bolus of saline. A greater temperature change will correspond to a 
lower cardiac output. Thermodilution derived CO measurement would normally be 
repeated 3 to 5 times and a mean measurement would then be taken as the true CO. 
2.6.2 Fick Principle 
The Fick principle states that if the oxygen concentration in arterial blood supplying an 
organ, the oxygen concentration in venous blood leaving an organ, and the rate of 
oxygen uptake by an organ per unit time is known, then the cardiac output can be 
calculated by the following equation: 
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Equation 2-9 
𝐶𝑂 =    𝑉𝑂!𝐶! −   𝐶! 
Where 𝑉𝑂! is the oxygen consumption (l/min), 𝐶! is the oxygen concentration of the 
blood sample taken from the artery (l/l), and 𝐶! is the oxygen concentration of the blood 
sample taken from the pulmonary artery (l/l). The blood samples are analyzed in a 
blood-gas analyzer to determine the oxygen concentration, and the oxygen 
consumption is measured by using spirometry. By assuming a value for oxygen 
consumption, cardiac output can be closely approximated to the actual value without 
the need for the spirometry equipment. The assumed oxygen consumption is typically 
calculated from the LaFarge equation: 
Equation 2-10 
𝑉𝑂!  ~!"#$% = 138.1 − 11.49 log! 𝑎𝑔𝑒 + (0.378𝐻𝑅) 
and 
Equation 2-11 
𝑉𝑂!  ~!"#$%"& = 138.1 − 17.04 log! 𝑎𝑔𝑒 + (0.378𝐻𝑅) 
Where 𝑉𝑂!  ~!"#$% is the assumed oxygen consumption in males and 𝑉𝑂!  ~!"#$%"& is the 
assumed oxygen consumption in females (ml / min / m2).  
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2.7 Echocardiographic Assessment 
Echocardiography was used in the second clinical study to assess RV function and 
aortic valve stenosis (AS) severity to determine if aortic valve replacement was 
needed. These measurements are performed as part of the routine care pathway for 
patients undergoing transcatheter aortic valve implantation (TAVI) at Papworth Hospital 
NHS Foundation Trust. 
2.7.1 Ultrasound Machines  
A Philips iE33 ultrasound scanner (Philips Healthcare, MA, USA) was used to perform 
transthoracic echocardiographic (TTE) and transesophageal echocardiographic (TEE) 
assessment of the patients’ aortic valve stenosis and right ventricular function during 
the transcatheter aortic valve implantation (TAVI) study. TEE was performed using an 
X7-2t transducer (Philips Healthcare, MA, USA). TTE was performed using either an 
X3-1 or S5-1 transducer (Philips Healthcare, MA, USA).  
2.7.2 Aortic Valve Assessment 
Initial aortic valve assessment was performed with a TEE ultrasound probe in an 
outpatients’ clinic to determine that the patients were suitable for undergoing a TAVI 
procedure. The difference in pressure between the LV and aorta in systole, the 
transvalvular gradient, is a standard measure of AS severity (Currie et al., 1985). A 
stenosis of the aortic valve creates an obstacle to aortic ejection, increasing the 
gradients between the LV and aorta. Doppler was used to measure the maximum 
velocity across the aortic valve and then the pressure gradient was determined using 
Bernoulli law. An apical 5 chamber view was used to align the Doppler beam with the 
jet through the aortic valve. The peak gradient was determined from the peak velocity 
of the jet. The mean gradient was determined by averaging the instantaneous gradient 
by the ejection period. Although there is a good correlation between peak and mean 
gradients, the relationship depends on the shape of the velocity curve which varies with 
the severity of AS, therefore, mean gradients are normally reported. Mean 
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transvalvular gradients greater than 40-mmHg are defined as severe AS (Baumgartner 
et al., 2009). 
Aortic valve area (AVA) is calculated based on the continuity-equation concept that the 
stroke volume (SV) ejected through the LV outflow tract (LVOT) all passes through the 
stenotic aortic valve. Because volume flow rate through any cross sectional area (CSA) 
is equal to the CSA times flow velocity over the ejection period (the velocity time 
integral (VTI) of the systolic velocity curve), the aortic valve area can be determined: 
Equation 2-12 
𝐴𝑉𝐴 =   𝐶𝑆𝐴!"#$×𝑉𝑇𝐼!"#$𝑉𝑇𝐼!"  
Where 𝐶𝑆𝐴!"#$ is the CSA of the LVOT, 𝑉𝑇𝐼!"#$ is the VTI of the LVOT and 𝑉𝑇𝐼!" is 
the VTI of the aortic valve. A parasternal long-axis view was used to measure the 
diameter of the LVOT. The LVOT diameter was measured at the start of diastole. In 
adults the LVOT diameter is approximately 18-25 mm. An apical five-chamber view 
was used to measure the VTI of the LVOT and across the aortic valve. In adults the 
AVA is approximately 3-4 cm2, severe AS is defined as an AVA <1.0 cm2 (Baumgartner 
et al., 2009). The effective orifice area index (EOAI) is used to correct an AVA 
measurement in small or large patients. The EOAI was calculated by dividing the AVA 
by the patients’ body surface area, severe AS is defined as an EOAI <0.6 cm2/m2 
(Baumgartner et al., 2009). 
The final step in evaluating the severity of AS is to determine the LV EF. The LV EF is 
calculated from the difference between the EDV – ESV divided by the EDV. An apical 
four-chamber view was used take a 2D measurement of the LV volume at end-systole 
and end-diastole. The LV EF function on the ultrasound scanner was used to trace the 
endocardial boarder at end-systole and again at end-diastole to compute the LV EF. 
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An LV EF greater than 50% is good, between 30-49% is moderate and below 30% is 
poor (Baumgartner et al., 2009). 
2.7.3 RV Functional Assessment 
Tricuspid annular plane systolic excursion (TAPSE) represents the distance of systolic 
excursion of the RV annular plane to the RV apex. It was obtained using M-Mode 
aligned through the triscupid lateral annulus in a four-chamber view and measuring the 
longitudinal displacement at systole. In the normal RV, TAPSE should be greater than 
15-20 mm (Jurcut et al., 2010), and has been shown to correlate well with isotopic RV 
ejection fraction (Kaul et al., 1984).  
RV fractional area change (FAC) expresses the percentage change in RV area 
between end-diastole and end-systole. An apical four-chamber view was used take a 
2D measurement of the RV volume at end-systole and end-diastole. The RV FAC 
function on the ultrasound scanner was used to trace the endocardial boarder at end-
systole and again at end-diastole to compute the RV FAC. RV FAC has been shown to 
have a good correlation with MRI-derived RV ejection fraction (Morcos et al., 2009). 
The main limitation when calculating RV FAC is the need for good endocardial boarded 
delineation, which can be challenging in the trabeculated RV.  
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2.8 Electrical Safety   
The electrical medical devices used in this study were electrically safety tested by the 
Clinical Engineering Department at Papworth Hospital NHS Foundation Trust. The 
devices are tested to the IEC 60061-1 standard. The devices are tested annually and 
this is recorded on the medical device asset register and the devices will be labelled 
with a next test due label.  
The Millar MPVS Ultra, ADInstruments PowerLab’s 16/30 and Windows Laptop running 
the Millar MPVS Ultra Control Unit and ADInstruments LabChart software are operated 
in a medical electrical system to perform conductance derived PV-loop measurements. 
The IEC power sockets on the Millar MPVS Ultra, ADInstruments PowerLab’s and 
power transformer on the Windows Laptop are powered through an ONEAC (Chloride 
Power, Columbus, OH, USA) PCM1000I medical grade isolation transformer. The 
isolation transformer provides 1000 VA at a maximum of 4.2 A, which allows the 
system to be operated with a single earth point and limits the earth leakage current to 
levels acceptable in the IEC 60061-1 standard. 
2.9 Summary 
This chapter has described the materials and methods common to the experimental 
and clinical research completed for the remainder of this thesis. 
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3 The Development of an Porcine Model of Right 
Ventriculoarterial Coupling  
This chapter describes the methodological development of the porcine model of right 
ventriculoarterial coupling used in Chapter 4. The aim of this chapter is to develop a 
porcine model which can be used to determine if the theory of LV ventriculoarterial 
coupling and the Pressure-Volume relationship described by Sunagawa et al. (1987) 
can be translated to the thinner-walled RV that pumps at lower pressures. Section 1.6 
describes a mathematical theory of using the pressure-volume relationship to assess 
LV ventriculoarterial coupling. This theory can be assessed in the RV to confirm if it is 
consistent between ventricular chambers. To test the theory of ventriculoarterial 
coupling of the RV, the technique of a working heart perfusion rig to assess LV 
ventriculoarterial interaction and coupling must be validated. Once confirmation of the 
work described by Sunagawa et al. (1987) has been achieved, the RV working heart 
perfusion rig can be developed to determine if similar pressure-volume relationships of 
the RV and pulmonary artery exist.  
Section 3.1 describes the validation of an ex-vivo model of LV ventriculoarterial 
coupling and the Pressure-Volume relationship described by Sunagawa et al. (1987). 
This was performed to ensure that the working heart apparatus used in this study could 
successfully validate the findings previously described by Sunagawa. After 
demonstrating this work was repeatable, Section 3.2 describes the translation of this 
work into an ex-vivo model of RV ventriculoarterial coupling and the Pressure-Volume 
relationship. Due to complexities in RV physiology and limitations with the RV working 
heart apparatus it was not possible to develop a physiologically accurate ex-vivo model 
of RV ventriculoarterial coupling. Therefore, Section 3.3 describes the development of 
an in-vivo model of RV ventriculoarterial coupling. The model developed in Section 3.3 
is then used in Chapter 4 to define the optimal ventriculoarterial coupling ratio of the 
porcine RV – PA. 
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As this work was not funded from the grant awarded to me by the NIHR some 
methodological compromises had to be accepted. This work was carried out under Dr 
Simon Messer’s Project License 70/7967 - Is the circulatory determined death (DCD) 
donor heart suitable for transplantation. Their experimental protocol required that 
baseline PV-Loop assessments were performed following sternomoty, pericardectomy 
and with the hearts paced atrial. The operating theatre at the Royal Veterinary College 
does not have access to a mobile fluoroscopy unit. Therefore, the conductance 
catheters were placed in the ventricle via an apical puncher rather than percutaneously 
under fluoroscopic guidance.  
3.1 An Ex-Vivo Model of Left Ventriculoarterial Interaction: 
Validation of Sunagawa’s Model 
3.1.1 Introduction 
This section describes the validation of an ex-vivo model of LV ventriculoarterial 
coupling and the Pressure-Volume relationship described by Sunagawa et al. (1987). 
This was performed to ensure that the working heart apparatus used in this study could 
successfully validate the findings previously described by Sunagawa. The design and 
development of an LV working heart model perfusion rig for the ex-vivo assessment in 
a porcine model of LV ventriculoarterial interaction and coupling will be described.  
3.1.2 Methods  
This work was carried out at the Royal Veterinary College (Hatfield, London) under the 
Project Licence 70/7967 as previously described in Section 2.2.3. As previously 
described in Section 2.2.5, Dr Hatim Alibhai (Consultant Veterinary Anaesthetist) was 
responsible for the humane care of the animals and performed the anaesthetic 
preparation of the animals. Dr Simon Messer performed the surgical preparation. 
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3.1.2.1 Development of an LV Working Heart Perfusion Rig 
3.1.2.1.1 Concept Design Requirements  
The basic concept design requirements for an LV working heart perfusion rig is shown 
in Figure 3-1. An isolated heart needs to be perfused by Langendorff (Langendorff, 
1895) retrograde perfusion of the coronary arteries within a system that can be 
modified into an LV working heart for functional assessment. The heart is perfused in a 
reverse fashion via the aorta; this backwards flow causes the aortic valve to close 
forcing the blood into the coronary arteries to perfuse the myocardium. The isolated 
heart is suspended in a chamber so that the perfused blood can drain into the 
reservoir. A centrifugal pump pumps the perfused blood from the reservoir through a 
blood filter and oxygenator. A heating mechanism warms the blood to 37°C. Typically 
this is achieved by circulating heated water through the oxygenator. The warm, 
oxygenated blood is then pumped along the circuit and into the aorta to perfuse the 
coronary arteries retrograde. Compliance chambers are placed in series with the inflow 
and outflow of the heart. Compliance chambers help to regulate the cyclic pressure by 
correcting for any intrinsic cyclic instability from perfusion pump pressure. The flow 
circuitry is designed so that the same pump can be used in a modified working heart 
configuration to fill the heart via the left atrium and pump blood out through the aorta 
into the aortic afterload chamber and then drain into the blood reservoir. A monitoring 
device is required to measure LA and aortic flows and pressures. 
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Figure 3-1 Concept design for the LV working heart perfusion rig 
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3.1.2.1.2 LV Working Heart Perfusion Rig 
The TransMedics Organ Care System (OCS) (Andover, MA, USA) provides a 
Langendorff heart perfusion system with all the necessary connectors, tubing, 
compliance chambers, oxygenators, heaters, infusion pumps, flow sensors and 
pressure monitors contained in a single mobile unit (Figure 3-2). TransMedics have 
proprietary priming and maintenance solutions (this is used to replenish nutrients and 
substrates into the blood). The priming solution is mixed with 20 mEq of 8.4% sodium 
bicarbonate and 250 mg methylprednisolone, before emptying into the blood reservoir 
with approximately 1.5 litres is blood from the sacrificed animal. 30 units of insulin are 
added to the maintenance solution before priming the line and attaching to the built-in 
Alaris pump (30 ml / hr). A 500 ml bag of 5% glucose had 0.25 ml adrenaline and 50 
units of insulin added to it, before priming a line and attaching it to a second built-in 
Alaris pump (10 ml / hr).  
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Figure 3-2 TransMedics (Andover, MA, USA) Organ Care System (OCS) 
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The TransMedics OCS was modified to provide an LV working heart perfusion (Figure 
3-3). A Biomedicus centrifugal pump (BPX-80 BIO Pump Plus, Medtronic, USA) was 
connected to the system so that the propriety TransMedics OCS pump could be 
bypassed in the circuitry. The Biomedicus pump was then used to pump the perfused 
blood from the reservoir through the oxygenator and heater. The pump was replaced to 
provide a constant pulsatile flow so that functional assessment could be performed 
using the conductance technique. This tube was then split into two; one to act as the 
flow controlled Langendorff, and the second to act as the LA inflow port. The 
compliance chamber was then moved to the inflow of the aorta, for flow controlled 
Langendorff. The inflow to the aorta was then split a second time, to act as the 60-
mmHg afterload, set by the height of the afterload chamber. Again a compliance 
chamber was added to this circuitry. This combination of modifications to the propriety 
TransMedics OCS circuitry would allow us to clamp off the Langendorff perfusion and 
put the isolated heart into an LV working heart perfusion. 
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Figure 3-3 Modified TransMedics (Andover, MA, USA) OCS in LV working heart mode 
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3.1.2.2 Surgical Preparation  
The pigs were fasted for 12 hours leading up to the procedure. Water was allowed until 
one hour before premedication. Premedication was undertaken with intramuscular 
injection of midazolam (0.5 mg/kg), ketamine (15 mg/kg) and atropine (0.02 mg/kg). 
Induction of anaesthesia was performed using an intravenous (IV) injection of fentanyl 
(5.0 mcg/kg) over 5 min and propofol (2.0-4.0 mg/kg) administered to effect. Oral 
endotracheal intubation was established for institution of mechanical ventilation 
(Aestiva 5, GE Healthcare, Hatfield, UK) with a respiratory rate of 12-15 breaths per 
min and tidal volume 10 ml/kg. The ventilator was set with volume control with peak 
pressure was always lower than 12 cmH2O and positive end-expiratory pressure 
(PEEP) of 5 cmH2O. Paralysis was induced with an IV injection of pancuronium (0.15 
mg/kg). Maintenance of anaesthesia was performed using syringe drivers (Asena CC, 
CareFusion, Hatfield, UK) with a constant rate infusion of fentanyl (0.2 mcg/kg/min) 
and propofol (0.2 mg/kg/min). Arterial and venous cannulas were located for 
measurement of arterial blood pressure and central venous pressure respectively using 
multi-parameter anaesthesia monitor (GE Healthcare S5, Hatfield, UK). Before to 
placing the conductance catheter into the RV an IV injection of lidocaine (100mg, total 
dose) was administered.  
The chest was prepared with a surgical scrub and draped to create a sterile operating 
environment. A midline sternotomy was performed, and the pericardium was removed. 
A small incision into the wall at the apex of the LV and sewing a purse string around 
the opening allowed a Millar conductance catheter to be securely located in the LV for 
functional assessment using the conductance catheter. A 7-F, 8 electrode conductance 
catheter (Millar Instruments, Houston, Texas, USA) was inserted through a puncher in 
the LV apex and placed along the long axis of the ventricle (Section 2.4). PV-loop 
morphology was used to confirm the correct placement of the catheter within the LV. 
Routine Swan-Gantz catheterization was performed via a 7-F sheath placed in the right 
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jugular vein, and the thermodilution technique was used to calculate cardiac output 
(Section 2.6.1).  
3.1.2.3 Surgical Preparation of the Isolated Heart  
After performing an initial assessment of hemodynamic function within the native 
physiological system to ensure that the hearts were healthy, a small incision was then 
made in the wall of the right atrium and a cannula was inserted into the heart. This 
cannula was used to collect 1.5L of blood to prime the TransMedics OCS in addition to 
500mls of propriety priming solution (Figure 3-4). The TransMedics OCS pump flow 
was set to approximately 0.5 l/min so the blood was circulated and allowed to warm to 
34°C. Retrieval of the heart was undertaken by cross clamping the ascending aorta, 
venting the heart and delivering 500mls of pressurised cold crystalloid cardioplegia at 
4°C directly into the aorta. Cardioplegia is delivered to intentionally cause the cessation 
of cardiac activity, lowering the metabolic activity of the heart and prevent cell death 
during the period of prolonged ischemia. The heart was then explanted in a standard 
fashion using surgical scissors to cut the pulmonary vessels, aorta and pulmonary 
artery; and submerged in a bowl of iced water. The aorta and pulmonary artery were 
then dissected and trimmed. A ¾ inch cannula was secured in the aorta using a sterile 
cable tie. The outflow tubing was then secured in the pulmonary artery using surgical 
silk.  
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Figure 3-4 Modified TransMedics (Andover, MA, USA) OCS primed with blood  
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The cannulised heart was then instrumented upon the TransMedics OCS, to provide 
retrograde Langendorff perfusion of the coronary arteries. The pump flow was then 
increased (approx. 0.75 - 1lt / min) to maintain a mean arterial pressure of 65 mmHg. 
The volumetric pumps (Alaris GP, CareFusion, San Diego, USA) containing the 
TransMedics propriety maintenance solution (30 ml / hr) and adrenaline solution (10 ml 
/ hr) were started (Section 3.1.2.1.2). Atrial and ventricular pacing wires were then 
sutured into the RV, connected to a Reocor external pacing box (Biotronik, Oregan, 
USA) and the heart was paced at 100 beats per minute (BPM). A small incision was 
then made in the apex of the LV, and a purse string was sutured in to allow the LV vent 
to be secured in place. The vent would later be replaced (when the heart was put into a 
working mode perfusion) by the conductance catheter for data collection. The inferior 
vena cava (IVC) and pulmonary veins were located and tied-off using surgical silk. A 
purse string was then sutured around a pulmonary vein to secure the LA cannula to 
allow the heart to be put into working mode perfusion.  
3.1.2.4 Functional Assessment of the Isolated LV Working Heart 
After 2 hours retrograde Langendorff reperfusion, the temperature of the circulating 
blood was increased to 37°C. The heart was allowed to reperfuse for this period to 
allow the myocardium to recover from the ischemic injury of cardioplegia and 
explanation. The Millar MPVS Ultra, ADInstruments PowerLab hardware and 
ADInstruments LabChart software was set up and calibrated as described in Chapter 
2. The LV vent was then removed, and the conductance catheter was positioned in the 
LV for data collection. The propriety TransMedic OCS pump was then switched over to 
the Biomedicus centrifugal pump (BPX-80 BIO Pump Plus, Medtronic, USA). The left 
side of the heart was put into working mode with an afterload set by height to 60 mmHg 
and a left atrial filling pressure of 20 mmHg. The CO; mean, systolic and diastolic LA 
pressures; mean, systolic and diastolic aortic pressures were recorded. Five steady-
state PV-loops were recorded to generate load-dependant parameters of the systolic 
and diastolic function. A family of PV-loops were recorded while partially clamping the 
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inflow to the LA to generate load-independent parameters of systolic and diastolic 
function during a preload reduction. This family of PV-loops was used to determine 
Ees. A second family of PV-loops were recorded while partially clamping the outflow to 
the aorta to generate load-independent parameters of systolic and diastolic function 
during an afterload increase (Figure 3-5). This was family of PV-loops was acquired to 
determine how the LV functions adapted to changes in Ea. 
A bolus of inotrope dopamine equivalent to a 20-minute infusion at 5 µg/kg/min was 
then given directly to the blood reservoir to increase contractility. This was perfused for 
15 minutes before repeating the measurement protocol. The CO; mean, systolic and 
diastolic LA pressures; mean, systolic and diastolic aortic pressures were recorded. 
Five steady-state PV-loops were recorded and families of PV-loops were recorded 
during a preload reduction and an afterload increase. This was performed to determine 
the effect of increasing Ees on LV function.  
This controlled variation of Ea while keeping Ees and heart rate constant, and then the 
independent variation of Ees while keeping Ea and heart rate constant, would allow us 
to describe ventriculoarterial coupling (Ees/Ea) for an isolated LV working heart. 
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Figure 3-5 Modified TransMedics (Andover, MA, USA) OCS in working heart mode and functional 
assessment with PV-loops 
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3.1.3 Results 
3.1.3.1 Demographics 
The demographic data is shown in Table 3-1. This demonstrated that this work was 
carried out on a porcine heart with normal baseline haemodynamics (CO and mPAP).  
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Table 3-1 Demographic data 
  Heart 
Demographics  
 Weight, kg 86.5 
 Height, cm 136.0 
Baseline Haemodynamics Prior to Explanation 
 Heart Rate, BPM 100 
 MAP, mmHg 50.0 
 MPAP, mmHg 22.0 
 Mixed Venous Sats,% 61.9 
 CO, L 6.4 
 CI, L/m2 3.8 
LV Working Mode Haemodynamics  
 MAP, mmHg 52.0 
 CO, L 3.0 
MAP = mean aortic pressure; MPAP = mean pulmonary arterial pressure; CO = 
Cardiac Output; CI = Cardiac Index. 
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3.1.3.2 Preload and the Pressure-Volume Relationship 
Figure 3-6 shows the effect of a preload reduction on LV function. The slope of the 
ESPVR determined that the load-independent marker of contractility, Ees = 1.63 
mmHg/ml. Table 3-2 shows the beat-to-beat analysis starting at baseline (PV-loop = 1) 
and then sequentially as the PV-loop morphology adapted due to the preload reduction 
(PV-loop = 6). This demonstrated that there was a gradual reduction in SW, ESP, EDP, 
EDV, ESV, dP/dt max and dP/dt min with decreasing preload. However, CO, SV and 
Ea remained constant. Therefore, the ventriculoarterial coupling ratio remained fairly 
constant increasing from Ees/Ea = 0.31 mmHg/ml at baseline to Ees/Ea = 0.32 
mmHg/ml at the greatest preload reduction.  
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Figure 3-6 A family of PV-loops recorded during a preload reduction 
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Table 3-2 LV haemodynamic data for each PV-loop during a preload reduction 
PV-loop 
Number 
SW CO SV ESP EDP EF Ea dp/dt 
max 
dp/dt 
min 
1 1530 3.3 20.9 121.6 10.1 56.5 5.3 2284 -1519 
2 1283 3.3 20.5 118.5 9.4 59.9 5.8 2206 -1473 
3 1149 3.4 21.1 115.8 8.7 62.7 5.5 2081 -1417 
4 800 3.6 22.2 115.8 7.2 71.4 5.2 1809 -1270 
5 810 3.4 21.4 113.4 6.4 64.6 5.3 1714 -1217 
6 698 3.5 21.9 110.6 6.2 66.1 5.1 1644 -1196 
SW = stroke work, mmHg.ml; CO = cardiac output, L; SV = stroke volume, ml; ESP = 
end-systolic pressure, mmHg; EDP = end-diastolic pressure, mmHg; EF = ejection 
fraction, %; Ea = Effective arterial Elastance, mmHg / ml; dP/dt max = maximum rate of 
isovolumic contraction, mmHg/s; dP/dt min = maximum rate of isovolumic relaxation, 
mmHg/s. 
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3.1.3.3 Afterload and the Pressure-Volume Relationship 
Figure 3-7 shows the effect of an increase in afterload on LV function. Table 3-3 shows 
the beat-to-beat analysis starting at baseline (PV-loop = 1) and then sequentially as the 
PV-loop morphology adapted due to the increase in afterload (PV-loop = 10). This 
change in PV-loop morphology confirmed that Ea increased with increasing afterload. 
Since Ees was calculated from the preload reduction as 1.63 mmHg/ml, the 
ventriculoarterial coupling ratio reduced from Ees/Ea = 0.31 at baseline to Ees/Ea = 
0.16 as the LV struggled to maintain ejection of blood against the increasing afterload. 
The reduction in SV and CO combined with the increases to SW, ESP, EDP, dP/dt 
max and dP/dt min, would indicate that the RV was struggling to maintain output with 
increasing afterload.  
  
 Page 117 
 
Figure 3-7 A family of PV-loops recorded during an increasing afterload  
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Table 3-3 LV haemodynamic data for each PV-loop during an afterload increase 
PV-
loop  
SW CO SV ESP EDP EF Ea dp/dt 
max 
dp/dt 
min 
1 936 3.0 18.6 98.3 9.9 49.7 5.3 1048 -844 
2 809 3.0 18.7 95.9 9.9 51.2 5.1 1072 -857 
3 833 2.9 18.0 102.9 10.0 48.0 5.7 1109 -900 
4 813 2.6 16.5 109.9 10.2 42.8 6.7 1156 -975 
5 777 2.7 16.9 119.7 10.5 43.2 7.1 1186 -1027 
6 1113 2.7 16.9 128.1 11.1 41.2 7.6 1265 -1130 
7 1027 2.5 15.9 133.8 11.5 36.9 8.4 1283 -1155 
8 1153 2.6 16.4 139.3 12.7 37.0 8.5 1332 -1202 
9 1216 2.4 15.2 141.5 13.2 33.1 9.3 1349 -1210 
10 1083 2.3 14.6 146.5 14.7 31.7 10.0 1365 -1226 
SW = stroke work, mmHg.ml; CO = cardiac output, L; SV = stroke volume, ml; ESP = 
end-systolic pressure, mmHg; EDP = end-diastolic pressure, mmHg; EF = ejection 
fraction, %; Ea = Effective arterial Elastance, mmHg / ml; dP/dt max = maximum rate of 
isovolumic contraction, mmHg/s; dP/dt min = maximum rate of isovolumic relaxation, 
mmHg/s. 
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3.1.3.4 Contractility and the Pressure-Volume Relationship 
Figure 3-8 shows the effect of an increase in contractility on LV function. While Ea 
remained fairly constant after using the inotrope dopamine to increase contractility, 
after performing a further preload reduction the slope of the ESPVR determined that 
the load-independent marker of contractility, Ees had increased to 3.22 mmHg/ml. This 
change confirmed that increasing LV contractility increased Ees while Ea remained 
constant, causing a two-fold increase in the ventriculoarterial coupling ratio (0.31 to 
0.64). The other indices of LV hemodynamic function are shown in Table 3-4. 
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Figure 3-8 Steady-state LV PV-loops at baseline (Blue) and after 5 µg/kg/min dopamine (Red) 
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Table 3-4 LV haemodynamic data at baseline and after a dopamine Infusion to Increase 
contractility 
  Baseline Dopamine 
 CO, L 3.0 3.8 
 SV, ml 19.5 23.1 
 EF, % 45.0 64.0 
 ESV, ml 27.3 27.5 
 EDV, ml 40.0 44.5 
 ESP, mmHg 89.0 116.3 
 EDP, mmHg 9.8 9.4 
 dp/dt max, mmHg/s 1029 2173 
 dp/dt min, mmHg/s -812 -1388 
CO = cardiac output; SV = stroke volume; EF = ejection fraction; ESV = end-systolic 
volume; EDV = end-diastolic volume; ESP = end-systolic pressure; EDP = end-diastolic 
pressure; dP/dt max = maximum rate of isovolumic contraction; dP/dt min = maximum 
rate of isovolumic relaxation. 
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3.1.4 Discussion 
This work has shown that the isolated LV working heart perfusion rig could be used to 
confirm Sunagawa’s theory on the relationship between LV ventriculoarterial coupling 
and the PV-loop. Firstly, this work has confirmed that an acute reduction in preload 
could be used to determine the Ees, and this reduction in preload caused the leftwards 
shift of the EDV point on the PV-loop while Ea remained constant. Although the SV did 
not decrease as would be expected from Sunagawa’s statement that “a decrease to 
the end-diastolic volume will cause the arterial ESPVR Ea to shift to the left. Hence, SV 
decreases” (Sunagawa et al., 1987); this work has confirmed that variations in preload 
have no effect on contractility (Ees) or afterload (Ea). Hence, the LV ventriculoarterial 
coupling ratio (Ees/Ea) remained constant.  
Secondly, this work has confirmed that an acute increase in afterload caused the 
rightwards shift of ESV point on the PV-loop and increased Ea. Although it was not 
possible to prevent the LV from dilating and filling with blood, which subsequently 
prevented the EDV from remaining constant. These experimental findings support 
Sunagawa’s statement that “increasing the arterial resistance increases the slope of 
the arterial ESPVR (Ea), hence the SV decreases as the intersection between the 
arterial and ventricular ESPVR moves to the right” (Sunagawa et al., 1987). Although 
the perceived increases in dP/dt max and dP/dt min suggest an immediate increase in 
contractility in response to the acute increases in afterload, this in fact just highlights 
the load-dependency of the measurement. The acute load variations used to determine 
Ees and the relationship between different RV hemodynamic parameters with Ees/Ea 
and Ea can be considered valid due to auto-regulation, termed the “Anrep Effect” - 
increasing afterload increases contractility and maintains CO, but it takes between 30 
to 60 seconds for contractility to adapt in response to acute loading variations (von 
Anrep, 1912). Data were acquired during partial occlusions over approximately 10 
seconds. Therefore, the perceived increases to dP/dt max and dP/dt min were due to 
the increase in ESP amplifying the measurement. Therefore, this work has confirmed 
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that while variations in afterload have no effect on contractility (Ees), Ea is increased; 
hence, the LV ventriculoarterial coupling ratio (Ees/Ea) reduces with increasing 
afterload.  
Finally, this work has confirmed that an increase in contractility increases the slope of 
the Ees and increases the SV. These experimental findings support Sunagawa’s 
statement that “An increase to the LV contractility will increase the slope of the 
ventricular ESPVR (Ees) while maintaining the same volume intercept V0. Since the 
slope of the arterial ESPVR (Ea) remains constant, SV increases” (Sunagawa et al., 
1987). Therefore, this work has confirmed that while variations in contractility have no 
effect on Ea, Ees is increased; hence, the LV ventriculoarterial coupling ratio (Ees/Ea) 
increases. These measurements have successfully replicated and validated 
Sunagawa’s work on the relationship between the PV-loop and ventriculoarterial 
coupling in the LV. 
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3.2 An Ex-Vivo Model of Right Ventriculoarterial Interaction 
3.2.1 Introduction 
The aim of this section was to translate the working heart apparatus developed in 
Section 3.1 for the ex-vivo model of LV ventriculoarterial coupling and develop a RV 
working heart perfusion rig to model RV ventriculoarterial coupling.  
3.2.2 Methods  
This work was carried out at the Royal Veterinary College (Hatfield, London) under the 
Project Licence 70/7967 as previously described in Section 2.2.3. As previously 
described in Section 2.2.5, Dr Hatim Alibhai (Consultant Veterinary Anaesthetist) was 
responsible for the humane care of the animals and performed the anaesthetic 
preparation of the animals. Dr Simon Messer performed the surgical preparation. 
3.2.2.1 RV Working Heart Perfusion Rig 
3.2.2.1.1 Concept Design Requirements  
The basic concept design requirements for an isolated RV working heart rig (Figure 
3-9) are the same as those described for the isolated LV working heart rig in Section 
3.1.2.1.1. However, the circuitry was designed so that the same pump can be used in a 
modified configuration to fill the heart via the right atrium and pump blood out through 
the pulmonary artery into the pulmonary afterload chamber and then drain into the 
blood reservoir, while maintaining perfusion of the coronary arteries. The monitoring 
device is now required to measure RA, PA and aortic flows and pressures. 
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Figure 3-9 Schematic of the RV working heart perfusion rig 
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3.2.2.1.2 RV Working Heart Perfusion 
The isolated RV working heart perfusion rig was manufactured in-house (Figure 3-10) 
from Perspex sheet, off-the-shelf oxygenators (QUADROX-i, Maquet, Rasstat, 
Germany), venous blood reservoirs (VHK 2000/2001, Maquet, Rasstat, Germany), 
silicon tubing and connectors, syringe pumps (Alaris CC CareFusion, San Diego, 
USA), water heaters (BioCal 370 BIOMEDICUS Cardiopulmonary Bypass Temperature 
Controller, Medtronic, Minneapolis, USA), centrifugal pumps (BPX-80 BIO-Medicus 
Pump Plus, Medtronic, Minneapolis, USA) and monitors (Datex Ohmeda S5, GE 
Healthcare, Buckinghamshire, UK). A cradle was made in-house using Perspex sheet 
to rest the isolated heart on and allow the perfused blood to drain into the reservoir. 
The centrifugal pump was used to circulate the blood from the reservoir through the 
oxygenator and heat exchanger. This tube was then split into two, one to act as the 
flow controlled Langendorff and the second to act as the RA inflow port. A compliance 
chamber was put at the inflow to the aorta and the RA. A second afterload chamber 
was manufactured and would be connected to the PA so that the system could be put 
into an RV working heart mode, with an afterload of 20-mmHg and RA preload of 5-
mmHg. The isolated heart can be perfused in Langendorff, and then modify the blood 
flow through the heart for an RV working mode perfusion that could be assessed with a 
conductance catheter. The syringe pump was used to deliver a 5µg/kg/min infusion of 
the inotrope Dopamine; this was used to improve the contractility of the stunned 
isolated heart. 
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Figure 3-10 In-house isolated RV working heart perfusion rig 
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3.2.2.2 Surgical Preparation 
The large white pig was surgically prepared as previously described in Section 3.1.2.2. 
However, a small incision into the wall at the apex of the RV and sewing a purse string 
around the opening allowed a Millar conductance catheter to now be securely located 
in the RV for functional assessment using the conductance catheter. A 7-F, 8 electrode 
conductance catheter (Millar Instruments, Houston, Texas, USA) was inserted through 
a puncher in the RV apex and placed along the long axis of the ventricle. PV-loop 
morphology was used to confirm the correct placement of the catheter within the RV. 
3.2.2.3 Surgical Preparation of the Isolated Heart  
The heart was surgically prepared as previously described in Section 3.1.2.3. However, 
the heart was instrumented in the in-house isolated RV working heart perfusion rig 
(Figure 3-11). A purse string was then sutured around the superior vena cava and the 
PA to secure the RA and PA cannulas respectively to allow the heart to be put into an 
isolated RV working heart perfusion. 
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Figure 3-11 Porcine heart instrumented on the RV working heart rig in Langendorff perfusion 
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3.2.2.4 Functional Assessment of the Isolated RV Working Heart 
Functional assessment was performed as described in Section 3.1.2.4. However, the 
conductance catheter was located in the RV for data collection. The right-sided heart 
was put into working mode with an afterload set by height to 20-mmHg and a left atrial 
filling pressure of 5-mmHg. The CO; mean, systolic and diastolic RA pressures; mean, 
systolic and diastolic PA pressures were recorded. A family of PV-loops were recorded 
while partially clamping the inflow to the RA to generate load-independent parameters 
of systolic and diastolic function during a preload reduction. This family of PV-loops 
was used to determine Ees. A second family of PV-loops were recorded while partially 
clamping the outflow to the PA to generate load-independent parameters of systolic 
and diastolic function during an afterload increase. This was performed to determine 
how the RV function adapted to changes in Ea (Figure 3-12). 
A bolus of inotrope dopamine equivalent to a 20-minute infusion at 5 µg/kg/min was 
then given directly to the blood reservoir to increase contractility. This was perfused for 
15 minutes before repeating the measurement protocol. This was performed to 
determine the effect of increasing Ees on RV function. 
This controlled variation of Ea while keeping Ees and heart rate constant, and then the 
independent variation of Ees while keeping Ea and heart rate constant, would allow us 
to describe ventriculoarterial coupling (Ees/Ea) for an isolated RV working heart. 
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Figure 3-12 RV working heart mode with functional assessment with PV-loops 
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3.2.3 Results 
3.2.3.1 Demographics 
Demographic data is shown in Table 3-5. This demonstrated that this work was carried 
out on a porcine heart with normal baseline haemodynamics (CO and mPAP).  
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Table 3-5 Demographic data 
  Pig (n=1) 
Demographics  
 Weight, kg 89.5 
 Height, cm 139.0 
Baseline Haemodynamics  
 Heart Rate, BPM 100 
 MAP, mmHg 86.0 
 MPAP, mmHg 15.0 
 Mixed Venous Sats,% 53.3 
 CO, L 7.1 
 CI, 4.1 
MAP = mean aortic pressure; MPAP = mean pulmonary arterial pressure; CO = 
Cardiac Output; CI = Cardiac Index. 
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3.2.3.2 RV Functional Assessment 
After modifying the rig into an RV working heart mode, the isolated heart did not have 
the contractile function to eject blood against the 20-mmHg PA afterload chamber. 
After altering the height of the afterload chamber to reduce the pressure the RV had to 
pump against, it soon became apparent that the heart would not be able to eject blood 
without greater contractile support. Increasing the inotropic support to an infusion of 10 
µg/kg/min allowed the heart to ejected against the 20-mmHg afterload (Table 3-6). 
However, the PV-loop morphology was physiologically abnormal and suggested a high 
degree of pulmonary regurgitation (Figure 3-13). Therefore, it was not possible to test if 
the theory described Sunagawa for LV ventriculoarterial coupling could be translated to 
the RV-PA using this ex-vivo working heart perfusion rig.  
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Figure 3-13 Steady-state RV PV-loops at during a 10 µg/kg/min dopamine infusion 
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Table 3-6 RV PV-loop data 
  10µg/kg/min Dopamine 
 CO, L 2.2 
 SV, ml 18 
 EF, % 35.0 
 ESV, ml 39.8 
 EDV, ml 54.1 
 ESP, mmHg 22.5 
 EDP, mmHg 1.4 
 dp/dt max, mmHg/s 603 
 dp/dt min, mmHg/s -229 
CO = cardiac output; SV = stroke volume; EF = ejection fraction; ESV = end-systolic 
volume; EDV = end-diastolic volume; ESP = end-systolic pressure; EDP = end-diastolic 
pressure; dP/dt max = maximum rate of isovolumic contraction; dP/dt min = maximum 
rate of isovolumic relaxation. 
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3.2.4 Discussion 
This work has shown that the isolated RV working heart perfusion rig could not be used 
to translate Sunagawa’s theory on the relationship between LV ventriculoarterial 
coupling and the PV-loop to the RV. Although with increased inotropic support it was 
possible to get the isolated RV to eject blood against the PA afterload chamber, the 
PV-loop morphology would indicate that as the pressure was increased within the RV 
during systole, there was significant pulmonary regurgitation. It is now understood that 
there was a fundamental flaw with the design of our RV working heart perfusion rig. 
The basic RV physiology described in Chapter 1 established the normal RV to be a 
complex geometrical shape (Dell'Italia, 1991). The higher systemic pressures in the LV 
(Zipes and Braunwald, 2005) mean the inter-ventricular septum remains concave 
towards the RV throughout the cardiac cycle (Dell'Italia, 1991). Tethering between the 
RV and LV muscle fibres through the septum cause ventricular interdependence 
phenomena (Dell'Italia, 1991; Brookes et al., 1998); which means the size, shape and 
compliance of one ventricle can directly affect the size, shape and haemodynamic 
function of the contralateral ventricle (Santamore and Dell'Italia, 1998a). Since the 
muscle fibres of the RV free-wall predominantly shorten in the long axis during systole, 
it is the LV oblique orientation of the septal muscle fibres that generates the septal twist 
and shortening during a contraction that accounts for the majority of the RV ejection 
force during systole. 
The perfusion rig isolated the RV to put the heart into a right-sided working heart mode. 
Although this model works well for the isolated heart in an LV working heart mode, with 
our work described earlier in this Chapter validating the results of Sunagawa et al. 
(1987). LV ejection is provided by the oblique contraction of the LV muscle fibres. 
Therefore, an isolated LV working heart model remains physiologically appropriate with 
an empty RV. However, the same cannot be said for an isolated RV working heart 
model when the LV remains unfilled. The septum will only remain concave to the RV 
when the pressure within the LV is greater. Since the LV does not fill with blood in an 
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isolated RV working heart perfusion rig, the system now becomes non-physiological as 
the pressure within the LV becomes less than the pressure in the RV. Consequently, 
this causes the increasing pressure within the RV to dilate the ventricle, overfilling it 
with blood, so that the septum now becomes concave to the LV wall. Outwith the 
abnormal RV geometry, this has a knock-on effect to the RV ejection force during 
systole. Since the LV wall is now contracting against an empty ventricular chamber, it 
is not able to transmit any ejection force across the septum to the RV. Therefore, the 
RV is relying on the peristaltic movement of the RV wall to eject blood. This abnormal 
physiology to the RV PV-loop means the RV working heart perfusion rig is not suitable 
for evaluating a model of RV-PA ventriculoarterial coupling.  
While biventricular working heart perfusion rigs are possible to manufacture, two 
separate sub-circulations are required to independently pump the blood through the left 
and right sides of the heart. This necessitates the use of two centrifugal perfusion 
pumps. While this seems relatively straightforward to create, ventricular 
interdependence phenomena mean it is virtually impossible to manually control and 
maintain the flows and pressures in both the LV and RV without causing pressure or 
volume overload to one or both sides of the heart. After attempting to use a 
biventricular working mode perfusion rig, the LV could be switched from a Langendorff 
perfusion to an LV working heart with constant pressures and flows maintained. 
However, when the second pump was used to put the RV into a working heart mode, 
as the RV filled with blood, ventricular interdependence cause the pressures and flows 
to alter within the LV. It was not possible to manually control the pump flows through 
both the left and right sides of the heart, without causing significant problems to the 
contralateral ventricle. Although a group in Canada have reported the use of 
biventricular porcine working heart models, they used a computer-controlled closed-
loop algorithm to simultaneously control the pump flows to maintain the desired 
constant preload and afterload pressures on both sides of the heart (Colah et al., 
2012). While this should have been able to work to allow the assessment of RV 
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ventriculoarterial coupling, on a working heart perfusion rig that provided a 
physiologically normal RV PV-loop. The complexities of designing the closed-loop 
control algorithm software and hardware modifications that would need to be made to 
the centrifugal pumps to allow them to be controlled by the software were not feasible 
to develop during these studies.  
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3.3 An In-Vivo Model of Right Ventriculoarterial Interaction 
3.3.1 Introduction  
The aim of this section was to describe the development of an in-vivo model of RV 
ventriculoarterial coupling that would be used in Chapter 4 to define the optimal 
ventriculoarterial coupling ratio of the porcine RV-PA. After establishing that it was not 
possible to develop an isolated right-sided working heart perfusion rig that can provide 
physiological normal RV function; with the development of a closed-loop computer 
controlled biventricular perfusion right that could provide physiological normal RV 
function being the resources of this PhD; the decision was made to investigate the 
possibility of performing this assessment of RV ventriculoarterial coupling in-vivo, in a 
surgically prepared open-chested porcine model. 
An anaesthetised surgically prepared open-chested porcine heart should provide a 
model that has physiologically normal RV function. Although the pericardial constraint 
has to be removed, this is no different to the isolated working heart perfusion rig model, 
where the heart is suspended in a chamber to collect the ejected blood and return it to 
the blood reservoir. The main advantage of utilising an in-vivo model is that both the LV 
and RV remain physiologically normal, in a normal circulatory system. Therefore, 
ventricular interdependence phenomena allow the LV to support and maintain RV 
contraction. By using surgical silk ties to loop around the IVC and PA, these loops can 
be snared to partially occlude the IVC and PA causing a preload reduction and 
afterload increase respectively. Therefore, families of PV-loops could be recorded, and 
the relationship between the RV-PA ventriculoarterial coupling could be explored in an 
RV system that had a functional LV. 
3.3.2 Methods  
This work was carried out at the Royal Veterinary College (Hatfield, London) under the 
Project Licence 70/7967 as previously described in Section 2.2.3. As previously 
described in Section 2.2.5, Dr Hatim Alibhai (Consultant Veterinary Anaesthetist) was 
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responsible for the humane care of the animals and performed the anaesthetic 
preparation of the animals. Dr Simon Messer performed the surgical preparation. 
3.3.2.1 Surgical Preparation  
The large white pigs were surgically prepared as previously described in Section 
3.1.2.2. However, a small incision into the wall at the apex of the RV and sewing a 
purse string around the opening allowed a Millar conductance catheter to now be 
securely located in the RV for functional assessment using the conductance catheter. 
A 7-F, 8 electrode conductance catheter (Millar Instruments, Houston, Texas, USA) 
was inserted through a puncher in the RV apex and placed along the long axis of the 
ventricle. PV-loop morphology was used to confirm the correct placement of the 
catheter within the RV. 
3.3.2.2 RV Functional Assessment of the Open-Chested Porcine Heart 
After surgically preparing the open-chested porcine heart (Figure 3-14A) the Millar 
MPVS Ultra, ADInstruments PowerLab hardware and ADInstruments LabChart 
software was set up and calibrated as described in Chapter 2. The conductance 
catheter was positioned in the RV for data collection. Five steady-state PV-loops were 
recorded to generate load-dependant parameters of the systolic and diastolic function. 
Two families of PV-loops were recorded during ventilation suspension. A snare was 
looped around the inferior vena cava (IVC) and partially occluded to record a family of 
PV-loops during a preload reduction. This family of PV-loops was used to determine 
Ees. A separate snare was looped around the PA and partially occluded over a 10 to 
15 second period so that multiple data points could be recorded to determine how RV 
hemodynamic parameters varied with acute changes in PA afterload (Figure 3-14B). 
This was used to determine how the RV function adapted to changes in Ea.  
A 20-minute infusion of dopamine at 5 µg/kg/min was then given directly in a central 
intravenous line to increase contractility. The measurement protocol was repeated. 
This was performed to determine the effect of increasing Ees on RV function. 
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This controlled variation of Ea while keeping Ees and heart rate constant, and then the 
independent variation of Ees while keeping Ea and heart rate constant, would allow us 
to describe ventriculoarterial coupling (Ees/Ea) for the RV - PA. 
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Figure 3-14 In-vivo open-chested porcine heart instrumented with the conductance catheter (A) 
with PA snare released (b) with PA snare partially occluded to increase the afterload on the RV 
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3.3.3 Results 
3.3.3.1 Demographics 
Two pigs were studied and the demographic data is shown in Table 3-7. A typical 
steady-state RV PV-loop is shown in Figure 3-15. The graphical pressure-volume 
relationship was described for pig 1 (Contractility) and pig 2 (Preload and Afterload).  
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Table 3-7 In-vivo porcine demographic data 
  Pig 1 Pig 2 
Demographics   
 Weight, kg 89.5 80 
 Height, cm 135 118 
 Heart Rate, BPM 100 102 
 MAP, mmHg 86 95 
 MPAP, mmHg 15 17 
 Mixed Venous Sats, % 55.3 73.1 
 CO, L 7.1 6.6 
 CI, 4.1 4.5 
Values are mean ± S.D. or n (%) 
MAP = mean aortic pressure; MPAP = mean pulmonary arterial pressure; CO = 
Cardiac Output; CI = Cardiac Index. 
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Figure 3-15 In-vivo porcine steady-state RV PV-loop 
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3.3.3.2 Preload and the Pressure-Volume Relationship 
Figure 3-16 shows the effect of a preload reduction on RV function. The slope of the 
ESPVR determined that the load-independent marker of contractility, Ees = 0.31 
mmHg/ml. Table 3-8 shows the beat-to-beat analysis starting at baseline (PV-loop = 1) 
and then sequentially as the PV-loop morphology adapted due to the preload reduction 
(PV-loop = 13). This demonstrated that there was a gradual reduction in SW, CO, SV, 
ESP, EDP, dP/dt max and dP/dt min with decreasing preload. However, Ea remained 
fairly constant. Therefore, the ventriculoarterial coupling ratio remained fairly constant 
increasing from Ees/Ea = 0.89 mmHg/ml at baseline to Ees/Ea = 1.03 mmHg/ml at the 
greatest preload reduction.  
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Figure 3-16 A family of PV-loops recorded during an IVC snare 
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Table 3-8 RV haemodynamic data for each PV-loop during an IVC snare 
PV-
loop  
SW CO SV ESP EDP EF Ea dp/dt 
max 
dp/dt 
min 
1 711 5.3 52.4 18.3 0.4 58.6 0.35 261 -167 
2 716 5.3 52.5 18.0 0.5 58.5 0.34 249 -167 
3 708 5.4 53.3 18.3 0.4 60.3 0.34 253 -164 
4 686 5.1 51.0 16.8 0.4 59.3 0.33 240 -162 
5 592 4.8 47.5 17.7 0.2 60.3 0.37 236 -164 
6 543 4.8 48.1 15.8 0.0 65.2 0.33 218 -154 
7 535 4.8 47.1 13.9 -0.2 65.2 0.30 207 -147 
8 546 4.8 47.9 14.1 -0.1 66.7 0.29 210 -144 
9 382 4.2 41.8 11.4 -0.3 69.7 0.27 187 -136 
10 428 4.3 42.8 13.0 -0.2 68.6 0.30 183 -132 
11 367 4.1 40.8 11.8 -0.3 70.2 0.29 170 -125 
12 319 3.9 39.5 10.2 -0.2 73.0 0.26 162 -118 
13 270 3.6 35.7 10.8 -0.5 68.5 0.30 154 -115 
SW = stroke work, mmHg.ml; CO = cardiac output, L; SV = stroke volume, ml; ESP = 
end-systolic pressure, mmHg; EDP = end-diastolic pressure, mmHg; EF = ejection 
fraction, %; Ea = Effective arterial Elastance, mmHg / ml; dP/dt max = maximum rate of 
isovolumic contraction, mmHg/s; dP/dt min = maximum rate of isovolumic relaxation, 
mmHg/s. 
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3.3.3.3 Afterload and the Pressure-Volume Relationship 
Figure 3-17 shows the effect of an increase in afterload on RV function. Table 3-9 
shows the beat-to-beat analysis starting at baseline (PV-loop = 1) and then 
sequentially as the PV-loop morphology adapted due to the increase in afterload (PV-
loop = 11). This confirmed that Ea increased with increasing afterload. Since Ees was 
calculated from the preload reduction as 0.31 mmHg/ml, the ventriculoarterial coupling 
ratio reduced from Ees/Ea = 0.92 at baseline to Ees/Ea = 0.24 as the RV struggled to 
maintain ejection of blood against the increasing afterload. The reduction in SW, SV 
and CO combined with the increases to ESP, dP/dt max and dP/dt min, would indicate 
that the RV was struggling to maintain sufficient output with increasing afterload. 
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Figure 3-17 A family of PV-loops recorded during an PA snare 
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Table 3-9 RV haemodynamic data for each PV-loop during an PA snare 
PV-
loop  
SW CO SV ESP EDP EF Ea dp/dt 
max 
dp/dt 
min 
1 1292 6.5 64.6 21.8 1.0 69.5 0.34 375 -253 
2 1192 6.3 61.9 22.9 0.9 69.7 0.37 366 -253 
3 1308 6.5 64.5 24.8 1.1 69.7 0.38 379 -260 
4 1296 6.0 60.4 24.5 1.1 65.5 0.41 377 -284 
5 1158 5.0 49.9 26.4 0.8 57.0 0.53 366 -323 
6 1114 4.5 44.5 30.3 0.8 50.2 0.68 359 -354 
7 1018 3.8 37.8 33.4 0.9 41.9 0.88 348 -360 
8 862 2.9 29.1 36.7 0.6 31.1 1.26 336 -376 
9 799 2.6 25.7 38.9 1.2 27.2 1.52 354 -370 
10 860 2.8 28.0 38.0 1.1 28.8 1.36 347 -366 
11 897 3.0 29.8 37.9 1.2 30.6 1.27 346 -361 
SW = stroke work, mmHg.ml; CO = cardiac output, L; SV = stroke volume, ml; ESP = 
end-systolic pressure, mmHg; EDP = end-diastolic pressure, mmHg; EF = ejection 
fraction, %; Ea = Effective arterial Elastance, mmHg / ml; dP/dt max = maximum rate of 
isovolumic contraction, mmHg/s; dP/dt min = maximum rate of isovolumic relaxation, 
mmHg/s. 
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3.3.3.4 Contractility and the Pressure-Volume Relationship 
Figure 3-18 shows the effect of an increase in contractility on RV function. Ea remained 
relatively constant after using the inotrope dopamine to increase contractility. However, 
after performing a further preload reduction, the slope of the ESPVR determined that 
the load-independent marker of contractility Ees had increased to 0.34 mmHg/ml. This 
confirmed that increasing RV contractility increased Ees while Ea remained constant, 
causing an increase in the ventriculoarterial coupling ratio (1.00 to 1.26). The other 
indices of RV hemodynamic function are shown in Table 3-10. 
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Figure 3-18 Steady-state RV PV-loops at baseline (Blue) and after 5 µg/kg /min dopamine (Red) 
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Table 3-10 RV PV-loop data 
 
 
Baseline Dopamine 
(5ug/kg/min) 
 CO, L 7.1 8.4 
 SW, mmHg.ml 1047 1350 
 SV, ml 70.8 81.9 
 HR, BPM 100.2 100.9 
 EF, % 56.4 70.1 
 ESV, ml 73.2 55.1 
 EDV, ml 128.8 132.9 
 ESP, mmHg 21.9 22.3 
 EDP, mmHg 8.0 9.8 
 dp/dt max, mmHg/s 278 366 
 dp/dt min, mmHg/s -228 -194 
CO = cardiac output; SW = stroke work; SV = stroke volume; EF = ejection fraction; HR 
= Heart Rate; ESV = end-systolic volume; EDV = end-diastolic volume; ESP = end-
systolic pressure; EDP = end-diastolic pressure; dP/dt max = maximum rate of 
isovolumic contraction; dP/dt min = maximum rate of isovolumic relaxation. 
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3.3.4 Discussion 
This work has shown that a surgically anesthetised open-chested porcine heart could 
be used to translate Sunagawa’s theory on the relationship between LV 
ventriculoarterial coupling and the PV-loop to the RV and PA. Firstly, this work has 
confirmed that an acute reduction in preload could be used to determine the Ees, and 
this reduction in preload caused the leftwards shift of the EDV point on the PV-loop; 
reducing SV while Ea remained constant. This validated Sunagawa’s statement that “a 
decrease to the end-diastolic volume will cause the arterial ESPVR Ea to shift to the 
left. Hence, SV decreases” (Sunagawa et al., 1987) could be directly translated into the 
RV; this work has confirmed that variations in preload have no effect on contractility 
(Ees) or afterload (Ea). Hence, the RV ventriculoarterial coupling ratio (Ees/Ea) 
remained constant.  
Secondly, this work has confirmed that an acute increase in afterload caused the 
rightwards shift of ESV point on the PV-loop, while EDV remained constant and 
increased Ea. This validated Sunagawa’s statement that “increasing the arterial 
resistance increases the slope of the arterial ESPVR (Ea). Hence the SV decreases as 
the intersection between the arterial and ventricular ESPVR moves to the right” 
(Sunagawa et al., 1987) could be directly translated into the RV. Therefore, this work 
has confirmed that while variations in afterload have no effect on contractility (Ees), Ea 
is increased; hence, the RV ventriculoarterial coupling ratio (Ees/Ea) reduces with 
increasing afterload. 
Finally, this work has confirmed that an increase in contractility increases the slope of 
the Ees and increases the SV. These experimental findings support Sunagawa’s 
statement that “An increase to the LV contractility will increase the slope of the 
ventricular ESPVR (Ees) while maintaining the same volume intercept V0. Since the 
slope of the arterial ESPVR (Ea) remains constant, SV increases” (Sunagawa et al., 
1987) could be directly translated into the RV. Therefore, this work has confirmed that 
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while variations in contractility have no effect on Ea, Ees is increased; hence, the RV 
ventriculoarterial coupling ratio (Ees/Ea) increases. These measurements have 
successfully translated Sunagawa’s work on the relationship between the PV-loop and 
ventriculoarterial coupling in the LV to the RV and PA. 
Some limitations of our study must be recognized. Firstly, the open-chested porcine 
model of RV-PA ventriculoarterial interaction has an open pericardium that reduces RV 
contractility. However, this remains the best physiological model of assessing the 
response of normal RV function to changes in afterload, as LV-RV interdependence is 
retained and others have used this model (Nicolosi et al., 1996; Kuehne et al., 2003; 
Missant et al., 2007; Ghuysen et al., 2008; Guihaire et al., 2015). Second, the acute 
load variations used to determine Ees and the relationship between different RV 
hemodynamic parameters with Ees/Ea and Ea can be considered valid due to auto-
regulation, termed the “Anrep Effect”; increasing afterload increases contractility and 
maintains CO, but it takes between 30 to 60 seconds for contractility to adapt in 
response to acute loading variations (von Anrep, 1912). Data were acquired for an 
adequate duration to detect these changes within the animal model. Thirdly, while the 
conductance catheter is designed for orientation along the long-axis of the ventricle 
with the pigtail positioned in the apex of the heart, many researchers have presented 
work with the conductance catheter inserted through the LV and RV apex (Chaturvedi 
et al., 1998; Messer et al., 2016). 
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3.4 Summary 
The purpose of this chapter was to describe the development of an in-vivo model of RV 
ventriculoarterial coupling that could be used in Chapter 4 to define the optimal 
ventriculoarterial coupling ratio of the porcine RV-PA. Firstly, this chapter demonstrated 
that it was possible to develop an LV working heart apparatus to validate ex-vivo model 
of LV ventriculoarterial coupling and the Pressure-Volume relationship described by 
Sunagawa et al. (1987). Secondly, this chapter described the translation of this work 
into an ex-vivo model of RV ventriculoarterial coupling and the Pressure-Volume 
relationship. Due to complexities in RV physiology and limitations with the RV working 
heart apparatus it was not possible to develop a physiologically accurate ex-vivo model 
of RV ventriculoarterial coupling. Specifically, the absence of a functional LV in the 
isolated RV working heart perfusion rig impaired RV function to the extent that it was 
not possible to replicate Sunagawa’s work for the RV. Finally, this chapter 
demonstrated it was possible to replicate Sunagawa’s work in an in-vivo RV model. 
This in-vivo porcine model appeared suitable to further study RV – PA ventriculoarterial 
coupling that was most efficient… i.e. to determine the optimal relationship between 
the RV and PA. The in-vivo model will now be used in Chapter 4 to define the optimal 
ventriculoarterial coupling ratio of the porcine RV-PA. 
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4 The Determination of Maximal Efficiency and SW from an In-
Vivo Porcine Model of Right Ventriculoarterial Coupling 
4.1 Introduction 
The in-vivo porcine model of RV ventriculoarterial interaction developed in Chapter 3 
was used to determine the maximal efficiency and maximal SW, and define the optimal 
ventriculoarterial coupling ratio of the porcine RV – PA.  
4.2 Methods 
Eighteen open-chested large white pigs with a median weight of 77 kg (range 67 to 92) 
were studied. This work was carried out at the Royal Veterinary College (Hatfield, 
London) under the Project Licence 70/7967 as previously described in Section 2.2.3. 
As previously described in Section 2.2.5, Dr Hatim Alibhai (Consultant Veterinary 
Anaesthetist) was responsible for the humane care of the animals and performed the 
anaesthetic preparation of the animals. Dr Simon Messer performed the surgical 
preparation. 
4.2.1 Surgical Preparation 
The large white pigs were surgically prepared as previously described in Section 
3.3.2.1. 
4.2.2 RV Functional Assessment of the Open-Chested Porcine Heart 
The RV functional assessment in the open-chested porcine heart was performed as 
previously described in Section 3.3.2.2. The beat-to-beat PV-loop data recorded during 
the PA snare were used to determine parameters of RV hemodynamic function at 
maximal SW (Figure 4-1), maximal efficiency (SW/PVA) and at maximal PA occlusion. 
This data was then pooled from each of the 18 subjects to give 324 data points. 
Regression lines with 95% prediction intervals were fitted to the data to determine how 
different parameters of RV hemodynamic function varied with the afterload loading 
condition (Ea) and ventriculoarterial coupling (Ees/Ea).  
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Figure 4-1 SW-Ea RV PV-loop relationship recorded during the PA snare in a single subject. RV 
energetic reserve is highlighted in the green-hatched box (Ea ≤ 0.5); RV failure is highlighted in the 
red-hatched box (Ea < 0.5). 
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4.2.3 Statistical Analysis 
Statistical significance was determined as described in Section 2.2.2.  
4.3 Results 
4.3.1 Demographics 
The demographic data is shown in Table 4-1. At baseline, none of the pigs had 
pulmonary hypertension or evidence of RV dysfunction. A typical steady-state RV PV-
loop was previously shown in Figure 3-15. The data was used to determine maximal 
RV efficiency from the SW/PVA-Ea pressure-volume relationship and maximal SW 
from the SW-Ea pressure-volume relationship, as previously described for the LV in 
Chapter 1. 
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Table 4-1 In-vivo porcine demographic data 
  Group (n=18) 
Demographics  
 Weight, kg 78.8 ± 6.7 
 Height, cm 128.2 ± 5.2 
 Heart Rate, BPM 101.3 ± 02.0 
 MAP, mmHg 78.5 ± 12.6 
 MPAP, mmHg 20.3 ± 3.4 
 Mixed Venous Sats, % 65.5 ± 8.7 
 CO, L/min 6.6 ± 1.1 
 CI, L/min/m2 4.2 ± 0.6 
Values are mean ± S.D. 
MAP = mean aortic pressure; MPAP = mean pulmonary arterial pressure; CO = 
Cardiac Output; CI = Cardiac Index.  
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4.3.2 Stroke Work, Efficiency and the Pressure-Volume Relationship 
Figure 4-2 shows a family of RV PV-loops recorded during a PA occlusion to increase 
afterload. The first highlighted PV-loop (Blue) was recorded at baseline and shows a 
typical triangular shape RV PV-loop. As the afterload on the RV increased, the ESP 
and ESV increased, while EDP and EDV remained relatively constant, which resulted 
in a reduced SV and increased developed pressure. The PV-loops at maximal 
efficiency and maximal SW were determined from the theory described in Chapter 1. 
As the afterload increased from baseline, the PV-loops at maximal efficiency and 
maximal SW were determined from the beat-to-beat analysis starting at baseline (PV-
loop 1) and then sequentially reviewing each PV-loop as the morphology adapted due 
to the increasing afterload until maximal occlusion (PV-loop 13). The PV-loop 
highlighted in green was recorded at maximal efficiency and the PV-loop highlighted in 
Red was recorded at maximal SW. Beyond this point of maximal SW, as the afterload 
continued to increase, the SW that could be provided by the failing RV reduced.  
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Figure 4-2 RV PV-loops recorded during a PA Snare to Increase afterload. PV-loops are highlighted 
at baseline (Blue); maximal efficiency (Green) and maximal SW (Red) 
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Load-independent indices of RV hemodynamic function derived from the conductance 
catheter at baseline demonstrated the systolic contractility Ees = 0.32 ± 0.07 mmHg/ml, 
preload recruitable stroke work (PRSW) = 16.8  ± 4.8 mmHg.ml3 and diastolic function 
End-diastolic pressure volume relationship (EDPVR) = 0.05  ± 0.02 mmHg/ml.  
Conductance catheter data at baseline and during the PA snare are described in Table 
4-2 and Figure 4-3. This shows the RV was slightly uncoupled at baseline (0.94 ± 0.18) 
and maximal efficiency occurred at a higher Ees/Ea than maximal SW: Ees/Ea 0.84 ± 
0.23 vs. 0.68 ± 0.23 respectively. In terms of RV afterload, maximal efficiency occurred 
at a lower Ea than maximal SW: Ea (mmHg/ml) 0.39 ± 0.05 vs. 0.50 ± 0.14 
respectively. While HR (p=0.829) and Tau (p=0.930) remained constant there was a 
significant increase in dP/dtmin (p<0.001). This can be explained by the load-
dependency of dP/dtmin and the significant rise in ESP (p<0.001) with EDP (p=0.626) 
remaining constant. Beyond a threshold Ea = 0.50 mmHg/ml, an increase in Ea 
resulted in reductions in RV SW and efficiency and CO declined. All other parameters 
of RV hemodynamic function are shown in Table 4-2. 
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Table 4-2 Animal model RV hemodynamic data at baseline, maximal efficiency, maximal SW and 
during the maximal occlusion 
 
 
Baseline Maximal 
Efficiency 
Maximal 
SW 
Maximal 
Occlusion 
P-Value 
 CO, L/min 6.6 ± 0.9 6.7 ± 0.9 6.4 ± 1.1 4.2 ± 1.2 <0.001 
 ESV, ml 66.1 ± 18.8  65.9 ± 18.9 70.0 ± 18.9 96.7 ± 21.3 <0.001 
 EDV, ml 107.7 ±18.5 105.6 ±18.5 106 ± 19.4 120.5 ±22.3 0.103 
 SV, ml 65.2 ± 8.9 66.1 ± 8.9 63.1 ± 9.8 40.7 ± 11.6 <0.001 
 EF, % 64.0 ± 6.6 65.5 ± 9.0 61.3 ± 8.8 35.4 ± 9.9 <0.001 
 ESP, mmHg 22.0 ± 3.7  25.7 ± 4.3 30.6 ± 6.9 43.9 ± 7.0 <0.001 
 EDP, mmHg 5.2 ± 3.0 5.8 ± 3.2 5.7 ± 3.0 6.6 ± 3.2 0.626 
 HR, BPM 101.7 ± 1.8 101.8 ± 1.8 101.4 ± 1.8 103.2 ± 6.1 0.829 
 dp/dt max, mmHg/s 307 ± 61 352 ± 77 350 ± 71 344 ± 55 0.176 
 dp/dt min, mmHg/s -217 ± 36 -248 ± 50 -299 ± 56 -360 ± 54 <0.001 
 Tau, ms 61.5 ± 27.0 58.7 ± 27.4 56.6 ± 25.0 61.5 ± 23.6 0.930 
 Ea, mmHg/ml 0.34 ± 0.06 0.39 ± 0.05 0.50 ± 0.14 1.18 ± 0.43 <0.001 
 SW, mmHg.ml 899 ± 205 1138 ± 263 1246 ± 285 844 ± 393 0.002 
 PVA, mmHg.ml 1616 ± 709 1327 ± 424 1614 ± 483 2152 ± 621 0.002 
 SW/PVA 0.63 ± 0.22 0.90 ± 0.21 0.80 ± 0.20 0.42 ± 0.23 <0.001 
 Ees/Ea 0.94 ± 0.18 0.84 ± 0.23 0.68 ± 0.23 0.32 ± 0.15 <0.001 
Values are mean ± S.D. 
CO = cardiac output; ESV = end-systolic volume; EDV = end-diastolic volume; SV = 
stroke volume; EF = ejection fraction; ESP = end-systolic pressure; EDP = end-
diastolic pressure; HR = heart rate; dP/dt max = maximum rate of isovolumic 
contraction; dP/dt min = maximum rate of isovolumic relaxation; Tau = time constant of 
diastolic relaxation; Ea = effective arterial elastance; SW = stroke work; PVA = 
pressure volume area; SW/PVA = RV efficiency; Ees/Ea = ventriculoarterial coupling 
ratio.   
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Figure 4-3 Animal model RV hemodynamic data for (A) SW; (B) CO; (C) ESV; (D) SW/PVA; (E) Ea; 
and (F) ESP at baseline (BL) and the PA occlusion time point for maximal efficiency (Max Eff), 
maximal SW (Max SW) and maximal PA occlusion (Max Occ). * p < 0.05; ** p < 0.01; *** p < 0.001. 
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4.3.3 Relations between Afterload Quantified by Ea and RV Function 
Pooled data from 18 subjects (n=324) with mean regression lines and 95% confidence 
intervals are displayed in Figure 4-4 for the relation between afterload quantified by Ea 
and SW (A); and SW/PVA (B); and CO (C). The regression lines fitted to the data 
determined that maximal efficiency occurred at a lower afterload loading condition than 
at maximal SW. However, as the afterload increased further past this point, there was 
a decline in CO, since the RV fails to maintain sufficient output against the increasing 
loading conditions. 
Figure 4-5 shows Ea at maximal SW vs. maximal efficiency (SW/PVA) determined from 
families of PV-loops recorded during each of the 18 subjects’ PA Occlusions that 
increased RV afterload loading conditions. The majority of the data points fell above 
the line of identity, indicating a greater Ea was observed at maximal SW, when 
compared to Ea at maximal efficiency.  
Relations between afterload quantified by Ea and other hemodynamic parameters of 
RV function (ESV, EDV, ESP, EDP, dP/dt max, dP/dt min, EF, SV, Tau) are presented 
in Appendix A. 
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Figure 4-4 Animal model relation between afterload quantified by Ea and A) SW; B) SW/PVA; and C) 
CO. Pooled data from 18 hearts are shown (n=324). Mean regression lines with 95% prediction 
intervals are displayed. 
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Figure 4-5 Optimum Ea for maximal SW vs. maximal efficiency determined from the 18 Porcine 
subjects. Dotted line – shows line of Identity. 
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4.3.4 Relations between Ventriculoarterial Coupling Quantified by Ees/Ea and 
RV Function 
Pooled data from 18 subjects (n=324) with mean regression lines and 95% prediction 
intervals are shown in Figure 4-6 for the relation between the ventriculoarterial coupling 
ratio (Ees/Ea) and SW (A); and SW/PVA (B); and CO (C). The regression lines fitted to 
the data determined that maximal efficiency occurred at a higher coupling ratio than 
maximal SW. However, unlike the graphic representation of the relation between Ea 
and CO shown in Figure 4-4 where CO appears to decline with increasing afterload 
gradually. Figure 4-6 shows that CO remains fairly constant and is maintained as the 
coupling ratio decreases up to the point of maximal SW. However, beyond the point of 
maximal SW, as the coupling ratio continues to decrease the CO decreases. This 
would suggest that the RV fails to maintain sufficient output against increasing 
afterloads beyond the ventriculoarterial coupling ratio at maximal SW.  
Figure 4-7 shows the ventriculoarterial coupling ratio (Ees/Ea) at maximal SW vs. 
maximal efficiency (SW/PVA) determined from families of PV-loops recorded during 
each of the 18 subjects’ PA occlusions that increased RV afterload loading conditions. 
The majority of the data points fall below the line of identity, indicating a lower coupling 
ratio was observed at maximal SW, when compared to Ees/Ea at maximal efficiency. 
Relations between ventriculoarterial coupling quantified by Ees/Ea and other 
hemodynamic parameters of RV function (ESV, EDV, ESP, EDP, dP/dt max, dP/dt 
min, EF, SV, Tau) are presented in Appendix B. 
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Figure 4-6 Relation between the ventriculoarterial coupling ratio (Ees/Ea) and A) SW; B) SW/PVA 
(SW/PVA); C) CO. 
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Figure 4-7 Optimum Ees/Ea coupling ratios for maximal SW vs. maximal efficiency determined 
from the 18 porcine subjects. Dotted line – shows line of Identity.  
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4.4 Discussion 
This is the first study to use the conductance technique to determine the interaction 
between the RV and PA in a large animal model that can be used to define an Ees/Ea 
coupling threshold for maximal SW. The interaction between the RV and the PA 
determines the external work and metabolic efficiency of the ventricle. This data has 
shown that maximal SW occurred at an Ees/Ea coupling threshold of 0.68 ± 0.23 (Ea = 
0.50 ± 0.14 mmHg/ml), beyond which RV dysfunction ensued. While maximal efficiency 
is important from the perspective of understanding ideal energy transfer conditions 
between RV work and oxygen consumption, the threshold of maximal SW is the 
determinant factor in RV failure. We have demonstrated acute RV adaptation in 
response to acute changes in afterload. There is an immediate response where the RV 
systolic pressure rises to maintain ejection. Then as the afterload continues to 
increase, there are only relatively small increases to EDP and EDV as the RV dilates 
and distends to accommodate the increasing systolic pressure required to attempt to 
facilitate ejection. As the systolic pressure rises beyond the threshold point of maximal 
SW, ESV increases and combined with the relatively small change in EDV results in a 
reduction in SV. This decrease in SV causes a decline in CO and SW, as the RV fails 
to maintain sufficient output against the increasing loading conditions. Therefore, in 
terms of efficiency and SW, as the afterload loading conditions increase from baseline, 
RV output is adequately maintained through the arbitrary point of maximal efficiency 
until the loading conditions reach a threshold point of maximal SW at an Ees/Ea = 0.68. 
Beyond this threshold of maximal SW, SW and CO may continue to offer sufficient 
output to meet demand at rest. However, if the afterload loading conditions are 
increased further (as is observed during modest exercise), there is insufficient RV 
energetic reserve and the RV will fail to meet demand. Quantifying afterload by Ea can 
be used as an indicator of RV failure; the Ea at maximal SW could determine disease 
severity and guide management.  
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We have established a threshold for RV-PA ventriculoarterial uncoupling in an animal 
model, beyond which, there is an insufficient energetic reserve to maintain adequate 
RV function. Theoretical models have predicted optimal mechanical coupling 
corresponded to an Ees/Ea = 1 (Sunagawa et al., 1984); with current literature 
suggesting in a healthy individual RV-PA ventriculoarterial coupling is between 1 to 2 
(Naeije and Manes, 2014) and that the values for the LV and RV are comparable. 
While we demonstrate agreement with previous work at baseline, with slight 
uncoupling between the RV-PA at rest (Ees/Ea = 0.94 ± 0.18), our work has shown 
that maximal SW occurs at an Ees/Ea = 0.68 ± 0.23 and that uncoupling only occurred 
beyond this threshold as there was insufficient RV energetic reserve to maintain 
function. This finding is supported by previous work (Fourie et al., 1992) where authors 
suggested the RV uncoupled around an Ees/Ea = 0.6 mmHg/ml. One explanation for 
this apparent inefficient energy transfer between the RV and PA could be the complex 
pulmonary vascular structure. Whereas the LV is coupled with an elastic aorta and all 
energy expended during the pulsatile contraction is converted into flow energy due to 
the elastic recoil of the aorta (Yaginuma et al., 1985; Sasayama and Asanoi, 1991), the 
pulmonary artery has relatively short elastic proximal vessels which branch into the 
pulmonary trunk, so that 25-40% of the energy expended during the contraction of the 
RV is not converted into flow energy due to the restricted elastic recoil of the 
pulmonary vessels (Grignola et al., 2007; Saouti et al., 2010). This would explain the 
lower coupling ratio we observed. 
Some limitations of this study must be recognized. First, the open-chested porcine 
model of RV-PA ventriculoarterial interaction has an open pericardium that reduces RV 
contractility. However, this remains the best physiological model of assessing the 
response of normal RV function to changes in afterload, as LV-RV interdependence is 
retained and others have used this model (Nicolosi et al., 1996; Kuehne et al., 2003; 
Missant et al., 2007; Ghuysen et al., 2008; Guihaire et al., 2015). Second, the acute 
load variations used to determine Ees and the relationship between different RV 
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hemodynamic parameters with Ees/Ea and Ea can be considered valid due to auto-
regulation, termed the “Anrep Effect”; increasing afterload increases contractility and 
maintains CO, but it takes between 30 to 60 seconds for contractility to adapt in 
response to acute loading variations (von Anrep, 1912). Data were acquired for an 
adequate duration to detect these changes within the animal model. Third, while the 
conductance catheter is designed for orientation along the long-axis of the ventricle 
with the pigtail positioned in the apex of the heart, many researchers have presented 
work with the conductance catheter inserted through the LV and RV apex (Chaturvedi 
et al., 1998; Messer et al., 2016).  
Finally, conductance derived PVA is only an approximation of myocardial efficiency. 
The correlation between PVA and myocardial efficiency excludes the energy 
consumption costs of excitation contraction coupling and basal metabolism (De Tombe 
et al., 1993). PVA is therefore an underestimate. De Tombe et al. (1993) have 
demonstrated that the Ea at maximal efficiency is closer to the Ea at maximal SW 
when calculated directly from MVO2. However, the use of PVA derived from the same 
conductance catheterisation as used to determine SW, allows for a simplified 
approximation of myocardial efficiency, and a precise measure of maximal SW from 
the pressure volume relation derived from the Ea-SW relationship. 
4.5 Summary 
The research question for this chapter was to establish whether the in-vivo porcine 
model of RV Ventriculoarterial interaction developed in Chapter 3 could be used to 
determine the optimal coupling ratio at maximal efficiency and maximal SW. This work 
has shown that although maximal efficiency is important from a perspective of 
understanding ventriculoarterial coupling and the maximal RV work at minimal oxygen 
consumption, in RV failure, maximal SW derived from the pressure-volume 
relationship, is a key determinant of clinical and therapeutic outcomes. In terms of RV 
performance upon exercise (increased loading), if at rest, the RV is already pumping 
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against an afterload loading condition equal to or greater than that of maximal SW, as 
the PA afterload increases with exercise both SW and CO will fall. The RV will not be 
able to maintain an adequate output in the face of additional loading generated from 
exercise.  
To investigate the clinical viability of these findings the first clinical study assessed how 
maximal SW and ventriculoarterial coupling ratio derived from the pressure-volume 
relationship may give insight into RV remodelling in two cohorts with pathological RV 
loading: in symptomatic (Chronic Thromboembolic Pulmonary Hypertension – CTEPH) 
and asymptomatic (Chronic Thromboembolic Disease - CTED) thromboembolic 
disease (elevated Ea – Chapter 5). The second clinical study investigated how 
ventricular interdependence affects RV contractility and the RV-PA ventriculoarterial 
coupling ratio following Transcatheter Aortic Valve Implantation (TAVI), which relieves 
the afterload of the LV by replacing the aortic valve using percutaneous therapy 
(changing Ees – Chapter 6). 
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5 Ventricular Remodelling in Patients with Chronic 
Thromboembolic Pulmonary Vascular Disease and 
Hypertension: Unlocking Pathology through 
Ventriculoarterial Interaction 
The aim of this chapter was to determine if ventriculoarterial (Ees/Ea = 0.68) coupling 
ratio at maximal SW defined in Chapter 4 from the in-vivo porcine model of RV 
ventriculoarterial interaction could be translated to human physiology to better 
characterise patients’ with symptomatic (Chronic Thromboembolic Pulmonary 
Hypertension) and asymptomatic (Chronic Thromboembolic Disease) thromboembolic 
obstruction. 
5.1 Introduction 
Chronic thromboembolic pulmonary hypertension (CTEPH) occurs when organized 
thrombi obstruct the pulmonary arteries (PA) increasing pulmonary vascular resistance 
(PVR) and mean PA pressure (mPAP) (Simonneau et al., 2013). There is a sub-group 
of patients who present with chronic thromboembolic disease (CTED), who have 
mPAP < 25 mmHg at rest, but who are nevertheless symptomatic and possibly 
deserving of treatment. Right ventricular (RV) dysfunction in these patients may limit 
pressure generation resulting in under-diagnosis. Invasive hemodynamic assessment 
by right heart catheterization is reportedly the gold standard diagnostic test and these 
data are the primary determinant of prognosis (Champion et al., 2009). However, it is 
pressure focused and patients with CTED and occult RV dysfunction that is 
contributory to their symptoms will again be overlooked (Castelain et al., 2001; Gan et 
al., 2007). The under-diagnosis of RV dysfunction in CTED and the limited 
understanding of its clinical course are significant unmet clinical needs. The concept of 
ventriculoarterial coupling and RV energetic reserve may offer novel insight in to the 
pathophysiology of CTED and CTEPH and more accurately define the disease state. 
Pressure-Volume (PV)-loop methodology allows for RV-PA Ees/Ea coupling to be 
defined as the matching between RV contractility (End-systolic elastance - Ees) and 
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PA afterload (Effective arterial elastance – Ea) (Kelly et al., 1992). There has been an 
emerging trend of clinical studies performed using Ees/Ea coupling to detect changes 
in patients with different PH etiologies and disease severity. In the normal healthy RV 
McCabe et al. (2014) demonstrated normal values of Ea = 0.30 ± 0.10 mmHg/ml, Ees 
= 0.44 ± 0.20 mmHg/ml and Ees/Ea = 1.46 ± 0.30. In patients with a clinical diagnosis 
of CTED/CTEPH (McCabe et al., 2014), PH and associated systemic sclerosis 
(Tedford et al., 2013), and those with PH and without overt RV failure (Kuehne et al., 
2004),  it was demonstrated that Ees/Ea uncoupling was due to a disproportional 
increase in Ea and the inability to augment contractility (Ees). These observations 
suggest that in early stage PH, decreased Ees/Ea coupling is mainly reflected in 
increased afterload (Ea) and insufficient augmentation of RV contractility. However, in 
late stage PH, the continued progression of the disease state leads to the clinical 
development of RV failure and further impairs Ees/Ea coupling due to decreased 
contractility (Ees) (Kuehne et al., 2004). While there is potential for Ees/Ea coupling to 
be used as a marker of RV function and illustrate the transition from RV adaptation to 
RV maladaptation, it still remains unclear at what specific coupling ratio the RV 
becomes uncoupled to the PA. Previous animal model data suggests maximal stroke 
work (SW) was achieved at an Ees/Eamax sw = 0.6 mmHg/ml, and RV dysfunction 
ensued with any further increase in afterload. However, this study determined Ees from 
a PA occlusion that is now known to overestimate true Ees, and Ea was determined 
from mean RV pressures rather than the end-systolic pressure (ESP).   
In health, the RV-PA is coupled to maintain optimal cardiac output but it is possible to 
determine the maximal SW in response to an acute artificial increase in afterload (Ea). 
The Ees/Ea coupling ratio at which this point is reached is termed Ees/Eamax sw. Below 
the threshold for maximal SW there is RV energetic reserve, however, above this cut-
off there is no energetic reserve and dysfunction will ensue (Burkhoff and Sagawa, 
1986).  
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5.2 Methods 
This work was carried out at Papworth Hospital NHS Foundation Trust (Papworth 
Everard, Cambridgeshire) under the Local Research Ethics Committee approval (REC 
number 12/EE/0085) as previously described in Section 2.2.4. As previously described 
in Section 2.2.5, Dr Stephen Hoole recruited the patients into the studies and the 
Consultant Interventional Cardiologist responsible for the care of the patient performed 
the interventional procedures.  
5.2.1 Patient Population 
Ten patients with a median age of 51 years (range 28 to 77) and a clinical diagnosis of 
CTEPH and ten patients with a median age of 64 years (range 28 to 73) and a clinical 
diagnosis of CTED were invited to participate. Patients were all in World Health 
Organization (WHO) Functional Class II/III. This is a means of classifying disease 
severity in PH: Class I has no symptom of PH at rest or exercise; Class II has no 
symptom of PH at rest but shortness of breath on exercise; Class III may not have 
symptoms at rest but activities greatly limited by shortness of breath; Class IV has 
symptoms at rest and severe symptoms with any activity. Exclusion criteria were a 
myocardial infarction in the preceding 12 weeks, previous permanent pacemaker 
implant or atrial fibrillation.  
5.2.2 Catheterization 
Routine Swan-Ganz catheterisation was performed via a 7-F sheath placed in the right 
femoral or jugular vein using lidocaine local anaesthetic. The catheter was advanced 
and positioned in the right atrium (right atrial pressures were measured), the RV and 
finally the PA (PA pressures were measured). An injection of cold saline (0.9% NaCl) 
was used to determine cardiac output (CO) by the standard thermodilution technique. 
This was repeated three times to determine an average measurement of CO. A 7-F, 8 
electrode conductance catheter (Millar Instruments, Houston, Texas, USA) was then 
inserted through the venous sheath, advanced across the tricuspid valve and placed 
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along the long axis of the ventricle in to the RV apex under fluoroscopic guidance 
Figure 5-1. 
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Figure 5-1 Conductance catheter positioned in the RV under fluoroscopic guidance 
  
 Page 183 
5.2.3 RV Functional Assessment  
The conductance technique was used to measure the PV-loop relationship during 
ventilation suspension. Five steady-state PV-loops were recorded to generate load-
dependent parameters of systolic and diastolic function. The conductance catheter 
data was analysed offline using LabChart software (LabChart 7.0, ADInstruments, New 
South Wales, Australia) as described in Chapter 2.  
PV-loop morphology was used to determine maximal RV efficiency from the 
SW/Pressure volume area (PVA) relationship. Ventricular efficiency is defined as the 
ratio between SW and oxygen consumption (Burkhoff and Sagawa, 1986). PVA is a 
linear surrogate of myocardial oxygen consumption (Suga et al., 1980; Suga et al., 
1983; Suga et al., 1984). PVA is the total mechanical work performed by the ventricle, 
calculated from the sum of the external stroke work (SW – determined from the area 
contained within the PV-loop) that propels the blood from the ventricle and mechanical 
potential energy (PE – the area bound by the ESPVR and EDPVR) stored in the 
ventricle at the end of each contraction (Figure 1) (Suga, 1979).  
5.2.4 Statistical Analysis 
Statistical significance was determined as described in Section 2.2.2.  
5.2.5 Outcomes 
The primary outcome was the characterisation of patients with chronic thromboembolic 
disease by ventriculoarterial (Ees/Ea = 0.68 ± 0.23)  coupling ratio at maximal SW to 
identify ocult RV dysfunction. 
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5.3 Results 
5.3.1 Demographics, Right Heart Catheterisation and RV Haemodynamic Data 
after Classification of Patients by mPAP 
Demographic human data from 10 patients with CTEPH and 10 patients with CTED are 
shown in Table 5-1. We confirmed that the mPAP (p<0.001) and PVR (p<0.001) were 
normal in the CTED group and elevated in the CTEPH group. Typical PV-loop 
morphologies for the CTED and CTEPH patient groups are shown in Figure 5-2. While 
the mean pulmonary arterial pressures were normal in the CTED group, the CTED PV-
loop morphology was abnormal when compared to a normal triangular shaped RV PV-
loop. During systolic ejection there is a rise in RV pressures, as the ventricle has to 
work harder to eject the blood past the thromboembolic masses in the PA. This caused 
the CTED RV PV-Loop to resemble a typical LV PV-loop (McCabe et al., 2014; 
Redington et al., 1990). While HR (p=0.560) and Tau (p=0.954) remained constant, 
there was a significant increase in dP/dt max (p=0.016) and dP/dt min (p<0.001). This 
is explained by the load-dependency of these measurements and the significant rise in 
ESP (p<0.001) with EDP (p=0.162) remaining constant. Ea (p=0.005) was elevated in 
the CTEPH group and beyond the cut-off for maximal SW (0.50 ± 0.14 mmHg/ml) 
defined in Chapter 4 in the animal Model. This would indicate the patients with CTED 
would have some RV energetic reserve, however, those with CTEPH would have 
significant RV dysfunction and no capacity to increase contractility in the presence of 
increased afterload.  
  
 Page 185 
Table 5-1 Demographics, right heart catheterisation and RV hemodynamic data after classification 
of patients by mPAP at rest. 
 
 
mPAP ≤ 25 
(n=10) 
mPAP > 25 
(n=10) 
p-value 
Demographics    
 Age, years 55 ± 17 51 ± 14 0.564 
 Male Sex, N (%) 4 (40.0) 6 (60.0) 0.656 
 BMI, kg/m2 31.2 ± 8.2 29.2 ± 4.4 0.880 
 6MWD, m 369 ± 79 377 ± 134 0.902 
 WHO Class II/III, N (%) 10 (100.0) 10 (100.0) 1.000 
Right Heart Catheter    
 mPAP, mmHg  18.8 ± 5.5 39.7 ± 7.1 <0.001 
 Systolic PAP, mmHg 30.7± 9.6 66.8 ± 16.4 <0.001 
 Diastolic PAP, mmHg 10.1 ± 4.8 24.1 ± 6.6 <0.001 
 mRAP, mmHg 5.8 ± 4.2 8.0 ± 3.5 0.109 
 PCWP, mmHg 8.3 ± 4.3 10.8 ± 4.9 0.244 
 RV EDP, mmHg 5.8 ± 3.5  10.1 ± 3.4 0.012 
 SvO2,% 74.1 ± 4.2 71.5 ± 6.3 0.305 
 CO, L/min 5.3 ± 1.3 4.7 ± 1.0 0.249 
 CI, L/min/m2 2.6 ± 0.3 2.4 ± 0.6 0.334 
 PVR, dyn/s/cm5 163 ± 57 573 ± 220 <0.001 
RV Hemodynamics    
 Heart Rate, BPM 68 ± 10 71 ± 13 0.560 
 SW, mmHg.ml 1402 ± 500 2018 ± 732 0.041 
 CO, L/min 5.3 ± 1.4 4.9 ± 1.0 0.436 
 ESP, mmHg 34.2 ± 7.1 67.4 ± 16.6 <0.001 
 EDP, mmHg 10.3 ± 4.3 13.1 ± 4.4 0.162 
 ESV, ml 111.0 ± 44.4 85.2 ± 26.2 0.241 
 EDV, ml 149.8 ± 44.4 118.2 ± 37.7 0.104 
 SV, ml 78.7 ± 22.0 71.8 ± 26.3 0.532 
 EF, % 51.6 ± 8.3 55.5 ± 9.9 0.354 
 dP/dt max, mmHg/s 351 ± 76 502 ± 181 0.016 
 dP/dt min, mmHg/s -326 ± 92 -618 ± 173 <0.001 
 Ea, mmHg/ml 0.47 ± 0.18 1.10 ± 0.52 0.005 
 Tau, ms 63.9 ± 17.3 64.3 ± 16.4 0.954 
 Ees/Ea 2.29 ± 1.68 0.72 ± 0.59 0.026 
Values are mean ± S.D. or n (%). 
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BMI = body mass index; 6MWD = 6 minute walking distance; WHO Class = world 
health organisation classification; mPAP = mean pulmonary arterial pressure; mRAP = 
mean right atrial pressure; PCWP = pulmonary capillary wedge pressure; RV EDP = 
right ventricular end-diastolic pressure; SvO2 = mixed venous oxygen saturations; CO 
= cardiac output; CI = cardiac index; PVR = pulmonary vascular resistance; SW = 
stroke work; ESP = end-systolic pressure; EDP = end-diastolic pressure; ESV = end-
systolic volume; EDV = end-diastolic volume; SV = stroke volume; EF = ejection 
fraction; dP/dt max = maximum rate of isovolumic contraction; dP/dt min = maximum 
rate of isovolumic relaxation; Ea = effective arterial Elastance; Tau = time constant of 
diastolic relaxation. 
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Figure 5-2 Typical RV PV-loop morphologies for patients with CTED (Blue) and CTEPH (Red) 
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5.3.2 Demographics, Right Heart Catheterisation and RV Haemodynamic Data 
after Classification of Patients with CTED or CTEPH by the Ees/Ea 
Coupling Ratio at the Threshold for Maximal SW Determined from the 
Animal Model. 
After reclassifying patients according to the Ees/Eamax sw threshold established in the 
animal model (Table 5-2), we demonstrated that mPAP (p=0.006) and PVR (p=0.003) 
were normal in the Ees/Ea ≥ 0.68 group and elevated in the Ees/Ea < 0.68 group. 
There was a significant increase in HR (p=0.04) in the Ees/Ea < 0.68 group. While Tau 
(p=0.418) remained constant, there was a significant increase in dP/dtmin (p=0.003), 
again explained by the load-dependency of this measurement and the significant rise in 
ESP (p<0.001) whilst EDP (p=0.103) remained constant. Although SW (p=0.853) 
remained constant between the Ees/Ea subgroups, there was a significant reduction in 
CO (p=0.024), SV (p=0.006), ESV (p=0.034) and EDV (p=0.007) in the Ees/Ea < 0.68 
group. The differences in heart rate and volumetric indices were not identified when 
patients were stratified by pressure. 
Two patients with CTED were identified with an Ees/Ea < 0.68 indicating occult RV 
pathology (Figure 5-3) and three CTEPH patients still had RV contractile reserve 
(Ees/Ea ≥ 0.68). This equated to a reclassification of 25% of the entire cohort. The 
Ees/Ea coupling ratio for these three misclassified CTED patients was 0.35 and 0.45, 
even though they presented with normal mPAP (15 and 19 mmHg) and PVR (157 and 
230 dyne/s/cm5). 
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Table 5-2 Demographics, right heart catheterisation and RV hemodynamic data after classification 
of patients with CTED or CTEPH by the Ees/Ea coupling ratio at the threshold for maximal SW. 
 
 
Ees/Ea ≥ 0.68 
(n=11) 
Ees/Ea < 0.68 
(n=9) 
p-value 
Demographics    
 CTED, N (%) 8 (72.7) 2 (27.3) 0.072 
 CTEPH, N (%) 3 (22.2) 7 (77.7) 0.073 
 Age, years 55 ± 16 50 ± 16 0.516 
 Male Sex, N (%) 5 (45.4) 5 (55.6) 0.653 
 BMI, kg/m2 30.9 ± 7.4 29.1 ± 4.9 0.804 
 6MWD, m 380 ± 81 364 ± 137 0.747 
 WHO Class (II/III) 11 (100.0) 9 (100.0) 1.000 
Right Heart Catheter    
 mPAP, mmHg  22.8 ± 8.0 37.1 ± 12.5 0.006 
 Systolic PAP, mmHg 38.8 ± 17.1 60.9 ± 23.5 0.026 
 Diastolic PAP, mmHg 12.4 ± 6.0 22.9 ± 9.1 0.006 
 mRAP, mmHg 7.1 ± 4.7 6.7 ± 3.0 0.817 
 PCWP, mmHg 10.8 ± 5.8 8.0 ± 2.2 0.144 
 RV EDP, mmHg 7.6 ± 4.5  8.3 ± 3.5 0.709 
 SvO2,% 74.5 ± 4.7 71.0 ± 6.0 0.120 
 CO, L/min 5.3 ± 1.3 4.6 ± 1.0 0.217 
 CI, L/min/m2 2.7 ± 0.3 2.3 ± 0.5 0.082 
 PVR, dyne/s/cm5 181 ± 78 554 ± 250 0.003 
RV Hemodynamics    
 Heart Rate, BPM 65 ± 11 75 ± 10 0.04 
 SW, mmHg.ml 1683 ± 663 1743 ± 755 0.853 
 CO, L/min 5.6 ± 1.2 4.4 ± 0.8 0.024 
 ESP, mmHg 36.7 ± 11.6 68.1 ± 16.7 <0.001 
 EDP, mmHg 10.2 ± 3.8 13.5 ± 4.7 0.103 
 ESV, ml 114.0 ± 36.3 78.6 ± 31.4 0.034 
 EDV, ml 156.1 ± 35.5 107.0 ± 37.1 0.007 
 SV, ml 87.7 ± 22.1 60.1 ± 16.5 0.006 
 EF, % 53.3 ± 9.8 54.0 ± 8.8 0.875 
 dP/dtmax, mmHg/s 385 ± 114 475 ± 190 0.173 
 dP/dtmin, mmHg/s -358 ± 136 -612 ± 183 0.003 
 Ea, mmHg/ml 0.42 ± 0.10 1.22 ± 0.43 <0.001 
 Tau, ms 67.1 ± 13.7 60.8 ± 19.2 0.418 
 Ees/Ea  2.38 ± 1.49 0.45 ± 0.14 <0.001 
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Values are mean ± S.D. or n (%). 
CTED = chronic thromboembolic disease; CTEPH = chronic thromboembolic 
pulmonary hypertension; BMI = body mass index; 6MWD = 6 minute walking distance; 
WHO Class = world health organisation classification; mPAP = mean pulmonary 
arterial pressure; mRAP = mean right atrial pressure; PCWP = pulmonary capillary 
wedge pressure; RV EDP = right ventricular end-diastolic pressure; SvO2 = mixed 
venous oxygen saturations; CO = cardiac output; CI = cardiac index; PVR = pulmonary 
vascular resistance; SW = stroke work; ESP = end-systolic pressure; EDP = end-
diastolic pressure; ESV = end-systolic volume; EDV = end-diastolic volume; SV = 
stroke volume; EF = ejection fraction; dP/dt max = maximum rate of isovolumic 
contraction; dP/dt min = maximum rate of isovolumic relaxation; Ea = effective arterial 
Elastance; Tau = time constant of diastolic relaxation; Ees/Ea = Single-beat 
ventriculoarterial coupling ratio. 
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Figure 5-3 The individual data points for the patients with CTED or CTEPH overlaid on top of the 
mean regression lines determined from the animal model for the relation between ventriculoarterial 
coupling ratio (Ees/Ea) and A) SW; B) SW/PVA; and C) CO. 
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5.3.3 Demographics, Right Heart Catheterisation and RV Haemodynamic Data 
after Classification of Patients by Afterload as Quantified by Ea at the 
Threshold for Maximal SW Determined from the Animal Model. 
After reclassifying the patients for Ea at the threshold for maximal SW established in 
the animal model (Table 5-3), we still demonstrated mPAP (p=0.022) and PVR 
(p=0.013) were normal in the Ea ≤ 0.5 mmHg/ml group and elevated in the Ea > 0.5 
mmHg/ml group. While HR (p=0.224) and Tau (p=0.729) remained constant, there was 
a significant increase in dP/dtmin (p=0.014), again explained by the load-dependency 
of this measurement and the significant rise in ESP (p<0.001) with EDP (p=0.092) 
remaining constant. Although SW (p=0.903) remained constant between the Ea 
subgroups, there was a significant reduction in CO (p=0.004), SV (p=0.006), ESV 
(p=0.035) and EDV (p=0.010) in the Ea > 0.50 group. 
Three patients with CTED were identified in the Ea > 0.50 mmHg/ml group indicating 
occult RV pathology (Figure 5-4) and two CTEPH patients still had RV energetic 
reserve (Ea ≤ 0.5 mmHg/ml). The three patients with CTED identified in the Ea > 0.5 
group had normal mPAP (16.6 ± 2.1 mmHg) and PVR (178 ± 74 dyn/s/cm5), but were 
identified to have an elevated afterload as determined by the conductance catheter Ea 
= 0.69 ± 0.18 mmHg/ml. Interestingly, of these patients, four were the same as those 
reclassified by the Ees/Eamax sw threshold established in the animal model (Figure 5-5).  
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Table 5-3 Demographics, right heart catheterisation and RV hemodynamic data after classification 
of patients with CTED or CTEPH by afterload as quantified by Ea at the threshold for maximal SW. 
 
 
Ea ≤ 0.50 
(n=9) 
Ea > 0.50 
(n=11) 
p-value 
Demographics    
 CTED, N (%) 7 (77.7) 3 (22.2) 0.073 
 CTEPH, N (%) 2 (27.3) 8 (72.7) 0.072 
 Age, years 54 ± 16 52 ± 15 0.777 
 Male Sex, N (%) 4 (44.4) 6 (54.5) 0.524 
 BMI, kg/m2 31.8 ± 8.0 28.6 ± 4.4 0.285 
 6MWD, m 369 ± 79 377 ± 128 0.873 
 WHO Class (I/II/III/IV) 9 (100.0) 11 (100.0) 1.000 
Right Heart Catheter    
 mPAP, mmHg  22.4 ± 7.9 34.8 ± 12.9 0.022 
 Systolic PAP, mmHg 37.2 ± 16.2 58.2 ± 23.4 0.036 
 Diastolic PAP, mmHg 12.1 ± 6.5 21.2 ± 9.2 0.022 
 mRAP, mmHg 7.4 ± 5.1 8.2 ± 3.4 0.588 
 PCWP, mmHg 10.7 ± 6.5 8.6 ± 2.5 0.422 
 RV EDP, mmHg 7.7 ± 4.8  8.2 ± 3.4 0.783 
 SvO2,% 74.7 ± 4.7 71.5 ± 5.5 0.100 
 CO, L/min 5.5 ± 1.3 4.6 ± 0.9 0.063 
 CI, L/min/m2 2.8 ± 0.4 2.4 ± 0.5 0.081 
 PVR, dyn/s/cm5 176 ± 70 490 ± 266 0.013 
RV Hemodynamics    
 Heart Rate, BPM 66 ± 10 73 ± 12 0.224 
 SW, mmHg.ml 1688 ± 622 1727 ± 766 0.903 
 CO, L/min 5.8 ± 1.1 4.4 ± 0.8 0.004 
 ESP, mmHg 34.9 ± 9.8 63.9 ± 18.8 <0.001 
 EDP, mmHg 9.8 ± 4.2 13.2 ± 4.3 0.092 
 ESV, ml 117.3 ± 39.4 82.4 ± 29.7 0.036 
 EDV, ml 160.1 ± 37.2 112.7 ± 36.4 0.010 
 SV, ml 89.8 ± 19.4 63.4 ± 21.0 0.006 
 EF, % 48.1 ± 15.9 49.1 ± 16.8 0.866 
 dP/dt max, mmHg/s 398 ± 122 446 ± 180 0.540 
 dP/dt min, mmHg/s -355 ± 141 -569 ± 196 0.014 
 Ea, mmHg/ml 0.39 ± 0.07 1.11 ± 0.46 <0.001 
 Tau, ms 66.0 ± 15.1 63.0 ± 18.0 0.729 
Values are mean ± S.D. or n (%). 
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CTED = chronic thromboembolic disease; CTEPH = chronic thromboembolic 
pulmonary hypertension; BMI = body mass index; 6MWD = 6 minute walking distance; 
WHO Class = world health organisation classification; mPAP = mean pulmonary 
arterial pressure; mRAP = mean right atrial pressure; PCWP = pulmonary capillary 
wedge pressure; RV EDP = right ventricular end-diastolic pressure; SvO2 = mixed 
venous oxygen saturations; CO = cardiac output; CI = cardiac index; PVR = pulmonary 
vascular resistance; SW = stroke work; ESP = end-systolic pressure; EDP = end-
diastolic pressure; ESV = end-systolic volume; EDV = end-diastolic volume; SV = 
stroke volume; EF = ejection fraction; dP/dt max = maximum rate of isovolumic 
contraction; dP/dt min = maximum rate of isovolumic relaxation; Ea = effective arterial 
Elastance; Tau = time constant of diastolic relaxation; Ees/Ea = Single-beat 
ventriculoarterial coupling ratio. 
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Figure 5-4 The individual data points for the patients with CTED or CTEPH overlaid on top of the 
mean regression lines determined from the animal model for the relation between afterload 
quantified by Ea and A) SW; B) SW/PVA; and C) CO. 
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Figure 5-5 The individual data points for the patients with CTED or CTEPH to compare Ees/Ea with 
Ea. Patients with RV energetic reserve are highlighted in the green-hatched box (Ees/Ea ≥ 0.68 and 
Ea ≤ 0.5); patients with RV failure are highlighted in the red-hatched box (Ees/Ea < 0.68 and Ea < 
0.5). 
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5.4 Discussion 
This is the first study to use the conductance technique to determine the interaction 
between the RV and PA in a large animal model that can be used to define an Ees/Ea 
threshold for maximal SW and applied in a cohort of patients with CTED or CTEPH to 
help more accurately define RV pathophysiology. The interaction between the RV and 
the PA determines the external work and metabolic efficiency of the ventricle. Animal 
model data presented in Chapter 4 have shown that maximal SW occurred at an 
Ees/Ea coupling ratio threshold of 0.68 ± 0.23, beyond which RV dysfunction ensued. 
Redefining patients with CTED and CTEPH using this Ees/Eamax sw threshold, 
discovered three patients with CTEPH who had an Ees/Ea ≥ 0.68, demonstrating RV 
energetic reserve and two patients with CTED who had Ees/Ea < 0.68 confirming 
occult RV dysfunction that was not apparent on current gold-standard right heart 
catheterization. Any additional afterload increases in these three patients will inevitably 
result in RV compromise and a reduction in CO. These findings provide novel insight 
into RV energetics observed in CTED and CTEPH and potentially better identifies 
those at risk of deterioration. This may also offer a more sensitive assessment of 
response to treatment than standard right heart catheterization.  
The natural history of CTED is poorly defined. This is the first study to use an animal 
model to define the Ees/Ea coupling ratio at maximal SW and apply this threshold to 
re-evaluate patients with CTED and CTEPH by assessing RV function. Previous 
studies have relied on single-beat estimation methodologies, to determine Ees from a 
real end-systolic point on the baseline PV-loop and a second theoretical point 
(Bellofiore and Chesler, 2013). This enables RV-PA ventriculoarterial coupling ratio 
adaption in response to increased loading conditions in PH to be observed. Our group 
has previously used this methodology to confirm that ventriculoarterial coupling is 
maintained in patients with CTED, through proportional increases to both Ees and Ea, 
whereas, in patients with CTEPH, Ea increases disproportionately and the RV 
uncoupled from the PA (McCabe et al., 2014). However, it remained unclear whether 
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the degree of uncoupling related to RV dysfunction and patient prognosis. Applying the 
Ees/Ea threshold from our animal model has now confirmed that although those 
patients with CTED retain RV energetic reserve, some do not, while most patients with 
CTEPH have significant RV dysfunction but a few still retain RV energetic reserve. 
After reclassification, those patients with Ees/Ea uncoupling suffer a reduced SV, and 
therefore, HR and ESP was significantly increased to maintain adequate CO at rest. 
Reclassification was made in 25% of our cohort which is clinically important. This 
inability to increase contractility in the presence of increased afterload has also been 
observed by Tedford et al. (2013) in a cohort of patients with systemic sclerosis. 
Patients with associated PH had elevated Ea but relatively smaller increases in Ees 
than those without PH, resulting in greater uncoupling.  
However, simply using Ea may adequately define those that lack RV energetic reserve. 
The Ea threshold at maximal SW, also reclassified four out of the five patients that 
were identified using the Ees/Ea coupling ratio threshold. While Ea is normally 
interpreted as a measure of pulmonary vascular afterload, its dependency on both 
pressure and volume allows it to be interpreted as a load-independent surrogate 
measure of RV Function. Ea determines the pumping pressure that the RV has to 
generate to pump a unit volume of blood into the PA; an Ea> 1 indicates that the RV 
has to generate a pressure of >1-mmHg for every 1-ml ejected from the ventricle. 
Implicit in the definition of Ea, Ea can be elevated when ESP increases (as occurs with 
increasing afterload) but also when SV diminishes due to RV failure. Our 
measurements of Ea were made at rest but may also be useful to predict exercise-
induced RV dysfunction. In a study of patients with PH and normal Ees/Ea coupling at 
rest who subsequently developed uncoupling during exercise and RV dysfunction, the 
resting Ea was >0.5 in all subjects, whereas in normal controls, who augmented RV 
function during exercise, the resting Ea was universally <0.5 (Spruijt et al., 2015). This 
appears to validate our derived Ea threshold in a separate PH population.  
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Some limitations of this study must be recognized. First, the clinical study population 
derives from a pool of selected individuals referred to a single tertiary centre for 
invasive hemodynamic investigation. The clinical management of this patient group 
allowed for one venous access site. Therefore, patients did not have biventricular 
conductance measurements performed and we cannot comment on the effect of 
ventricular interdependence on our findings. However, all the patients had confirmed 
normal LV function an echocardiography and normal capillary wedge pressures at right 
heart catheterization. It is unlikely that any LV systolic or diastolic impairment 
contributed to our findings of RV dysfunction. It was only possible to recruit ten patients 
into each of the CTED and CTEPH groups. Therefore, the study is underpowered and 
it is likely that more hemodynamic parameters would be statistically significant if we 
were able to recruit large group sizes. 
Second, the single venous access site meant it was not possible perform an inferior 
vena cava (IVC) balloon occlusion to generate load-independent indices of contractility 
in the patients with CTED and CTEPH. Therefore, we used single beat methodology to 
determine the Ees/Ea coupling ratio. While this method has not been validated in the 
RV of patients with PH, it remains commonly used by others (Kuehne et al., 2004; 
McCabe et al., 2014; Herberg et al., 2013). 
Finally, conductance derived PVA is only an approximation of myocardial efficiency. 
The correlation between PVA and myocardial efficiency excludes the energy 
consumption costs of excitation contraction coupling and basal metabolism (De Tombe 
et al., 1993). PVA is therefore an underestimate. De Tombe et al. (1993) demonstrated 
that the Ea at maximal efficiency is closer to the Ea at maximal SW when calculated 
directly from MVO2. However, the use of PVA derived from the same conductance 
catheterisation as used to determine SW, allows for a simplified approximation of 
myocardial efficiency, and a precise measure of maximal SW from the pressure 
volume relation derived from the Ea-SW relationship. 
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5.5 Summary 
The research question for this chapter was to determine if threshold for the Ees/Ea 
coupling ratio at maximal SW defined in Chapter 4 from the in-vivo porcine model of 
RV ventriculoarterial interaction could be translated to human physiology to better 
characterise patients’ with symptomatic (Chronic Thromboembolic Pulmonary 
Hypertension) and asymptomatic (Chronic Thromboembolic Disease) thromboembolic 
obstruction. This work has shown that the threshold for Ees/Ea at maximal SW 
determined from the animal model in Chapter 4 has detected RV pathology at rest in 
patients with CTED and otherwise normal pulmonary hemodynamics, and 
demonstrated RV energetic reserve in some cases of CTEPH. Detailed 
ventriculoarterial coupling data may further risk stratify patients with CTED and CTEPH 
and usefully influence management. 
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6 Ventricular Remodelling Post Contralateral Transcatheter 
Aortic Valve Implantation (TAVI): A Ventricular 
Interdependence Paradox  
The aim of this chapter was to determine whether right ventricular (RV) diastolic 
function improves following left ventricular (LV) afterload reduction following 
transfemoral (TF) Transcatheter Aortic Valve Implantation (TAVI) due to ventricular 
interdependence phenomena leading to changes in LV – RV interaction through septal 
wall reconfiguration. After unloading the LV, ventricular interdependence phenomena 
would be expected to cause a shift in the septal wall as the inter-ventricular 
haemodynamics reconfigure. This septal wall reconfiguration has the potential to 
improve the RV ventriculoarterial coupling (Ees/Ea) ratio, due to the ventricular 
interdependence phenomena unloading the RV and potentially causing improvements 
to systolic contractility (Ees). 
6.1 Introduction  
Over the last decade TF-TAVI has been established as a minimally invasive alternative 
treatment option to open heart surgery (Cribier et al., 2002) to repair severe aortic 
valve disease in patients considered unsuitable for surgery due to severe comorbidities 
(NICE, 2012). A severe comorbidity is a pre-existing cardiovascular risk factor such as 
hypertension (high blood pressure), chronic kidney dysfunction (loss of kidney function 
which may require dialysis), chronic obstructive pulmonary disorder (collective term for 
multiple lung diseases that cause difficulties with breathing due to narrowing or 
obstruction of the airways), diabetes (elevated blood sugar levels which is know to 
cause long-term cardiovascular and kidney failure), peripheral arterial disease (fatty 
deposits build up in the arteries affecting the blood flow around the body) and cancer. 
The Society of Thoracic Surgeons (STS) Score and European System for Cardiac 
Operative Risk Evaluation (EuroSCORE II) are used to assess the patients’ 
comorbidities and evaluate their risk of mortality. The scores categorise the patients 
into groups of low (< 2), medium (2-5) and high (> 5) risk of mortality.  
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During the TAVI procedure, a balloon-mounted tissue valve is advanced along the 
patients’ femoral artery under fluoroscopic guidance and aligned across the aortic 
valve. The balloon is inflated inside the prosthetic valve while the heart is rapid paced 
(RP) between 140 to 210 BPM. RP stabilises the aortic valve and holds the tissue 
valve in situ for deployment. A RP Test Capture (RPTC) is routinely performed to 
ensure adequate ablation of LV ejection prior to valve deployment. While TAVI has 
been shown to have immediate and long-term benefits to LV function (Muratori et al., 
2015), data on RV function post TAVI is limited and somewhat confounding. 
Echocardiographic studies have shown both RV dysfunction (Ito et al., 2014) and no 
change in RV function (Kempny et al., 2012; Forsberg et al., 2011) following TAVI. 
Therefore, the mechanisms by which TAVI may influence RV systolic and diastolic 
performance remain unclear. Maintaining the healthy state of the RV appears to be 
important for TAVI success. Several parameters associated with poor TAVI outcome 
e.g. severe mitral regurgitation (Braunwald, 1969) or chronic lung disease (Burrows et 
al., 1972), also cause elevated pulmonary artery pressures and RV dysfunction. 
The TF-TAVI patient group were selected since RV function could be assessed 
following ventricular remodelling after the stiffened aortic valve was replaced in the 
contralateral ventricle. An aortic stenosis causes enlargement to the LV chamber and 
hypotrophy. LV hypertrophy is the enlargement and thickening of the ventricular walls. 
Replacing the aortic valve will reduce the afterload on the LV and lead to septal wall 
reconfiguration. The reduction in afterload will cause the inter-ventricular LV pressure 
to decline and potentially allow the LV volume to decrease. This reduction in LV 
pressure and volume has the potential benefit of allowing the septal wall to reposition 
between the LV and RV chamber. The changes in RV chamber morphology will alter 
RV contractility (Ees) and should subsequently improve the RV ventriculoarterial 
coupling ratio (Ees/Ea). Therefore, this TF-TAVI cohort offers a clinical example of how 
altering Ees affects systolic and diastolic function in humans. This study was 
undertaken to use the conductance technique (Chapter 2) to assess RV function during 
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TF TAVI with the Edwards Lifesciences (Irvine, California, US) SAPIEN XT or SAPIEN 
3 device (Figure 6-1).   
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Figure 6-1 Edwards SAPIEN 3 transcatheter heart valve taken from 
http://www.edwards.com/eu/Products/TranscatheterValves/Pages/sapien3.aspx?WT.ac=S3campaig
nprod (accessed 30.01.2016) 
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6.2 Methods 
This work was carried out at Papworth Hospital NHS Foundation Trust (Papworth 
Everard, Cambridgeshire) under the Local Research Ethics Committee approval (REC 
number 12/EE/0085) as previously described in Section 2.2.4. As previously described 
in Section 2.2.5, Dr Stephen Hoole recruited the patients into the studies, a Consultant 
Cardiologist performed the echocardiographic assessments, and the Consultant 
Interventional Cardiologist responsible for the care of the patient performed the 
interventional procedures.  
6.2.1 Patient Population 
Forty patients were screened for eligibility from the TF-TAVI waiting list and studied 
between June 2013 to February 2016. All patients had high-risk or inoperable aortic 
valve stenosis determined at a multi-disciplinary team meeting. Exclusion criteria 
included a myocardial infarction within the preceding 12 weeks, transapical TAVI, 
tricuspid stenosis, permanent pacemaker and atrial fibrillation.  Nine were excluded 
due to: atrial fibrillation (3), refused consent (3), recruitment into another study (2) and 
permanent pacemaker (1). Thirty-one patients subsequently consented of whom 8 did 
not subsequently undergo RV assessment due to: logistical reasons (5), withdrawal of 
consent (1), occult mitral valve stenosis necessitating surgical replacement of aortic 
and mitral valves (1) and new-onset atrial fibrillation (1). Twenty-three patients with 
median age of years 75 (range 68 to 93) were studied under a general anaesthetic (GA 
sub-group: n = 13) or conscious sedation (CS sub-group: n = 10) protocol. One patient 
required emergency inotropic support immediately after valve deployment in the GA 
sub-group and was excluded from the final analysis. 
6.2.2 Study Protocol 
A schematic flow diagram of the study protocol is shown in Figure 6-2. 
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Figure 6-2 Flowchart illustrating the study protocol and timeline 
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6.2.3 Anaesthetic Protocol 
In the GA sub-group, anaesthesia was induced with a bolus of propofol (0.5-1.5 mg/kg) 
and a remifentanil infusion (0.05-0.1 µg/kg/hr), and atracurium (0.5 mg/kg) were 
given. Endotracheal intubation was performed, and the patient ventilated with FIO2 0.5 
mixed with sevoflurane 0.8-1.0 MAC (minimum alveolar concentration), titrated to 
maintain 40-60 BIS (bispectral index). The bispectral index is a measure of the depth of 
anaesthesia, where 0 represents no anaesthesia and 100 represents a silent 
electrocardiograph. A BIS value between 40 to 60 indicates the appropriate depth of 
anaesthesia for a general anaesthetic. In the CS sub-group, a regional ilio-inguinal 
nerve block was performed using 40-60mL of 1% lidocaine to maintain access-site 
analgesia. Sedation was induced with a remifentanil infusion (0.05 µg/kg/hr). 
Flucloxacillin 1g and gentamicin 160mg for antibiotic prophylaxis and a bolus of 
heparin (70-100 U/Kg) was administered after 16-20F femoral arterial access in all 
patients. An activated coagulation time was maintained >250 s throughout the 
procedure. No hemodynamic-altering medication was administered during the study. 
6.2.4 Pre-TAVI Cardiac Catheterization 
A 7F sheath was placed in the jugular (GA sub-group) or femoral (CS sub-group) 
veins. A 6F multipurpose catheter was positioned in the pulmonary artery (PA) to 
measure mean pulmonary pressure and obtain mixed venous blood gas saturations for 
determination of indirect Fick cardiac output as described in Chapter 2. Right atrial 
pressure (RA) was also recorded. Blood was also sampled to measure blood 
resistivity. A 7F 8-Electrode conductance catheter (Millar Instruments, Houston, USA) 
was connected to an MPVS Ultra (Millar Instruments, Houston, USA) signal-
conditioning unit in series with an ADInstruments PowerLab 16/30 Series 
(ADInstruments, New South Wales, Australia) sixteen-channel amplifier as described in 
Chapter 2. The conductance catheter was submerged in a bath of saline and the 
pressure transducer zeroed before introduction via the venous sheath and placement 
along the long axis of the RV under fluoroscopic guidance (Figure 6-3).  
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Figure 6-3 (Top) Fluoroscopic image of preload reduction by IVC balloon occlusion and RV PV-loop 
acquisition with a conductance catheter (Bottom) Fluoroscopic image of a conductance catheter 
located in the RV during SAPIEN XT valve deployment.  
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6.2.5 Pressure Volume Loop Data Acquisition 
A 6F sheath placed in the right femoral vein for the temporary pacing wire was upsized 
to a 12F sheath to accommodate an Amplatzer 34mm Sizing Balloon II (St Jude 
Medical, St Paul, MN, USA) that was positioned in the inferior vena cava (IVC) at the 
mouth of the RA under fluoroscopic guidance. The conductance technique was used to 
measure the Pressure-Volume (PV)-loop relationship during ventilation suspension 
(GA Sub-Group) or breath hold in mid-expiration (CS Sub-Group) to provide a beat-to-
beat assessment of RV function at steady state and pre-load reduction during IVC 
balloon occlusion for at least 5-cardiac cycles (Figure 6-3). PV-loop data was 
continuously recorded during the procedure including during RP Test Capture (RPTC). 
PV-loop recordings during pre-load reduction were repeated with a similar IVC balloon 
occlusion post-TAVI (Figure 6-3). Post-TAVI measurements were recorded a median 
time of 17 minutes (IQR 12 to 23) after valve replacement. 
6.2.6 Echocardiographic Assessments 
At an outpatients’ clinic appointment transthoracic echocardiographic (TTE) 
parameters of aortic stenosis severity (peak gradient (mmHg), mean gradient (mmHg) 
and aortic valve area (cm2) effective orifice area index (cm2/m2)), aortic annulus size 
(mm), LV function (ejection fraction (Good >50%; Moderate 30-49%; Poor <30%), 
stroke volume (mL)) and RV function (tricuspid annulus plane systolic excursion – 
TAPSE (cm), fractional area change – FAC (%) and tissue Doppler imaging – TDI S 
(cm/sec)) were recorded pre-operatively as described in Chapter 2. In the GA sub-
group transesophageal (TEE) and in the CS sub-group TTE echocardiographic 
parameters of RV and LV function were repeated immediately prior to valve 
replacement, post-TAVI and again at 3-months (Figure 6-2). TEE was performed using 
an X7-2t transducer (Philips Healthcare, MA, USA) and an iE33 scanner (Philips 
Healthcare, MA, USA). TTE was performed using either an X3-1 or S5-1 transducer 
(Philips Healthcare, MA, USA) with an iE33 scanner (Philips Healthcare, MA, USA). 
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6.2.7 Rapid Pacing 
After baseline echocardiographic and PV-loop during IVC balloon occlusion data 
acquisition, the sizing balloon was removed from the 12F venous sheath and replaced 
with a temporary pacing wire that was positioned at the RV apex. RPTC was 
performed at the operators’ discretion aiming for a capture threshold of <1mV and 
suppression of LV ejection to a systolic BP < 40mmHg. The total number of RP beats 
was determined for RPTC and post-TAVI by multiplying pacing-rate by the pacing-
duration.  
6.2.8 TAVI implantation 
After baseline echocardiographic and PV-loop data was collected the 6F femoral 
arterial sheath was then upsized to 18F to allow placement of the Edwards 
Lifesciences (Irvine, California, US) SAPIEN XT or III device. An Edwards SAPIEN XT 
or III Transcatheter Heart Valve (Edwards Lifesciences Irvine, California, US), 
appropriately sized to the aortic annulus, was inserted retrograde via an eSheath 
Expandable Introducer Sheath (Edwards Lifesciences, Irvine, California, USA) over an 
Amplatz Extra-stiff 0.035” guidewire. It was positioned under fluoroscopic and 
echocardiographic guidance across the stenosed valve using the Novaflex+ delivery 
system and deployed by balloon-expansion during RP determined by the operator. 
Once a satisfactory result had been confirmed by further imaging, the delivery system 
and the eSheath were removed using two Perclose Proglide suture-mediated closure 
devices (Abbott Vascular, Santa Clara, CA, USA), again using RP where necessary to 
lower systemic pressures and gain haemostasis. Finally, the temporary pacing wire 
was removed to enable venous access for the sizing balloon and final PV-loop data 
acquisition during IVC balloon occlusion. The remaining sheaths were then removed, 
the procedure completed and the patient recovered to the ward. 
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6.2.9 Offline RV Hemodynamic Measurements  
The conductance catheter data was analysed offline using LabChart software 
(LabChart 7.0, ADInstruments, New South Wales, Australia) as described in Chapter 2. 
Five steady-state PV-loops were recorded pre-TAVI, post-RPTC and post-TAVI to 
generate load-dependant parameters of the systolic and diastolic function. A family of 
PV-loops were recorded during an IVC balloon occlusion pre-TAVI and post-TAVI 
generated load-independent parameters of RV systolic and diastolic function. 
6.2.10 Statistical Analysis 
Statistical significance was determined as described in Section 2.2.2.  
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6.3 Results 
6.3.1 Patient Characteristics 
Patient demographic data are shown in Table 1. One patient required emergency 
inotropic support immediately after valve deployment in the GA sub-group and was 
excluded from the final analysis. Twenty-two patients were included in the final 
conductance analysis. Although 2 patients in GA sub-group were categorised as low-
risk by STS and EuroSCORE II scores, both are categorised as high-risk due to 
previous NHL mantle radiotherapy and one of these patients also had a porcelain 
aorta. The severity of the aortic stenosis assessment showed the patients met the 
TAVI clinical acceptability criteria of peak gradient ≥ 40 mmHg and/or an aortic valve 
area ≤ 1.0 cm2. All patients had successful TAVI without complication, and there was 
zero 30-day mortality and only one death at 6-months follow-up.  
Non-Hodgkin Lymphoma (NHL) mantle radiotherapy is used for the treatment of NHL. 
NHL is a type of blood cancer that develops in the lymphatic system, part of the 
immune system and damage the correct function of the white blood cells. Radiotherapy 
is normally used in combination with chemotherapy to treat the lymphoma cells. 
Porcelain aorta is the extensive calcification of the aorta or aortic arch and can be 
completely or near complete circumferential. Both pathologies increase cardiovascular 
risk factors and any patient presenting with either condition would automatically be 
rated as high-risk to any future cardiovascular procedure.  
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Table 6-1 Patient demographic data 
 
 
TAVI 
(n = 22) 
GA Sub-Group 
(n=12) 
CS Sub-Group 
(n=10) 
P-value 
Demographics     
 Age, years 78 ± 8 78 ± 9 79 ± 8 0.895 
 Male sex, % 17 (77.3) 10 (83.3) 7 (70.0) 0.624 
 BMI, kg/m2 26.6 ± 5.2 25.1 ± 3.9 28.4 ± 4.4 0.136 
 Active or ex-smoker 12 (54.5) 8 (66.7) 4 (40.0) 0.391 
 EuroSCORE II 6.0 ± 3.8 5.2 ± 3.3 7.1 ± 4.6 0.307 
 STS 3.4 ± 2.0 3.8  ± 2.4 3.1 ± 1.4 0.413 
 CCS (I/II/II) 18/3/1 10/1/1 8/2/0 0.500 
 NYHA Class (II/III/IV) 6/14/2 5/7/0 1/7/2 0.104 
 Hypertension 12 (54.5) 6 (50.0) 6 (60.0) 0.691 
 Diabetes mellitus 6 (27.2) 2 (16.7) 4 (40.0) 0.348 
 Previous MI 6 (27.2) 6 (50.0) 0 (0.0) 0.015 
 Previous PVD 5 (22.7) 2 (16.7) 3 (30.0) 0.624 
 Previous CABG 11 (50.0) 7 (58.3) 4 (40.0) 0.670 
 Previous BAV 8 (36.3) 6 (50.0) 2 (20.0) 0.204 
 Hb, g/L  122.7 ± 18.2 126.8 ± 22.0 116.7 ± 11.6 0.339 
 Cr, mg/dL 1.40 ± 0.49 1.43 ± 0.50 1.36 ± 0.50 0.488 
Right Heart Catheter     
 MRAP, mmHg 10.0 ± 5.8 9.2 ± 3.3 11.1 ± 7.9 0.715 
 MPAP, mmHg 24.4 ± 11.2 20.1 ± 4.4 29.5 ± 14.5 0.120 
 PA Sats,% 72.0 ± 7.2 76.9 ± 3.8 66.0 ± 5.4 <0.001 
 Ao Sats, % 96.8 ± 1.9 97.3 ± 1.5 96.1 ± 2.2 0.159 
 CO, L 5.3 ± 1.3 5.6 ± 1.5 4.8 ± 0.9 0.118 
 CI, 2.8 ± 0.7 3.0 ± 0.7 2.5 ± 0.5 0.059 
 SVI 41.3 ± 47.1 ± 13.1 34.1 ± 9.3 0.016 
Severity of Aortic Stenosis    
 Peak Gradient, mmHg 73.7 ± 28.0 71.3 ± 32.2 77.0 ± 22.5 0.655 
 Mean Gradient, mmHg 43.4 ± 17.4 41.8 ± 19.8 45.5 ± 14.3  0.637 
 AVA, cm2 0.72 ± 0.13 0.69 ± 0.14 0.76 ± 0.12 0.250 
 EOA Index,  0.38 ± 0.07  0.37 ± 0.05 0.40 ± 0.08 0.348 
 Annulus size, mm 22.4 ± 2.5 22.5 ± 2.1 22.1 ± 3.1 0.728 
 LVH 16 (72.7) 8 (66.7) 8 (80.0) 0.646 
Values are mean ± S.D. or n (%). P-values displayed for GA Sub-Group vs. CS Sub-
Group. 
BMI = body mass index; STS = society of thorasic surgeons risk score; CCS = 
Canadian cardiovascular society functional classification of angina; NYHA Class = ; MI 
 Page 214 
= myocardial infarction; PVD = peripheral vascular disease; CABG = coronary artery 
bypass graft; BAV = balloon aortic valvulaplasty; Hb = Haemoglobin; Cr = Creatinine; 
MRAP = mean right atrial pressure; MPAP = mean pulmonary arterial pressure; AVA = 
aortic valve area; EOA Index = effective orifice area Index; LVH = left ventricular 
hypotrophy. 
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6.3.2 Echocardiographic Assessment 
Echocardiographic assessment performed in the catheter laboratory demonstrated that 
there was an immediate reduction in transaortic gradients after the prosthetic valve 
was implanted (Table 6-2). This reduction in transaortic gradients was preserved at the 
3-month follow-up assessment. Although baseline RV echocardiographic function was 
normal (Table 6-2), 5 individual patients were identified with RV dysfunction at baseline 
(included within the 8 identified by RV haemodynamic assessment). There was no 
improvement in RV function following TAVI at 3-months. 
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Table 6-2 Echocardiographic data 
 Pre-TAVI Post-TAVI 
3-Month 
Follow-Up 
P value 
Aortic Valve Area     
Peak Gradient, mmHg 73.7 ± 28.0 11.4 ± 3.6 21.0 ± 11.6 <0.001 
Mean Gradient, mmHg 43.4 ± 17.4 5.4 ± 1.8 11.5 ± 6.2 <0.001 
AVA, cm2 0.72 ± 0.13 2.25 ± 0.55 1.83 ± 0.35 <0.001 
EOA Index,  0.38 ± 0.07  1.18 0.26 0.98 ± 0.22 <0.001 
EF, % 53.4 ± 13.4 - 55.3 ± 8.1 0.890 
RV Function     
TAPSE, cm 1.94 ± 0.55 - 1.80 ± 0.61 0.387 
TDIs, cm s-1 10.5 ± 2.5 - 11.0 ± 2.9 0.288 
FAC, % 47.4 ± 10.3 42.7 ± 9.8 47.2 ± 7.2 0.481 
RV Function CS - Sub     
TAPSE, cm 2.25 ± 0.51 2.15 ± 0.50 1.84 ± 0.58 0.084 
TDIs, cm s-1 10.7 ± 2.7 10.8 ± 1.8 11.1 ± 2.1 0.815 
FAC, % 42.2 ± 11.4 45.1 ± 8.8 44.2 ± 10.0 0.507 
Values are mean ± S.D. Pre-TAVI vs. 3-Month Follow-Up p-values calculated using 
paired t-tests. Pre-TAVI vs. Post-TAVI vs. 3-Month Follow-Up p-values calculated 
using one-way repeated measures ANOVA. 
AVA = aortic valve area; EOA Index = effective orifice area Index; EF = ejection 
fraction. TAPSE = tricuspid annular plane systolic excursion; TDIs = tissue Doppler 
imaging; FAC = fractional area change.  
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6.3.3 RV Hemodynamic Assessment 
Baseline RV hemodynamic systolic (Ees/Ea = 1.1 ± 0.4 mmHg/ml) and diastolic (Tau = 
58.0 ± 15.5 ms) (McCabe et al., 2014) function was normal. However, 8 patients were 
identified with evidence of RV diastolic dysfunction (Tau > 56.2 ± 6.7 ms) (McCabe et 
al., 2014). RPTC delivered a median number of 24 RP beats (IQR 19 to 37) at a mean 
rate of 198 ± 16 BPM, compared to a median number of 120 RP beats (IQR 87 to 205) 
accrued post-TAVI at a mean rate of 201 ± 18 BPM. RV diastolic dysfunction was 
evident after RPTC prior to valve implantation and stunning was apparent late after 
valve implantation at the time point of the post-TAVI measurements. Table 6-3 and 
Figure 6-4 shows that RPTC prior to valve implantation caused a reduction in diastolic 
function increasing Tau (p = 0.003) and EDP (p < 0.001). RV diastolic dysfunction 
persisted immediately after valve implantation (Tau: p < 0.001; EDP: p < 0.001). Load-
independent indices of systolic contractility: Ees (p = 0.020) and PRSW (p = 0.001) 
both diminished post-TAVI. Since Ea remained constant (p = 0.478), this reduction in 
systolic contractility caused right ventriculoarterial (Ees/Ea) uncoupling (p = 0.004) 
indicating that the RV was failing. Although the gradient of EDPVR slope remained 
constant (p = 0.693), the upward and leftwards shift of the EDPVR slope suggested a 
reduction in ventricular compliance and increased diastolic dysfunction post-TAVI 
(Figure 6-5). We observed a significant increase in ESV following TAVI (Table 6-3), but 
the remaining indices of RV function remained unchanged after TAVI. 
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Table 6-3 RV hemodynamic data 
 Pre-TAVI Post-RPTC Post-TAVI P Value 
Heart rate, beats/min 68 ± 13 69 ± 16 72 ± 17 0.350 
Systolic BP, mmHg 133 ± 29 - 136 ± 25 0.936 
Diastolic BP, mmHg 58 ± 14 - 60 ± 11 0.906 
Mean BP, mmHg 80 ± 19 - 82 ± 15 0.957 
ESP, mmHg 31.6 ± 15.5  42.6 ± 18.7 34.0 ± 15.2 <0.001 
EDP, mmHg 8.5 ± 5.8 11.6 ± 6.1 10.7 ± 5.9 <0.001 
ESV, ml 87.9 ± 31.4 98.6 ± 42.7 113.1 ± 39.7 0.007 
EDV, ml 131.4 ± 40.4 142.8 ± 47.2 147.1 ± 43.1 0.173 
SV, ml 81.9 ± 25.4 78.4 ± 29.8 87.8 ± 25.0 0.150 
SW, mmHg.ml 1542 ± 529 1751 ± 798 1508 ± 502 0.278 
CO, L/min 5.4 ± 1.3 5.1 ± 1.8 6.0 ± 1.6 0.187 
EF, % 59.9 ± 13.8 54.1 ± 19.3 55.2 ± 13.3 0.244 
dP/dt max, mmHg/s 460 ± 154 527 ± 169 436 ± 157 <0.001 
dP/dt min, mmHg/s -259 ± 119 -341 ± 144 -253 ± 124 0.028 
Tau, ms 58.0 ± 15.5 72.3 ± 21.8 80.1 ± 24.4 <0.001 
Ea, mmHg/ml 0.38 ± 0.15 - 0.40 ± 0.18 0.478 
Ees, mmHg/ml 0.39 ± 0.19 - 0.28 ± 0.17 0.020 
EDPVR, mmHg/ml 0.08 ± 0.06 - 0.08 ± 0.07 0.693 
Ees/Ea 1.10 ± 0.40 - 0.80 ± 0.37  0.004 
PRSW, mmHg/ml3 21.0 ± 10.5 - 14.7 ± 8.4 0.001 
Values are mean ± S.D. Pre-TAVI vs. Post-TAVI p-values calculated using paired t-
tests. Pre-TAVI vs. Post-RPTC vs. Post-TAVI p-values calculated using one-way 
repeated measures ANOVA. 
BP = Blood Pressure; RP = Rapid Pacing; ESP = end-systolic pressure; EDP = end-
diastolic pressure; ESV = end-systolic volume; EDV = end-diastolic volume; SV = 
stroke volume; SW = stroke work; CO = cardiac output; EF = ejection fraction; dP/dt 
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min = maximum rate of isovolumic relaxation; dP/dt max = maximum rate of isovolumic 
contraction; Tau = time constant of diastolic relaxation; Ea = effective arterial 
Elastance; Ees = end-systolic Elastance; EDPVR = end-diastolic pressure volume 
relationship; Ees/Ea = ventriculoarterial coupling ratio; PRSW = preload recruitable 
stroke work. 
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Figure 6-4 Comparisons of RV diastolic function (Left) Tau and (Right) EDP at baseline (Pre-TAVI – 
Blue) after rapid pacing test capture (RPTC – Black) and after valve deployment (Post-TAVI - Red). 
** p < 0.01, *** p < 0.001. 
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Figure 6-5 Families of RV PV-loops recorded at baseline (Pre-TAVI - Blue) and after valve 
deployment (Post-TAVI - Red) during preload reduction with IVC balloon occlusion to determine 
Ees and EDPVR 
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6.3.3.1 Comparisons between Early and Late Recovery 
Comparisons of RV function during early recovery (+1 mins after valve deployment) 
with late recovery (median +17 mins after valve deployment) demonstrated persistent 
diastolic dysfunction (Figure 6-6: tau - early +50.8% vs. late +42.2%, p = 0.86; RVEDP 
- early +73.7% vs. late +32.4%, p < 0.001). However, systolic function reached supra-
baseline levels at +1 minute into recovery that subsequently deteriorated at +15 mins 
post valve deployment (Figure 6-6: dP/dt max – early +40.4% vs. late – 6.4%, p < 
0.001; SW – early +35.29% vs. -13.0%, p < 0.001). This observation is consistent with 
RV stunning.  
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Figure 6-6 Comparisons of diastolic function (Top Left) Time constant of isovolumic relaxation – 
tau, (Bottom Left) end-diastolic pressure – EDP, and systolic function (Top Right) maximal rate of 
isovolumic contraction – dP/dt max, (Bottom Right) stoke work – SW, normalised to pre-TAVI 
values at baseline (pre-TAVI), during valve deployment (VD) at 1, 2, 3 mins post valve deployment 
and late (median 17 min: IQR 12 to 23) after valve deployment (post-TAVI). Mean ± SEM. 
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6.3.3.2 Comparisons between Anaesthetics Protocols and Pacing Burden 
There were no significant differences in RV hemodynamic data between the GA and 
CS Sub-Groups (Figure 6-7). However, there was a significant two-fold increase in the 
number of RP paced beats delivered at the post-TAVI time point in GA Sub-Group 
compared to CS Sub-Group (p < 0.001). When comparing those with the highest 
pacing burden with the lowest, we were not able to determine a threshold below 
which RV dysfunction did not occur. The increase in RV diastolic dysfunction 
measured by Tau (Figure 6-8A) and EDP (Figure 6-8B) was immediately apparent 
after a minimal period of RP, and we did not observe any dose effect from greater 
pacing durations. 
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Figure 6-7 Comparisons between GA Sub-Group (blue) and CS Sub-Group (red) for: (A) Tau, (B) 
EDP, (C) dP/dt max, (D) PRSW, (E) Ees/Ea normalised to pre-TAVI values, and (F) number of RP 
beats after RPTC and Post-TAVI. Mean ± SEM. 
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Figure 6-8 Comparisons of pacing burden and diastolic function for (A) Tau and (B) EDP displayed 
for those with baseline normal RV function (Blue) and RV dysfunction (Red). 
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6.3.3.3 Comparisons between Baseline RV Dysfunction and Pulmonary 
Hypertension 
Those patients with pre-existing RV dysfunction identified by baseline 
echocardiographic assessment, were confirmed by hemodynamic assessment to have 
worse Tau (p < 0.01) and EDP (p = 0.05) at baseline (Figure 6-9A and B). RPTC 
caused RV dysfunction in those with or without RV dysfunction and the decline in RV 
function was not dramatically different between groups (Post RPTC ΔTau: +15.5 ± 
3.0% vs. +22.5 ± 24.6%, p = 0.516; ΔEDP: +35.5 ± 27.3% vs. +59.1 ± 72.1%, p = 
0.773). In those with RV dysfunction at baseline, Tau and to some extent EDP 
appeared to plateau maximally after TAVI whereas there was further decline in those 
with RV functional reserve (Post TAVI ΔTau: +17.5 ± 13.7 vs. +47.8 ± 44.7%, p = 
0.205; ΔEDP: +19.8 ± 23.6 vs. +42.1 ± 45.0%, p = 0.308), so that by the end of the 
procedure, the degree of RV dysfunction measured by Tau was similarly impaired in 
both groups.  
Patients with pre-existing pulmonary hypertension had an elevated EDP at baseline but 
there was no significant difference in response to RPTC identified between groups with 
or without PH (ΔTau: +23.6 ± 15.9% vs. +19.5 ± 25.3%, p = 0.70; ΔEDP: +35.1 ± 
29.7% vs. +62.6 ± 76.5%, p = 0.487) (Figure 6-9C and D). However, in those patients 
with pulmonary hypertension, Tau continued to worsen post TAVI, whereas RV 
dysfunction numerically plateaued at a level that was less impaired in those with 
normal pulmonary pressures (ΔTau: +36.9 ± 26.3% vs. +17.9 ± 58.8%, p = 0.420; 
ΔEDP: +15.8 ± 27.7% vs. +47.3 ± 44.1%, p = 0.102). 
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Figure 6-9 Comparison of the effect of RP on subgroups with pre-existing RV dysfunction and 
diastolic function (A) Tau, (B) EDP, at baseline (Pre-TAVI), after the pacing check (Post-RPTC) and 
late after the valve was deployed (Post-TAVI). Comparisons of pre-existing pulmonary 
hypertension and diastolic function (C) Tau, (D) EDP, at baseline (Pre-TAVI), after the pacing check 
(Post-RPTC) and late after the valve was deployed (Post-TAVI). P-values are displayed between 
groups.  
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6.4 Discussion 
This is the first study to use the conductance technique to determine the effect of 
balloon-expandable TF TAVI implantation on right ventricular function in humans. We 
have established that RP during balloon-mounted TAVI implantation causes RV 
dysfunction that persists until at least the end of the procedure and was apparent and 
near-maximal after a relatively short period of RP required for RPTC. There was no 
echocardiographic improvement in RV function at 3-months post-TAVI, indicating that 
unloading the LV with TAVI did not transmit beneficial ventricular interdependence 
benefits to the RV. We postulate that the RV dysfunction is mediated by global 
ischemia precipitated by RP. We observed an early transient augmentation of RV 
systolic function due to reactive hyperemia to repay the oxygen debt after RP that 
dissipates to reveal RV dysfunction. Recovery to baseline was confirmed by echo at 
3-months. These findings provide persuasive evidence of RV stunning in humans after 
TF TAVI and this may influence practice, particularly in patients with pre-existing 
pulmonary hypertension and RV failure. 
Accurate assessment of RV function is important as it predicts 1-year mortality rates 
(Leon et al., 2010). Echo studies have provided inconsistent findings on the effect of 
TAVI on RV function, ranging from RV dysfunction (Ito et al., 2014) to improved RV 
function compared to SAVR (Forsberg et al., 2011). Conventional 2D echo assessment 
of RV function is challenging due to the complex geometry of the RV, and this may 
explain the discrepancies between studies (Lindman et al., 2015). More robust RV 
assessment using cardiac MR and 3D echo now report that RV function is maintained 
following SAVR (Crouch et al., 2015; Keyl et al., 2016) and that TAVI may lead to RV 
systolic dysfunction (Crouch et al., 2015). However, beat-by-beat, load independent 
assessment of RV function inter-operatively during TAVI can only be achieved by 
conductance catheter assessment. The mechanism of RV dysfunction observed 
following TAVI has not been elucidated. 
 Page 230 
The term myocardial stunning describes the phenomena of persistent contractile 
dysfunction after an ischemic insult, despite normal coronary flow in the absence of 
infarction that is completely reversible (Braunwald and Kloner, 1982; Bolli, 1990). This 
has been described in animal models of supply ischemia, which showed that LV 
stunning is proportional to the duration of the ischemic insult (Heyndrickx et al., 1975; 
Preuss et al., 1987). Exercise-induced demand ischemia has been shown to cause LV 
stunning in animals (Homans et al., 1991) and humans (Rinaldi et al., 1999; Barnes et 
al., 2002) as can RP-induced global supply and demand ventricular ischemia (Turer et 
al., 2011).  
RP is required to transiently ablate LV contractility enabling optimal TAVI positioning 
and deployment without the premature expulsion of the balloon-mounted valve from 
inadvertent LV ejection. Great lengths are taken to ensure adequate LV suppression 
(confirmed by a systolic <40mmHg) and stable ventricular capture by the temporary 
pacing wire by sometimes repeated testing (RPTC). RP is also sometimes used to help 
gain haemostasis. However, valves are emerging that maintain flow through the 
prosthesis, can be repositioned and are introduced through smaller sheathes, perhaps 
negating the need for RP. 
The RV appears to be exquisitely sensitive to the effects of RP. In this study, we have 
confirmed that even a short burst of RP required to assess RPCT was enough to cause 
near-maximal diastolic dysfunction. GA and CS sub-groups both had similar nadirs of 
RV dysfunction, despite the former having a two-fold greater number of RP beats 
delivered. In addition, those with preserved RV function and normal pulmonary 
pressures remained susceptible to significant RV dysfunction. Our data suggests there 
is no safe RP threshold – even a short burst of rapid pacing is deleterious to RV 
function. Although RP has previously been described as a safe and effective method to 
provide balloon stability for balloon aortic valvuloplasty (Daehnert et al., 2004), our data 
demonstrates that significant diastolic dysfunction is observed after as little as 24 RP 
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beats, equivalent to only 7 seconds of RP. We observed modest further worsening of 
RV dysfunction despite up to 5-fold more RP beats (median 120; IQR 87 to 205) 
required for the actual TAVI implantation. Attempting to mitigate the effects of RP on 
the RV by RP dose reduction in CS sub-group, did not improve matters.  
We demonstrated a transient augmentation of RV systolic function immediately after 
the valve was deployed and the RP was switched off, although diastolic dysfunction 
persisted during this period. We believe this can be explained by reactive hyperaemia 
– an augmentation of coronary flow due to coronary vasodilatation to repay the oxygen 
debt (Heyndrickx et al., 1975). During hyperemia there is an increase in microvascular 
volume and myocytes adjacent to these vessels are stretched, opening stretch-
activated calcium channels, causing calcium influx and an augmentation of calcium-
dependent myofibrillar contractility, known as the Gregg effect (Gregg, 1963). We have 
previously described this in a model of LV supply ischemia (Hoole et al., 2010) and this 
hyperemic response masks stunning in the early phase of reperfusion (Stahl et al., 
1986). Interestingly, diastolic dysfunction remains depressed during this period, and 
this may be due to a scaffold effect from distended coronary and collateral vessels 
during hyperemia acting on the thin walled RV that stiffens the ventricular cavity (Hoole 
et al., 2010). Alternatively, this may be explained by the sequence of the ischemic 
cascade -diastolic dysfunction is more profound as it occurs earlier. 
There was an increase in absolute RV volumes following valve implantation explained 
by ventricular interdependence across the shared septum; LV afterload diminishes 
post-TAVI, reducing LV volume and enabling ventricular reconfiguration and RV 
volume expansion. However, this did not improve RV ventriculoarterial coupling. To the 
contrary, the simultaneous reduction in Ees and PRSW uncoupled the RV from the PA, 
reducing efficiency. The interdependence of the ventricular cavities due to the shared 
septum should result in biventricular effects (Saleh et al., 2006) and by unloading the 
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LV, RV functional improvement should follow (Santamore and Dell'Italia, 1998b), but 
this was not observed.  
There are a number of limitations that need to be taken into account when interpreting 
the results of this study. First, although the conductance technique allowed the 
operator to determine the real-time load-independent beat-to-beat assessment of RV 
function, it was not ethically possible to perform a higher risk additional invasive 
procedure during the 3-month follow-up appointment. We were only able to measure 
load-dependant echocardiographic parameters of RV function, but these appeared to 
confirm that RV function returned to baseline – a pre-requisite of the definition of 
stunning.  
Second, it is not possible to accurately assess RV echocardiographic function with 
TEE. Difficulties in the alignment of the Doppler beam with the tricuspid annulus can 
cause significant underestimation of TAPSE and RV TDIs. Therefore, we were not able 
to present RV data immediately following valve deployment in the GA sub-group. 
However, we were able to present consistent TTE data for the CS sub-group and have 
no reason to believe these findings are not valid for the GA sub-group. 
Third, we did not confirm ischemia-induction by coronary sinus lactate sampling after 
RP, although this has been confirmed previously (Bagger et al., 1983). Nor were we 
able to assess coronary flow as this was impractical in an already complex human 
study. Again, the effect of RP on coronary flow and the subsequent reactive-hyperemia 
has been previously published (Hodgson and Mancini, 1985). The RV temporal 
dysfunction data post-TAVI are consistent with this being the most plausible 
mechanism.  
Fourth, the use of volatile anaesthetics can depress ventricular function (Horan et al., 
1977; Pagel et al., 1993) but can also be cardioprotective (Bland and Lowenstein, 
1976), which could have influenced the degree of RV stunning observed. However, RV 
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stunning occurred to a comparable degree in the GA and CS subgroups, and we 
believe the anaesthetic protocol had minimal effect on RV dysfunction observed. 
Fifth, this study population derives from a pool of patients who met the clinical 
acceptability criteria for TF TAVI. This patient group were high risk or inoperable and 
as a result of comorbidity had a degree of pulmonary hypertension (mPAP 24.4mmHg 
for the cohort) and possibly some pre-existing RV dysfunction. Despite this, patients 
acted as their own control and our observations rem Forsbergain valid. 
Finally, we were not able to establish a dose-response to RP that would have 
strengthened our assertion that RP was the cause of RV stunning. However, the RV 
dysfunction occurred without an observable threshold; it was an all-or-nothing effect  
6.5 Summary 
The research question for this chapter was to determine whether right ventricular (RV) 
diastolic function improves following left ventricular (LV) afterload reduction following 
transfemoral (TF) Transcatheter Aortic Valve Implantation (TAVI) due to ventricular 
interdependence phenomena leading to changes in LV – RV interaction through septal 
wall reconfiguration. This work has demonstrated that although ventricular 
interdependence phenomena caused septal reconfiguration increasing RV volumes 
after valve deployment due to the reduction in LV afterload; RP-induced ischemia was 
found to cause RV stunning after valve deployment. RV systolic and diastolic 
dysfunction was apparent in the stunned ventricle late after the RP-induced ischemic 
insult. Therefore, rather than the hypothesised improvements in RV ventriculoarterial 
coupling and diastolic function, uncoupling and diastolic dysfunction was observed. 
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7 Conclusions and Future Work 
In recent years, an increasing body of evidence has emerged postulating the role of 
ventriculoarterial uncoupling as a marker of RV adaptation and RV maladaptation, and 
how this may offer new insight into the pathophysiology of pulmonary hypertension. 
While the relationship between the pressure-volume relationship and ventriculoarterial 
coupling had been extensively described in the LV and used to determine optimal 
conditions for the efficient transfer to blood from the ventricle into the aorta, it remained 
unclear whether this relationship could be translated to the thinner walled RV that 
pumps at lower pressures against a more compliant pulmonary vascular system. The 
studies in this thesis were therefore undertaken to assess whether ventriculoarterial 
uncoupling due to pressure overload or sub-optimal contractility caused RV diastolic 
dysfunction. These studies comprised of the development of an in-vivo porcine model 
of RV ventriculoarterial coupling to define the optimal RV – PA ventriculoarterial 
coupling conditions. This animal model of RV-PA ventriculoarterial coupling was then 
translated in two clinical patient groups that have RV dysfunction: chronic RV afterload 
in patients with CTED and CTEPH, and assessing RV-LV ventricular interdependence 
through septal wall reconfiguration after TAVI. 
7.1 Animal Model 
An in-vivo animal model was developed to determine the PV-loop derived maximal 
SW-Ea and maximal SW-Ees/Ea relationships during acute increases to PA afterload. 
This work has shown that although maximal efficiency improves our understanding of 
ventriculoarterial coupling, in RV failure the maximal SW derived from the pressure-
volume relationship, is a key determinant of clinical and therapeutic outcomes. In terms 
of RV performance upon exercise (increased loading), if at rest the RV is already 
pumping against an afterload loading condition equal to or greater than that of maximal 
SW, further increasing the PA afterload will cause SW and CO to fall. The RV will not 
be able to maintain an adequate output in the face of additional loading generated from 
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exercise. Unlike historical LV ventriculoarterial coupling data that demonstrated 
maximal SW occurred at a coupling ratio of 1.25 ± 0.16 (De Tombe et al., 1993), this 
work has suggested that in a healthy porcine RV maximal SW occurred at a coupling 
ratio of 0.68 ± 0.23. This work is the first to demonstrate that there is fundamental 
inefficiency (low coupling ratio) even in health, as the RV has to expend excess energy 
to pump blood against the inelastic PA.  
7.2 RV Remodelling in Patients with Long Term Pressure Overload 
The first clinical study examined how the in-vivo porcine model of RV ventriculoarterial 
interaction could be translated to human physiology to better characterise two cohorts 
of patients’ with pathological chronic excess RV afterload. Although the natural history 
of CTED is poorly defined and it remains unclear whether patients with CTED 
deteriorate over time. This work has shown that the threshold for Ees/Ea at maximal 
SW determined from the animal model has detected RV pathology at rest in patients 
with CTED and otherwise normal pulmonary hemodynamics and demonstrated RV 
energetic reserve in some cases of CTEPH. Detailed ventriculoarterial coupling data 
may further risk stratify patients with CTED and CTEPH, and could usefully influence 
management.  
7.3 RV Remodelling in Patients with Aortic Valve Stenosis 
The second clinical study examined whether RV diastolic function improves following 
LV afterload reduction following TF-TAVI due to ventricular interdependence 
phenomena leading to changes in LV – RV interaction through septal wall 
reconfiguration. This work has demonstrated that although ventricular interdependence 
phenomena caused septal reconfiguration, increasing RV volumes after valve 
deployment due to the reduction in LV afterload. RP-induced ischemia caused 
overwhelming RV stunning after valve deployment. We established that RP during 
balloon-mounted TAVI implantation caused RV dysfunction that persists until at least 
the end of the procedure and was apparent and near-maximal after a relatively short 
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period of RP required for RPTC. We postulate that the RV dysfunction was mediated 
by global ischemia precipitated by RP; a presumed early hyperemic phase immediately 
after RP transiently augmented systolic RV function but both RV systolic and diastolic 
function were depressed once reactive hyperaemia had dissipated at +17 minutes. 
There was no echocardiographic improvement in RV function at 3-months post-TAVI, 
with RV function only recovering to baseline level. The potential ventricular 
interdependence benefits of unloading the LV after TAVI, has not manifested in an 
improvement in RV function, possibly due to this procedural factor. These findings 
have provided persuasive evidence of RV stunning in humans after TF TAVI and may 
give clinical insight in to why TAVI results are disappointing in those with pre-existing 
pulmonary hypertension and RV failure. Therefore, rather than the hypothesised 
improvements in RV ventriculoarterial coupling and diastolic function, uncoupling and 
diastolic dysfunction was observed. Changes to the valve deployment protocol 
avoiding RP may be required to prevent iatrogenic RV dysfunction and optimal TAVI 
results, particularly in patients with pre-existing right heart disease. 
7.4 Conclusion Summary 
In conclusion, the in-vivo animal model of RV ventriculoarterial coupling determined 
that maximal SW is a key determinant of clinical and therapeutic outcomes in RV 
failure. Beyond the threshold for maximal SW (Ees/Ea 0.68; Ea = 0.50 mmHg/ml) RV 
dysfunction occurs. This threshold for the RV Ees/Ea ratio at maximal SW was then 
used to detect occult RV dysfunction at rest in patients with CTED and otherwise 
normal pulmonary hemodynamics and demonstrated RV energetic reserve in some 
cases of CTEPH. Detailed ventriculoarterial coupling data may further risk stratify 
patients with CTED and CTEPH and usefully influence management. While global LV 
function was shown to improve in patients undergoing TAVI, ventricular 
interdependence improvements in RV contractility were overwhelmed by RP-induced 
RV ischemic dysfunction and stunning. Nevertheless, we were able to demonstrate 
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that a reduction in RV Ees led to a reduction in the RV Ees/Ea ratio and further 
deterioration of RV diastolic dysfunction. 
7.5 Future Work 
There are a number of avenues which need exploring further to build on the 
conclusions drawn from this work. While this work demonstrated that Ea could be a 
clinical relevant descriptor for classifying patients with PH, it is not feasible to 
interrogate every patient with the conductance catheter. However, it may be possible to 
validate a surrogate measure of Ea from the standard right heart catheterisation. If this 
is found to be reliable and accurate it could help identify those patients who have RV 
pathology at rest, but otherwise present with normal pulmonary haemodynamics.  
The findings from the TAVI have provided persuasive evidence of RV stunning in 
humans after TF TAVI and may give clinical insight in to why TAVI results are 
disappointing in those with pre-existing pulmonary hypertension and RV failure. Many 
avenues need exploring further to minimise the effects of RP on RV stunning during 
TAVI. Is it possible to deploy the Edwards device using a balloon that does not require 
RP and allows continued blood flow? Is it possible to use a device that does not require 
RP? There is also further work required to better understand how and why the process 
of RP causes RV stunning. Is abnormal septal function detected after performing a 
TEE at baseline, following RP test capture and again after device implantation? Finally, 
by performing an ECG at the same time points it would be possible to determine if the 
RV stunning is mediated by elongation of the QRS complex.  
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9 Appendices  
9.1 Appendix A – Relations between Afterload Quantified by Ea and 
RV Function 
 
Figure 9-1 (Top) Relation between afterload quantified by effective arterial elastance (Ea) and end-
systolic volume; (Bottom) and end-diastolic volume. 
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Figure 9-2 (Top) Relation between afterload quantified by effective arterial elastance (Ea) and end-
systolic pressure; (Bottom) and end-diastolic pressure. 
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Figure 9-3 (Top) Relation between afterload quantified by effective arterial elastance (Ea) and 
maximum rate of isovolumic contraction; (Bottom) and maximum rate of isovolumic relaxation. 
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Figure 9-4 (Top) Relation between afterload quantified by effective arterial elastance (Ea) and 
ejection fraction; (Bottom) and stroke volume. 
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Figure 9-5 Relation between afterload quantified by effective arterial elastance (Ea) and the time 
constant of diastolic relaxation (Tau). 
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9.2 Appendix B – Relations between Ventriculoarterial Coupling 
Quantified by Ees/Ea and RV Function 
 
Figure 9-6 (Top) Relation between the ventriculoarterial coupling ratio (Ees/Ea) and end-systolic 
volume; (Bottom) and end-diastolic volume. 
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Figure 9-7 (Top) Relation between the ventriculoarterial coupling ratio (Ees/Ea) and end-systolic 
pressure; (Bottom) and end-diastolic pressure. 
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Figure 9-8 (Top) Relation between the ventriculoarterial coupling ratio (Ees/Ea) and maximum rate 
of isovolumic contraction; (Bottom) and maximum rate of isovolumic relaxation. 
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Figure 9-9 (Top) Relation between the ventriculoarterial coupling ratio (Ees/Ea) and ejection 
fraction; (Bottom) and stroke volume. 
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Figure 9-10 Relation between the ventriculoarterial coupling ratio (Ees/Ea) and the time constant of 
diastolic relaxation. 
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